




CASE
COMPREHENSIVE
CANCER CENTER



American Society of Hematology (ASH) Annual Meeting

Dec 1-4, 2018

<http://www.hematology.org/Annual-Meeting/Program/>

****Case CCC Members in BOLD; Presenter UNDERLINED****

PRESENTATIONS/SESSION CHAIRS

Matt Kalaycio, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair and Speaker, [*Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies*](#)

Friday, Nov 30, 2018, 7-11 am; Hyatt, Coronado Ballroom, A-C

Hetty E. Carraway, MD, MBA

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [Hematology Oncology Training Program Directors Workshop](#)

Friday, Nov 30, 2018, 11 am-2 pm; Petco Park, The Auditorium

Speaker, [*Blood Drops: Career 101: Early career planning topics; Knocking Your Fellowship Interview Out of the Park: Tips to Make Sure Your Interview Day Is a Homerun*](#)

Friday, Nov 30, 2018, 3:30-3:45 pm; Western Metal Concourse (Petco Park)

Alok Khorana, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [*What's New in VTE? Evaluating the Latest Evidence and Grades of Recommendation*](#)

Friday, Nov 30, 2018, 12:30-4:30 pm; Hyatt, Coronado Ballroom, A-C

Mikael A. Sekeres, MD, MS

Case Comprehensive Cancer Center, Cleveland Clinic

Co-Chair, Education Program

Speaker, [*Blood Drops: Wellness: Topics to help your well-being; Telling It Like It Is: Essays About Medicine*](#)

Friday, Nov 30, 2018, 1:30-1:45 pm; Western Metal Concourse (Petco Park)

Co-Chair, [Late-Breaking Abstracts Session](#)

Tuesday, Dec 4, 2018, 7:30-9:00 am; San Diego Convention Center, Hall AB

Anne T Neff, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Blood Drops: Hematology 201: A mid-level clinical topic*](#)

Friday, Nov 30, 2018, 1:30-4:45 pm; Western Metal Concourse (Petco Park)

Aziz Nazha, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Blood Buddies/Mentor Session 1; Adult Clinical Malignant Hem*](#)

Friday, Nov 30, 2018, 2:30-3:00 pm; Section 124 – The Porch (Petco Park)

Speaker, [*Blood Buddies/Mentor Session 2; Adult Clinical Malignant Hem*](#)

Friday, Nov 30, 2018, 3:30-4:00 pm; Section 124 – The Porch (Petco Park)

Speaker, [*The MDS Genomics-Prognosis Symbiosis; The Molecular Maelstrom of Myelodysplastic Syndromes \(MDS\)*](#)

Saturday, Dec 1, 2018, 4:00-5:30 pm; San Diego Convention Center, Room 6A

Sunday, Dec 2, 2018, 9:30-11 am; San Diego Convention Center, Room 6A

Keith R. McCrae, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Blood Buddies/Mentor Session 1; Laboratory & Translational Hem*](#) and [*Adult Clinical Non-Malignant Hem*](#)

Friday, Nov 30, 2018, 2:30-3:00pm; Section 124 – The Porch (Petco Park)

Speaker, [*Blood Buddies/Mentor Session 2; Laboratory & Translational Hem*](#) and [*Adult Clinical Non-Malignant Hem*](#)

Friday, Nov 30, 2018, 3:30-4:00pm; Section 124 – The Porch (Petco Park)

Chair, [*Scientific Committee on Thrombosis and Vascular Biology: Microparticles and Exosomes: Ready for the Clinic?*](#)

Saturday, Dec 1, 2018, 9:30-11:00 am; San Diego Convention Center, Room 24B

Saturday, Dec 1, 2018, 4:00-5:30 pm; San Diego Convention Center, Room 11B

Co-Chair and Speaker, [*Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 2*](#)

Monday, Dec 3, 2018, 4:30-6:30pm; San Diego Convention Center, Room 30D

Navneet Majhail, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Career-Development Lunch Session Ballroom AB: Adult Clinical Malignant Hematology/BMT*](#)

Saturday, Dec 1, 2018, 11:15 am-12:15 pm; Sapphire Ballroom AB (Hilton San Diego Bayfront)

Alvin H. Schmaier, MD

Case Comprehensive Cancer Center, Case Western Reserve University

Chair, [*Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis*](#)

Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B

Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B

Co-Chair and Speaker, [*Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 1*](#)

Monday, Dec 3, 2018, 4:30-6:30pm; San Diego Convention Center, Room 30D

Mukesh Jain, MD

Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University

Speaker, [*Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis; Krüppel-Like Factors in Thrombosis and Hemostasis*](#)

Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B

Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B

Betty K. Hamilton, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation: Reining in Graft-Versus-Host Disease \(GVHD\) After Allogeneic Hematopoietic Cell Transplantation*](#)

Sunday, Dec 2, 2018 7:30-9:00 am; Manchester Grand Hyatt San Diego, Grand Hall D
Monday, Dec 3, 2018 10:30 am-12:00 pm; Manchester Grand Hyatt San Diego, Grand Hall D

Aaron T, Gerdts, MD, MS

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [Social Media for the Hematologist: Today and in the Future](#)

Sunday, Dec 2, 2018, 11:15-12:15 pm; San Diego Convention Center, Room 28D

Sudipto Mukherjee, MD, PhD, MPH

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Population Risks of Developing Myeloid Malignancies; From Fat Man to Agent Orange and Beyond: When Myeloid Malignancies Strike](#)

Sunday, Dec 2, 2018, 4:30-6:00 pm; San Diego Convention Center, Room 11B

Eric Kodish, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Ethical Conundrums in Pediatric Genomics; Using Genomics to Risk Stratify and Treat Kids](#)

Sunday, Dec 2, 2018, 9:30-11:00 am; Marriott Marquis San Diego Marina, San Diego Ballroom B

Monday, Dec 3, 2018, 7:00-8:30 am; Marriott Marquis San Diego Marina, San Diego Ballroom 21

ORAL ABSTRACTS – CASE CCC PRESENTER (with CASE CCC CO-AUTHORS)

[33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp \(Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine\) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Improving Frontline Therapy in ALL

Hematology Disease Topics & Pathways: antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Saturday, December 1, 2018: 8:00 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

[Anjali S. Advani, MD¹](#), Anna Moseley, M.S.^{2*}, Kristen Marie O'Dwyer, MD³, Brent Wood, MD PhD^{4*}, Min Fang, MD, PhD⁵, Matthew J. Wieduwilt, MD, PhD⁶, Ibrahim Aldoss, MD⁷, Jae H. Park, MD⁸, Rebecca Klisovic, MD^{9*}, Maria R. Baer, MD¹⁰, Wendy Stock, MD¹¹, Rupali Bhawe, M.D.^{12*}, Megan Othus, PhD², Mark R. Litzow, MD¹³, Richard M. Stone, MD¹⁴ and Harry P. Erba, MD, PhD¹⁵

¹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²SWOG Statistics and Data Management Center, Seattle, WA

³University of Rochester Medical Center, Rochester, NY

⁴Department of Laboratory Medicine and Division of Hematopathology, University of Washington, Seattle, WA

⁵Fred Hutchinson Cancer Research Center, Seattle, WA

⁶University of California, San Diego, La Jolla, CA

⁷University of Southern California, Duarte, CA

⁸Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

⁹Ohio State University, Columbus, OH (past during conduct of trial)/ Emory University, Atlanta, GA

¹⁰University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

¹¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

¹²Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC

¹³Division of Hematology, Mayo Clinic, Rochester, MN

¹⁴Dana-Farber Cancer Institute, Boston, MA

¹⁵University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL

206 A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Saturday, December 1, 2018: 2:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Aziz Nazha, MD¹, Zhen-Huan Hu, MPH^{2*}, Tao Wang, PhD^{2,3*}, Betty K. Hamilton, MD⁴, Navneet S. Majhail, MD, MS⁵, R. Coleman Lindsley, M.D., Ph.D.⁶, Ronald Sobecks, MD⁵, Uday Popat, MD⁷, Bart L Scott, MD⁸ and Wael Saber, MD, MS^{2*}

¹Cleveland Clinic, Cleveland, OH

²CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

³Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

⁴Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Dana-Farber Cancer Institute, Boston, MA

⁷Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

⁸Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

397 Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents

Hematology Disease Topics & Pathways: Diseases, Biological, apoptosis, Adult, Therapies, Non-Biological, Non-Hodgkin Lymphoma, chemotherapy, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018: 12:00 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

Paolo Caimi, MD¹, Deepa Jagadeesh, MD, MPH², Kirsten Marie Boughan, DO¹, Robert M. Dean, MD², Brenda Cooper, MD¹, Brad Pohlman, MD³, Molly M Gallogly, MD, PhD¹, Sarah L. Ondrejka, DO⁴, Erika Moore, MD^{5*}, Kwadwo Asare Oduro, MD, PhD⁵, Eric D. Hsi, MD⁴, Marcos de Lima, MD¹ and Brian T. Hill, MD, PhD^{6,7}

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

⁶Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

466 PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II

Hematology Disease Topics & Pathways: Diseases, antibodies, Biological, Therapies, MDS, checkpoint inhibitors, Myeloid Malignancies

Sunday, December 2, 2018: 5:15 PM; Grand Hall A (Manchester Grand Hyatt San Diego)

Aaron T. Gerds, MD, MS¹, Bart L Scott, MD², Peter L Greenberg, M.D.³, Samer K. Khaled, MD⁴, Tara L Lin, MD^{5,6}, Daniel A Pollyea, MD⁷, Amit Verma, MD⁸, Monique Dail^{9*}, Cherie Green^{9*}, Connie Ma^{9*}, Bruno C Medeiros⁹, Patrick Phuong^{9*}, Michael Wenger¹⁰, Mark Yan^{11*} and William B. Donnellan, MD¹²

¹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

³Stanford University Cancer Center, Stanford, CA

⁴City of Hope, Duarte, CA

⁵University of Kansas Medical Center, Kansas City, KS

⁶Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS

⁷University of Colorado School of Medicine, Aurora, CO

⁸Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY

⁹Genentech Inc, South San Francisco, CA

¹⁰F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹¹Hoffmann-La Roche Ltd, Mississauga, ON, Canada

¹²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

793 A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Prognosis and Prediction

Hematology Disease Topics & Pathways: AML, Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Monday, December 3, 2018: 2:45 PM; Grand Hall A (Manchester Grand Hyatt San Diego)

Aziz Nazha, MD¹, Rami S. Komrokji, MD², Manja Meggendorfer, PhD³, **Sudipto Mukherjee, MD, PhD, MPH⁴**, Najla Al Ali, M.Sc^{5*}, Wencke Walter, PhD^{3*}, Stephan Hutter, PhD^{3*}, Eric Padron, MD⁵, Yazan F. Madanat, MD⁶, David A Sallman, MD⁷, Teodora Kuzmanovic^{8*}, Cassandra M. Hirsch^{9*}, Vera Adema, PhD^{8*}, David P. Steensma, MD¹⁰, Amy E. DeZern, MD¹¹, Gail J. Roboz, MD¹², Guillermo Garcia-Manero, MD¹³, Alan F. List, MD¹⁴, Claudia Haferlach, MD³, **Jaroslav P. Maciejewski⁸**, Torsten Haferlach, MD¹⁵ and **Mikhael A. Sekeres, MD, MS¹⁶**

¹Cleveland Clinic, Cleveland, OH

²Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

³MLL Munich Leukemia Laboratory, Munich, Germany

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Dana-Farber Cancer Institute, Boston, MA

¹¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹²Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹³Department of Leukemia, MD Anderson Cancer Center, Houston, TX

¹⁴H. Lee Moffitt Cancer Center, Tampa, FL

¹⁵MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute Taussig Cancer Institute, Cleveland, OH

ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)

1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Program: General Sessions

Session: Plenary Scientific Session

Hematology Disease Topics & Pathways:

Biological, Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 2:00 PM-4:00 PM; Hall AB (San Diego Convention Center)

Pierre Fenaux, MD, PhD¹, Uwe Platzbecker, MD², Ghulam J. Mufti^{3*}, Guillermo Garcia-Manero, MD⁴, Rena Buckstein, MD, FRCPC⁵, Valeria Santini⁶, María Díez-Campelo^{7*}, Carlo Finelli, MD^{8*}, Mario Cazzola⁹,

Osman Ilhan, MD^{10*}, **Mikael A. Sekeres, MD, MS¹¹**, José F. Falantes^{12*}, Beatriz Arrizabalaga, MD, PhD^{13*}, Flavia Salvi^{14*}, Valentina Giai^{14*}, Paresh Vyas, MRCP FRCP FRCPath¹⁵, David Bowen, MD¹⁶, Dominik Selleslag, MD^{17*}, Amy E. DeZern, MD¹⁸, Joseph G. Jurcic, MD¹⁹, Ulrich Germing, MD^{20*}, Katharina S. Götze, MD²¹, Bruno Quesnel²², Odile Beyne-Rauzy^{23*}, Thomas Cluzeau, MD, PhD^{24*}, Maria Teresa Voso²⁵, Dominiek Mazure^{26*}, Edo Vellenga²⁷, Peter L Greenberg, M.D.²⁸, Eva Hellstrom Lindberg, MD, PhD²⁹, Amer M. Zeidan, MBBS, MHS^{30*}, Abderrahmane Laadem, MD³¹, Aziz Benzohra^{32*}, Jennie Zhang^{31*}, Anita Rampersad^{31*}, Peter G. Linde³³, Matthew L. Sherman³³, Rami S. Komrokji, MD³⁴ and Alan F. List, MD³⁴

¹Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

²University Hospital Dresden, Dresden, Germany

³Department of Haemato-Oncology, King's College London, London, United Kingdom

⁴Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁵Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

⁶MDS Unit, AOU Careggi, University of Florence, Florence, Italy

⁷Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

⁸Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy

⁹University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

¹⁰Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey

¹¹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville, Spain

¹³Department of Hematology, Hospital Universitario Cruces, Vizcaya, Spain

¹⁴Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy

¹⁵Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

¹⁶Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom

¹⁷Department of Haematology, AZ Sint-Jan, Bruges, Belgium

¹⁸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

¹⁹Division of Hematology/Oncology, Columbia University Medical Center, New York, NY

²⁰Klinik für Hämatologie, Onkologie and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany

²¹Department of Medicine III, Technical University of Munich, Munich, Germany

²²Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France

²³Médecine Interne, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

²⁴Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

²⁵Dipartimento di Biopatologia e Diagnostica per Immagini, University of Rome Tor Vergata, Rome, Italy

²⁶Universitair Ziekenhuis Gent, Ghent, Belgium

²⁷Department of Hematology, University Medical Center Groningen, Groningen, Netherlands

²⁸Stanford University Cancer Center, Stanford, CA

²⁹Department of Medicine, Karolinska Institutet, Stockholm, Sweden

³⁰Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

³¹Celgene Corporation, Summit, NJ

³²Celgene International, Boudry, Switzerland

³³Acceleron Pharma, Cambridge, MA

³⁴Moffitt Cancer Center, Tampa, FL

75 Neutrophil KLF2 Regulates Arterial and Venous Thrombosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and

Biochemistry: Vascular Physiology and Thrombosis

Hematology Disease Topics & Pathways: Biological Processes, inflammation

Saturday, December 1, 2018: 10:00 AM; Room 28D (San Diego Convention Center)

Lalitha V. Nayak, MD¹, Stephanie Lapping, MS^{2*}, Andrei Maiseyeu^{3*}, **Alvin H. Schmaier, MD⁴** and **Mukesh Jain, MD^{2,5*}**

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²Case Cardiovascular Research Institute, CWRU, Cleveland

³Case Cardiovascular Research Institute, Case Western Reserve University, Cleveland

⁴Case Western Reserve University, Cleveland, OH

⁵Case Western Reserve University / University Hospitals Health System, Cleveland, OH

91 Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting

Hematology Disease Topics & Pathways: Biological, Therapies, CAR-Ts

Saturday, December 1, 2018: 9:30 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

Loretta J. Nastoupil, MD¹, Michael D. Jain, MD, PhD², Jay Y. Spiegel, MD, FRCPC³, Armin Ghobadi, MD^{4*}, Yi Lin, MD, PhD⁵, Saurabh Dahiya, MD⁶, Matthew A. Lunning, DO⁷, Lazaros J. Lekakis, MD^{8*}, Patrick M. Reagan, MD⁹, Olalekan O. Oluwole, MBBS, MPH¹⁰, Joseph P. McGuirk, DO¹¹, Abhinav Deol, MD¹², Alison R. Sehgal, MD¹³, Andre Goy, MD¹⁴, **Brian T. Hill, MD, PhD^{15,16}**, Charalambos Andreadis, MD^{17,18}, Javier Munoz, MD¹⁹, Jason R. Westin, MD²⁰, Julio C. Chavez, MD²¹, Amanda F Cashen, MD²², Nora N Bennani, MD⁵, Aaron P. Rapoport, MD²³, Julie M. Vose, MD, MBA⁷, David B. Miklos, MD, PhD²⁴, Sattva S. Neelapu, MD²⁵ and Frederick L. Locke, MD²⁶

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

²Moffitt Cancer Center, Tampa, FL

³Stanford University Medical Center, Stanford, CA

⁴Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

⁵Division of Hematology, Mayo Clinic, Rochester, MN

⁶University of Maryland School of Medicine, Baltimore, MD

⁷University of Nebraska Medical Center, Omaha, NE

⁸Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

⁹Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

¹⁰Vanderbilt-Ingram Cancer Center, Nashville, TN

¹¹Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

¹²Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹³UPMC Hillman Cancer Center, Pittsburgh, PA

¹⁴John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

¹⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁶Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁷Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA

¹⁸Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

¹⁹Banner MD Anderson Cancer Center, Gilbert, AZ

²⁰Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston

²¹H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

²²Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

²³University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD

²⁴Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

²⁵Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX

²⁶H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

104 Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Biological Processes, Myeloid Malignancies, molecular interactions

Saturday, December 1, 2018: 9:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Yasunobu Nagata^{1*}, Hideki Makishima, MD, PhD², Tetsuichi Yoshizato, MD, PhD², Hiromichi Suzuki, M.D., Ph.D.^{2*}, Cassandra M. Hirsch^{3*}, Abhinav Goyal^{3*}, Hassan Awada, MD³, Mohammad Fahad B. Asad³, Teodora Kuzmanovic, BA^{3*}, Bartłomiej P. Przychodzen^{3*}, Kenichi Yoshida, MD, PhD^{2*}, Kenichi Chiba, PhD^{4*}, Hiroko Tanaka, BA^{4*}, Yuichi Shiraishi, PhD^{4*}, Satoru Miyano, PhD^{4*}, **Sudipto Mukherjee, MD, PhD, MPH⁵**, **Tomas Radivoyevitch, PhD^{3*}**, **Thomas Laframboise, PhD^{6*}**, **Aziz Nazha, MD⁵**, **Mikael A. Sekeres, MD, MS⁵**, Torsten Haferlach, MD⁷, Seishi Ogawa, MD, PhD⁸ and **Jaroslav P. Maciejewski³**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁷MLL Munich Leukemia Laboratory, Munich, Germany

⁸Department of Pathology and Tumor Biology, Kyoto University, Graduate School of Medicine, Kyoto, Japan

107 SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Technology and Procedures, Study Population, Myeloid Malignancies, inflammation

Saturday, December 1, 2018: 10:30 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Kathy L McGraw, PhD¹, Chia-Ho Cheng, Ph.D.^{2*}, Y. Ann Chen, Ph.D.^{3*}, Hsin-An Hou, MD, PhD^{4*}, Guilio Genovese, Ph.D.^{5*}, Thomas Cluzeau, MD, PhD^{6*}, Andrea Pellagatti, PhD^{7*}, Bartłomiej Przychodzen^{8*}, Mar Mallo, Ph.D.^{9*}, Arenillas Leonor, MD, PhD^{10*}, Azim M. Mohamedali, Ph.D.^{11*}, Pierre Fenaux, MD¹², David A Sallman, MD¹³, Eric Padron, MD¹⁴, Lubomir Sokol, MD, PhD¹⁵, Chimene Moreilhon^{16*}, Sophie Raynaud, MD, PhD^{17*}, Bjorn Nilsson, Ph.D.^{18*}, Hwei-Fang Tien, M.D., Ph.D.¹⁹, Jacqueline Boulwood, PhD⁷, Benjamin L. Ebert, MD, PhD²⁰, Francesc Sole, PhD²¹, Pierre Fenaux, MD, PhD²², Ghulam Mufti^{23*}, **Jaroslav P. Maciejewski²⁴**, Peter Kanetsky, Ph.D.^{2*} and Alan F. List, MD²

¹Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

²H. Lee Moffitt Cancer Center, Tampa, FL

³H. Lee Moffitt Cancer Center, Tampa

⁴Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan

⁵Broad Institute of the Massachusetts Institute of Technology, Cambridge, MA

⁶Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

⁷Bloodwise Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain

¹⁰Laboratori de Citologia Hematològica i Citogenètica, servei de Patologia, Hospital del Mar. GRETNHE- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain

¹¹Kings College London, London, GBR

¹²INSERM UMR-S1131, Institut Universitaire d'Hématologie, Hôpital St Louis/ Paris 7 University, PARIS, France

¹³Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

¹⁴H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹⁵Moffitt Cancer Center, Tampa, FL

¹⁶CHU of Nice, Nice, France

¹⁷CHU of Nice, Onco-hematology Laboratory, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France

¹⁸Lund University, Lund, Sweden

¹⁹Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

²⁰Brigham and Women's Hospital, Harvard Medical School, Boston, MA

²¹MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

²²INSERM UMR-S1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France

²³Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom

²⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

108 Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and

Germline Predisposition

Hematology Disease Topics & Pathways: Diseases, Adult, MDS, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement , NGS

Saturday, December 1, 2018: 10:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Hideki Makishima, MD, PhD¹, Tetsuichi Yoshizato, MD, PhD², Yasuhito Nannya, MD, PhD³, Yasuhide Momozawa, PhD^{4*}, Yoshiko Atsuta, MD, PhD^{5*}, Yusuke Shiozawa, M.D., Ph.D.^{2*}, Yuka Iijima-Yamashita^{6*}, Kenichi Yoshida, MD, PhD^{2*}, Yuichi Shiraishi, PhD^{7*}, Hiromichi Suzuki, M.D., Ph.D.^{2*}, June Takeda, MD^{8*}, Yasunobu Nagata^{9*}, Yusuke Sato^{10*}, Nobuyuki Kakiuchi, M.D.^{2*}, Makoto Onizuka, MD, PhD¹¹, Keisuke Kataoka, MD, PhD², Kenichi Chiba, PhD^{7*}, Hiroko Tanaka, BA^{7*}, Hiroo Ueno, MD^{2*}, Masahiro Marshall Nakagawa, MD, PhD¹², Hidehiro Itonaga, M.D., Ph.D.^{13*}, Yoshinobu Kanda, MD, PhD¹⁴, Yasushi Miyazaki, MD, PhD¹⁵, Keizo Horibe, MD, PhD^{16*}, Masashi Sanada, MD, PhD¹⁶, Yoichiro Kamatani, MD, Ph.D^{17*}, Michiaki Kubo, MD, Ph.D^{17*}, Satoru Miyano, PhD^{18*} and Seishi Ogawa, MD, PhD¹⁹

¹Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan

²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Tokyo University, Tokyo, Japan

⁴Center for Integrative Medical Sciences (IMS), RIKEN, Laboratory for Genotyping Development, Tsurumi, Japan

⁵Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

⁶Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan

⁷Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁸Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, KYO, Japan

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

¹¹Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan

¹²Graduate School of Medicine, Kyoto University, Kyoto, Japan

¹³Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

¹⁴Saitama Medical Ctr. Jichi Medical Univ., Saitama, Japan

¹⁵Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

¹⁶Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

¹⁷RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

¹⁸Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

¹⁹Department of Pathology and Tumor Biology, Kyoto University, Sakyo, Japan

157 Outcomes and Healthcare Utilization of Children with Mucopolysaccharidosis with and without Hematopoietic Stem Cell Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis

Hematology Disease Topics & Pathways: Pediatric, Technology and Procedures, Study Population, Clinically relevant, newborn screening

Saturday, December 1, 2018: 12:00 PM; Room 24B (San Diego Convention Center)

Cara E Carr, MD^{1*}, Nikita Goel, MD^{1*}, Nori Minich, BS^{2*}, Steven L Shein, MD^{1*} and Jignesh Dalal, MD¹

¹Rainbow Babies & Children's Hospital, Cleveland, OH

²Case Western Reserve University, Cleveland, OH

158 Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the GRNDaD Registry

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies

Saturday, December 1, 2018: 12:15 PM; Room 24B (San Diego Convention Center)

Matthew Sears, PhD¹, Sophie Lanzkron, MD, MHS², Carolyn Hoppe, MD³, Joshua J. Field, MD⁴, Payal C Desai, MD⁵, Elizabeth Williams^{6} and Jane Little, MD^{7,8}*

¹Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA

²Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD

³UCSF Benioff Children's Hospital, Oakland, CA

⁴Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

⁵Department of Hematology, The Ohio State University, Columbus, OH

⁶Johns Hopkins School of Medicine, Baltimore, MD

⁷CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH

⁸Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

207 Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question

Hematology Disease Topics & Pathways: Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, December 1, 2018: 2:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Mohamed L. Sorrow, MD, MSc^{1,2}, Barry E. Storer, PhD^{3,4}, Aaron T. Gerds, MD, MS⁵, Bruno C. Medeiros, MD⁶, Paul J Shami, MD⁷, John P. Galvin, MD, MS, MPH⁸, Kehinde U. Adekola, MBBS, MS⁹, Selina Luger, MD¹⁰, Maria R. Baer, MD¹¹, David A. Rizzieri, MD¹², Tanya M. Wildes, MD, MSCI¹³, Eunice S. Wang, MD¹⁴, Stefan Faderl, MD¹⁵, Jamie L. Koprivnikar, MD¹⁵, Mikkael A. Sekeres, MD, MS⁵, Sudipto Mukherjee, MD, PhD, MPH⁵, Julie Smith, MD^{16*}, Mitchell Garrison, MD^{16*}, Kiarash Kojouri, MD^{17*}, Jennifer E. Nyland, PhD^{1*}, Rachelle R. Moore, BS^{1*}, Sophie L. Fleuret, BS^{1*}, Ylinne Lynch, MD^{1,18*}, Pamela S. Becker, MD^{1,19}, Mary-Elizabeth M. Percival, MD, MS^{1,19}, Brenda M. Sandmaier, MD^{1,2}, Frederick R. Appelbaum, MD^{1,2} and Elihu H. Estey, MD^{1,19}*

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

²Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

³Department of Biostatistics, University of Washington School of Public Health, Seattle, WA

⁴Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

⁶Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA

⁷Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

⁸Feinberg School of Medicine, Northwestern University, Chicago, IL

⁹Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL

¹⁰Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA

¹¹University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

¹²Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

¹³Division of Oncology, Washington University School of Medicine, St Louis, MO

¹⁴Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁵John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁶Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA

¹⁷Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA

¹⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA

¹⁹Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development

Hematology Disease Topics & Pathways: Diseases, Therapies, Non-Biological, chemical interactions,

MDS, Biological Processes, Technology and Procedures, Clinically relevant, Myeloid Malignancies, genomics, RNA sequencing

Saturday, December 1, 2018: 2:00 PM; Room 7B (San Diego Convention Center)

Valeria Visconte, PhD¹, Bartlomiej P. Przychodzen^{1*}, Vera Adema, PhD^{1*}, Cassandra M. Hirsch^{2*}, Allison Noe^{2*}, Rachel Toth^{2*}, Christina Snider, BA², Hassan Awada, MD¹, Amy C Graham, BS, MS^{3*}, Yvonne Parker^{4*}, Yuriy Fedorov^{5*}, **Drew Adams^{5*}**, **Hetty E. Carraway, MD, MBA^{6,7}**, **Anjali S. Advani, MD⁸**, **Tomas Radivoyevitch^{2*}**, Heesun J. Rogers, MD, PhD⁹, Kevin R Kelly, MD, PhD^{10*}, Steffan T. Nawrocki, PhD¹¹, Jennifer S. Carew, PhD¹², **Daniel Lindner, MD, PhD^{2*}**, **Richard A Padgett^{13*}**, **Mikael A. Sekeres, MD, MS¹⁴**, **James G Phillips, PhD^{1*}** and **Jaroslav P. Maciejewski¹**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Genetics and Genome Sciences, Small-Molecule Drug Development Core, Case Western Reserve University School of Medicine, Cleveland

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Leukemia Program, Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Hematopathology, Cleveland Clinic, Cleveland

¹⁰Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA

¹¹Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ

¹²The University of Arizona Cancer Center, Tucson, AZ

¹³Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH

¹⁴Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH

216 A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development

Hematology Disease Topics & Pathways: Non-Biological, Therapies, chemical interactions, Biological Processes, epigenetics

Saturday, December 1, 2018: 3:15 PM; Room 7B (San Diego Convention Center)

Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD*, Charlotte Jarman*, Anand D. Tiwari, PhD*, **James G Phillips, PhD***, Caroline Schuerger*, Babal K. Jha* and **Yogenthiran Saunthararajah, MD**

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

217 Hepatocyte-Derived Tissue Plasminogen Activator Regulates Systemic Fibrinolysis

Program: Oral and Poster Abstracts

Type: Oral

Session: 321. Blood Coagulation and Fibrinolytic Factors: Animal Models and Therapeutic Targets in Thrombosis and Hemostasis

Hematology Disease Topics & Pathways: Diseases, Hemostasis, Bleeding and clotting, Biological Processes, Thrombosis

Saturday, December 1, 2018: 4:00 PM; Room 28D (San Diego Convention Center)

Ze Zheng, MD, PhD¹, Lalitha V. Nayak, MD², **Mukesh Jain, MD^{3*}** and Ira Tabas, MD, PhD^{4*}

¹Department of Medicine, Columbia University, New York, NY

²University Hospitals Cleveland Medical Center, Cleveland, OH

³Case Western Reserve University / University Hospitals Health System, Cleveland, OH

⁴Department of Medicine, Columbia University, New York City, NY

268 High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease

Program: Oral and Poster Abstracts

Type: Oral

Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Sickle Cell Disease—Role of Coagulation and Inflammation in Pathophysiology

Hematology Disease Topics & Pathways: Sickle cell disease, Diseases, Animal models, Biological Processes, Hemoglobinopathies, Study Population, Clinically relevant, inflammation, pathogenesis
Sunday, December 2, 2018: 8:15 AM; Room 33B (San Diego Convention Center)

Erica Sparkenbaugh, PhD, BS^{1*}, Kathryn Wilson, BS^{2*}, Malgorzata Kasztan, PhD^{3*}, David M. Pollock, PhD^{3*}, Keith R. McCrae, MD⁴ and Rafal Pawlinski, PhD⁵

¹UNC Chapel Hill McAllister Heart Institute, Chapel Hill, NC

²McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC

³Department of Medicine Division of Nephrology, The University of Alabama at Birmingham, Birmingham, AL

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC

308 Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, thalassemia, Pediatric, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, transplantation

Sunday, December 2, 2018: 7:45 AM; Grand Hall A (Manchester Grand Hyatt San Diego)

Chunfu Li, MD^{1,2}, Vikram Mathews, MD³, Biju George, DM³, Soyoung Kim^{4*}, Kyle Hebert^{5*}, Hua Jiang, MD^{6*}, Changgang Li, MD^{7*}, Yiping Zhu^{8*}, Daniel A Keesler, BS^{9*}, Rajni Agarwal, MD¹⁰, Jaap Jan Boelens, MD, PhD¹¹, Christopher C. Dvorak, MD¹², Jeffery Auletta, MD¹³, Rakesh K. Goyal, MBBS, MD^{14,15}, **Rabi Hanna, MD¹⁶**, Kimberly A. Kasow, DO^{17*}, David Margolis, MD⁹, Shalini Shenoy, MD¹⁸, Mark C. Walters, MD¹⁹ and Mary Eapen, MBBS, MS⁹

¹Nanfeng-Chunfu Children's Institute of Hematology & Oncology, Taixin Hospital, Dongguan, China

²Nanfeng Hosp. Southern Medical University, Guangzhou, China

³Department of Haematology, Christian Medical College, Vellore, India

⁴Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵CIBMTR and Medical College of Wisconsin, Milwaukee, WI

⁶Guangzhou Women and Children's Medical Center, Guangzhou, China

⁷Shenzhen Children's Hospital, Shenzhen, China

⁸West China Second University Hospital, Sichuan University, Chengdu, China

⁹Medical College of Wisconsin, Milwaukee, WI

¹⁰Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA

¹¹Pediatric Blood and Marrow Transplantation Program, Pediatric Blood and Marrow Transplantation Program University Hospital Utrecht, Utrecht, Netherlands

¹²Department of Pediatrics, University of California – San Francisco, San Francisco, CA

¹³Nationwide Children's Hospital, Columbus, OH

¹⁴Children's Mercy Hospital, Kansas City, MO

¹⁵School of Medicine, University of Missouri, Kansas City, Kansas City, KS

¹⁶Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

¹⁷University of North Carolina, Chapel Hill

¹⁸Washington University Medical Center, Saint Louis, MO

¹⁹UCSF Benioff Children's Hospital, Oakland, CA

314 Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 901. Health Services Research—Non-Malignant Conditions: Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Adult, Hemoglobinopathies, Study Population, Quality Improvement

Sunday, December 2, 2018: 7:45 AM; Room 28D (San Diego Convention Center)

Nebras Abu Al Hamayel, MBBS, MPH^{1*}, Jasmine Brooks, BA^{2*}, Hang Wang, PhD^{2*}, Rebecca Seufert, BS^{3*}, Carlton Haywood Jr., PhD, MA^{4*}, Ravi Varadhan, PhD^{5*}, Mustapha Saheed, MD^{6*}, Jodi Segal, MD^{7*}, Chiung-Yu Huang, PhD^{8*}, Joshua J. Field, MD⁹, Steven Frymark^{10*}, Jane Little, MD^{11,12}, Brandi Griffin, BSN, RN^{13*}, Nicole Arnold^{14*}, Joseph Ryan Shows, MD^{15*}, Allie Piehet, BS^{16*}, Marc Proudford^{17*}, Derek Robertson, MBA, JD^{18*}, Marcus Wallace, MD^{19*}, Adrienne Kincaid^{20*}, Charles Green^{21*}, Lorri Burgess, BS^{22*} and Sophie Lanzkron, MD^{23,24}

¹Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

²Johns Hopkins University, School of Medicine, Baltimore, MD

³School of Medicine, Johns Hopkins University, Baltimore, MD

⁴The Johns Hopkins University, Baltimore, MD

⁵Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD

⁶Johns Hopkins University, School of Medicine, Baltimore, MD

⁷School of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD

⁸Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA

⁹Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

¹⁰Froedtert Adult Sickle Cell Clinic, Blood Center of Wisconsin, Inc, Milwaukee

¹¹CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH

¹²Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

¹³Case Western Reserve University Hospital, Cleveland

¹⁴Case Western Reserve University Hospital, CI, OH

¹⁵Our Lady of the Lake Hospital, Baton Rouge

¹⁶Our Lady of the Lake Regional Medical Center, Baton Rouge, LA

¹⁷Johns Hopkins Community Based Organization Partner, Baltimore

¹⁸Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia

¹⁹Louisiana Health Care Connection, Baton Rouge, LA

²⁰Community Based Organization Partner, Kincaid's Kindred Spirits, Euclid

²¹Community Based Organization Partner, Blood Center of Wisconsin, Milwaukee

²²Community Based Organization Partner, Lady of the Lake Regional Medical Center, Baton Rouge, LA

²³Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

²⁴Department of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD

331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Combination Therapy
Hematology Disease Topics & Pathways: Diseases, AML, Adult, Therapies, Non-Biological, Study Population, Myeloid Malignancies

Sunday, December 2, 2018: 9:30 AM; Grand Hall B (Manchester Grand Hyatt San Diego)

Daniel J. DeAngelo, MD¹, Brian A. Jonas, MD, PhD², Jane L. Liesveld, MD³, Dale L. Bixby, MD, PhD^{4*}, Anjali S. Advani, MD⁵, Paula Marlton⁶, Michael E O'Dwyer, MD⁷, William E Fogler, PhD⁸, Curt D Wolfgang, PhD^{8*}, John L Magnani, PhD⁸, Helen M Thackray, MD⁸ and Pamela S. Becker, MD^{9,10}

¹Dana-Farber Cancer Inst., Boston, MA

²University of California, Davis, Sacramento, CA

³Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

⁴Internal Medicine, University of Michigan, Ann Arbor, MI

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Faculty of Medicine, University of Queensland, Brisbane, Australia

⁷National University of Ireland Galway, Galway City, Ireland

⁸GlycoMimetics, Inc., Rockville, MD

⁹Division of Hematology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁰Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

353 A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3K γ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs

Hematology Disease Topics & Pathways: Diseases, MPN, Myeloid Malignancies

Sunday, December 2, 2018: 10:30 AM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

Naval G. Daver, MD¹, Marina Kremyanskaya, MD, PhD^{2*}, Casey O'Connell, MD^{3*}, Kim-Hien Dao, DO, PhD⁴, Stephen T Oh, MD, PhD⁵, **Aaron T. Gerds, MD, MS⁶**, Srdan Verstovsek, MD, PhD⁷, Sue Erickson-Viitanen, PhD^{8*}, Feng Zhou^{8*}, Albert Assad, MD^{8*} and Abdulraheem Yacoub, MD^{9*}

¹The University of Texas MD Anderson Cancer Center, Houston, TX

²Mount Sinai Health System, New York, NY

³University of Southern California, Los Angeles, CA

⁴Oregon Health & Science University, Portland, OR

⁵Washington University School of Medicine, Saint Louis, MO

⁶Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷University of Texas MD Anderson Cancer Center, Houston, TX

⁸Incyte Corporation, Wilmington, DE

⁹University of Kansas Medical Center, Kansas City, KS

366 Economic Burden of Venous Thromboembolism in Cancer Patients - a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism

Program: Oral and Poster Abstracts

Type: Oral

Session: 901. Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thromboembolism, Clinically relevant, Quality Improvement

Sunday, December 2, 2018: 10:45 AM; Room 8 (San Diego Convention Center)

Surbhi Shah¹, Nathan Rubin, MS^{2*} and **Alok A. Khorana^{3,4,5,6,7,8,9}**

¹University of Minnesota, Minneapolis, MN

²UNIVERSITY OF MINNESOTA, Minneapolis, MN

³Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland

⁹Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH

371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Program: Oral and Poster Abstracts

Type: Oral

Session: 904. Outcomes Research—Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018: 10:30 AM; Room 25B (San Diego Convention Center)

Raffi Tchekmedyian, BS¹, **Tomas Radivoyevitch, PhD^{2*}**, **Aaron T. Gerds, MD, MS³**, **Aziz Nazha, MD⁴**, **Hetty E. Carraway, MD, MBA^{5,6}**, **Anjali S. Advani, MD⁶**, **Jaroslav P. Maciejewski²**, **Matt Kalaycio, MD⁷**, **Navneet S. Majhail, MD, MS⁷**, **Mikhael A. Sekeres, MD, MS⁸** and **Sudipto Mukherjee, MD, PhD, MPH⁸**

¹Cleveland Clinic Foundation, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

398 Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents

Hematology Disease Topics & Pathways:

Adult, Diseases, Biological, Therapies, B-Cell Lymphoma, Study Population, Lymphoid Malignancies

Sunday, December 2, 2018: 12:15 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

John Radford, MD, FRCP^{1*}, Brad S. Kahl, MD^{2*}, Mehdi Hamadani, MD³, Carmelo Carlo-Stella, MD⁴, Paolo Caimi, MD⁵, Kirit M. Ardeschna, MBBChir⁶, Jay Feingold, MD, PhD^{7*}, Shui He, PhD^{8*}, Erin Reid, MD^{9*}, Melhem Solh, MD¹⁰, Ki-Young Chung, MD^{11*}, Leonard Heffner, MD¹², David Ungar, MD^{13*} and Owen A. O'Connor, M.D., Ph.D.¹⁴

¹Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

²Siteman Cancer Center, Washington University, St Louis, MO

³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

⁴Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

⁵University Hospitals of Cleveland, Cleveland, OH

⁶Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom

⁷ADC Therapeutics, Inc, Murray Hill, NJ

⁸ADC Therapeutics, Inc., Murray Hill, NJ

⁹Department of Hematology/Oncology, Moores Cancer Center, University of California, San Diego, CA

¹⁰Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

¹¹Department of Hematology and Oncology, Greenville Health System, Greenville, SC

¹²Winship Cancer Institute / Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

¹³ADC Therapeutics America, Inc, Murray Hill

¹⁴Center for Lymphoid Malignancies, Department of Medicine, Columbia University, New York, NY

416 The Platelet Factor-4 (PF4)-Dependent p-Selectin Expression Assay (PEA) Is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Results of a 440-Sample Prospective Blinded Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, HIT

Sunday, December 2, 2018: 4:45 PM; Room 30D (San Diego Convention Center)

Deepti M. Warad, MD^{1,2}, Bethany T Samuelson Bannow, MD³, Curtis Jones, BS^{4*}, Shannon Pechauer^{4*}, Brian R. Curtis, PhD⁵, Daniel W. Bougie, PhD⁴, Parisa R Khalighi, BS⁶, Diane E. Grill, MS^{7*}, Rachel Leger, BAE^{8*}, Ruchika Sharma, MD⁹, Dong Chen, MD, PhD¹⁰, Richard H. Aster, MD¹¹, David A. Garcia¹² and Anand Padmanabhan, MD, PhD¹³

¹Division of Hematopathology, Special Coagulation Laboratory, Mayo Clinic, Rochester, MN

²Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN

³Department of Medicine, Division of Hematology, Oregon Health & Science University, Portland, OR

⁴BloodCenter of Wisconsin, Milwaukee, WI

⁵Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI

⁶Case Western Reserve University School of Medicine, Cleveland, OH

⁷Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

⁸Special Coagulation Laboratory, Mayo Clinic, Rochester, MN

⁹BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI

¹⁰Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

¹¹Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI

¹²Department of Medicine, Division of Hematology, University of Washington, Seattle, WA

¹³Pathology/Transfusion Medicine, Bloodcenter Of Wisconsin, Milwaukee, WI

417 Risk of Venous Thrombosis in Patients with Sickle Cell Trait after Orthopedic Surgery

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism

Hematology Disease Topics & Pathways: Diseases, Biological Processes, Hemoglobinopathies, Clinically relevant, immune mechanism, inflammation

Sunday, December 2, 2018: 5:00 PM; Room 30D (San Diego Convention Center)

Jahnvi Gollamudi, MD^{1*}, Sadeer Al-Kindi, M.D.^{2*}, Petra Martin^{3*}, Jane Little, MD^{4,5} and Lalitha V. Nayak, MD³

¹Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

²University hospitals case medical center, Cleveland

³University Hospitals Cleveland Medical Center, Cleveland, OH

⁴CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH

⁵Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

425 Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience

Program: Oral and Poster Abstracts

Type: Oral

Session: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios

Hematology Disease Topics & Pathways: Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, HIT, Study Population, serologic tests

Sunday, December 2, 2018: 5:30 PM; Room 33B (San Diego Convention Center)

Daniel S Carlson, DO^{1*}, Keith R. McCrae, MD² and Shruti Chaturvedi, MBBS, MS³

¹Cleveland Clinic Foundation, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

437 Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Minimal Residual Disease and Genetic Characterization

Hematology Disease Topics & Pathways: AML, Diseases, Therapies, Non-Biological, Elderly, chemotherapy, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, flow cytometry

Sunday, December 2, 2018: 5:30 PM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

James M. Foran, MD¹, Zhuoxin Sun, PhD^{2*}, Elisabeth Paietta, PhD³, Janis Racevskis, PhD^{3*}, David F. Claxton, MD⁴, Hillard M Lazarus, MD⁵, Daniel A. Arber, MD⁶, Jacob M. Rowe, MD⁷, Jessica K. Altman, MD⁸, Aref Al-Kali, MD⁹, Hong Zheng, MD, PhD¹⁰, Keith W. Pratz, MD¹¹, Edward R. Broun, MD¹², Bayard L. Powell, MD¹³, Kristen Marie O'Dwyer, MD¹⁴, John Godwin, MD¹⁵, Yanming Zhang, MD¹⁶, Martin S. Tallman, MD¹⁷, Selina Luger, MD¹⁸ and Mark R. Litzow, MD¹⁹

¹Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

²ECOG-ACRIN statistical center, Boston

³Cancer Center, Montefiore Medical Center, Bronx, NY

⁴Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁶University of Chicago, Chicago, IL

⁷The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

⁸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

⁹Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN

¹⁰Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA

¹¹John Hopkins University, Baltimore, MD

¹²OHC, Inc., Cincinnati, OH

¹³Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

¹⁴University of Rochester Medical Center, Rochester, NY

¹⁵Providence Portland Medical Center, Portland, OR

¹⁶Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

¹⁷Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

¹⁸Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹⁹Division of Hematology, Mayo Clinic, Rochester, MN

451 Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Biological, Therapies, Lymphoma (any), DLBCL, chemotherapy, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018: 4:30 PM; Ballroom 20D (San Diego Convention Center)

Shalin K. Kothari, MD¹, Shaoying Li, MD^{2*}, L. Jeffrey Medeiros, MD², Emily C. Ayers, MD³, Daniel J.

Landsburg, MD⁴, David A. Bond, MD⁵, Kami J. Maddocks, MD⁶, Anshu Giri, MD^{7*}, Brian T. Hess, MD⁸, Luu

Q. Pham^{9*}, Ranjana H. Advani, MD⁹, Yang Liu, MD^{10*}, Stefan Klaus Barta, MD, MRCP, MS¹¹, Julie M. Vose,

MD, MBA¹², Michael C. Churnetski, BS^{13*}, Jonathon B. Cohen, MD, MS¹⁴, Madelyn Burkart, MD^{15*}, Reem

Karmali, MD¹⁶, Joanna Zurko, MD^{17*}, Amitkumar Mehta, MD^{17*}, Adam J Olszewski, MD¹⁸, Sarah S Lee,

MD¹⁹, Brian T. Hill, MD, PhD^{20,21}, Timothy F. Burns, MD²², Frederick Lansigan, MD²², Emma Rabinovich,

MD^{23*}, David Peace, MD²⁴, Adrienne Groman, MS^{25*}, Kris Attwood, PhD, MS^{25*}, Francisco J. Hernandez-

Ilizaliturri, MD²⁶ and Pallawi Torka, MD²⁵

¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

²Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

³University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

⁴Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁵Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH

⁶Division of Hematology, Ohio State University Hospital, Columbus, OH

⁷Medical University of South Carolina, Charleston, SC

⁸Division of Hematology/Oncology; Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC

⁹Stanford University, Stanford, CA

¹⁰Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

¹¹Fox Chase Cancer Center, Philadelphia, PA

¹²University of Nebraska Medical Center, Omaha, NE

¹³Winship Cancer Institute--Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹⁴Winship Cancer Institute, Emory University, Atlanta, GA

¹⁵Northwestern University, Chicago, IL

¹⁶Division of Hematology, Northwestern University, Chicago, IL

¹⁷University of Alabama at Birmingham, Birmingham, AL

¹⁸Department of Medicine, Alpert Medical School of Brown University, Providence, RI

¹⁹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁰Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²²Dartmouth-Hitchcock Medical Center, Lebanon, NH

²³University of Illinois at Chicago, Chicago, IL

²⁴Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago

²⁵Roswell Park Comprehensive Cancer Center, Buffalo, NY

²⁶Departments of Medicine and Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

453 Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018: 5:00 PM; Ballroom 20D (San Diego Convention Center)

Emily C. Ayers, MD¹, Shaoying Li, MD^{2*}, Jeffrey Medeiros, MD^{2*}, David A. Bond, MD³, Kami J. Maddocks, MD⁴, Pallawi Torka, MD⁵, Angel Mier Hicks, MD^{6*}, Madeira Curry^{7*}, Nina D. Wagner-Johnston, MD⁷, Reem Karmali, MD⁸, Amir Behdad, MD^{9*}, Bitu Fakhri, MD, MPH¹⁰, Brad S Kahl, MD¹¹, Michael C Churnetski, BS^{12*}, Jonathon B. Cohen, MD, MS¹³, Nishitha Reddy, MD¹⁴, Dipenkumar Modi, MD¹⁵, Radhakrishnan Ramchandren, MD¹⁶, Christina Howlett, PharmD, BCOP^{17*}, Lori A. Leslie, MD¹⁸, Samuel Cytryn^{19*}, Catherine Diefenbach, MD²⁰, Rawan Faramand, MD²¹, Julio C. Chavez, MD²², Adam J Olszewski, MD²³, Yang Liu, MD^{24*}, Stefan Klaus Barta, MD, MRCP, MS²⁵, Dhruvika Mukhija, MD^{26*}, **Brian T. Hill, MD, PhD^{27,28}**, Helen Ma, MD²⁹, Jennifer E Amengual, MD³⁰, Sunita Nathan, MD³¹, Sarit Assouline, MD³², Victor M. Orellana-Noia, MD³³, Craig A. Portell, MD³⁴, Ashwin Chandar, MD³⁵, Kevin A. David, MD^{36*}, Anshu Giri, MD^{37*}, Brian T. Hess, MD³⁸ and Daniel J. Landsburg, MD³⁹

¹University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

²Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

³Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH

⁴Ohio State University Hospital, Columbus, OH

⁵Roswell Park Comprehensive Cancer Center, Buffalo, NY

⁶University at Buffalo, Buffalo, NY

⁷Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁸Division of Hematology, Northwestern University, Chicago, IL

⁹Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL

¹⁰Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

¹¹Department of Medicine, Washington University School of Medicine, Saint Louis, MO

¹²Winship Cancer Institute, Emory University, Atlanta, GA

¹³Emory University, Atlanta, GA

¹⁴Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

¹⁵Department of Hematology/Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹⁶Department of Oncology, Karmanos Cancer Institute, Detroit, MI

¹⁷John Theurer Cancer Center Hackensack Meridian Health, Hackensack, NJ

¹⁸John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

¹⁹NYU Langone Health; NYU Perlmutter Cancer Center, New York, NY

²⁰New York University School of Medicine, NYU Cancer Institute, New York, NY

²¹Moffitt Cancer Center/ Malignant Hematology, University of South Florida, Tampa, FL

²²H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

²³Division of Hematology-Oncology, Memorial Hospital of Rhode Island, Providence, RI

²⁴Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

²⁵Fox Chase Cancer Center, Philadelphia, PA

²⁶Cleveland Clinic, Cleveland, OH

²⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁹Columbia University Medical Center, New York, NY

³⁰Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY

³¹Rush University Medical Center, Chicago, IL

³²McGill University Jewish General Hospital, Montreal, QC, Canada

³³Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA

³⁴Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

³⁵Cancer Institute of New Jersey, New Brunswick, NJ

³⁶Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

³⁷Medical University of South Carolina, Charleston, SC

³⁸Division of Hematology/Oncology; Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC

³⁹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

[**455 Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Biological Processes, Non-Hodgkin Lymphoma, B-Cell Lymphoma, enzyme inhibitors, Study Population, Lymphoid Malignancies, Clinically relevant, signal transduction

Sunday, December 2, 2018: 5:30 PM; Ballroom 20D (San Diego Convention Center)

Daniel J. Landsburg, MD¹, Mitchell E. Hughes, PharmD^{1}, Alexa Koike^{1*}, David A. Bond, MD², Kami J. Maddocks, MD², Ling Guo, MD^{3*}, Allison M. Winter, MD⁴, **Brian T. Hill, MD, PhD^{4,5}**, Sarah L. Ondrejka, DO⁴, Eric D. Hsi, MD⁴, Sunita Dwivedy Nasta, MD¹, Jakub Svoboda, MD¹, Stephen J. Schuster, MD¹ and Agata M. Bogusz, MD, PhD^{1*}*

¹University of Pennsylvania, Philadelphia, PA

²Ohio State University, Columbus, OH

³Department of Pathology, Ohio State University, Columbus, OH

⁴Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

[**495 Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Hemophilia, Thrombosis, ITP, and Hereditary Transthyretin Amyloidosis

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Hodgkin Lymphoma, Biological Processes, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant, inflammation

Sunday, December 2, 2018: 5:00 PM; Room 24B (San Diego Convention Center)

Jahnavi Gollamudi, MD^{1}, Gouri Dharmavaram^{2*}, Petra Martin^{3*}, Kirsten Marie Boughan, DO⁴, **Brenda Cooper, MD⁴, Molly M Gallogly, MD, PhD⁴, Ehsan Malek, MD⁵, Leland Metheny, MD⁴, Folashade Otegbeye, MBBChir, MPH⁴**, Benjamin K. Tomlinson, MD⁶, **Marcos de Lima, MD⁴**, Lalitha V. Nayak, MD³ and **Paolo Caimi, MD⁴***

¹Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

²School of Medicine, Case Western Reserve University, Cleveland

³University Hospitals Cleveland Medical Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁶University Hospitals Seidman Cancer Center, Cleveland, OH

[**509 Efficacy and Safety of 1500mg Voxelotor in a Phase 2a Study \(GBT440-007\) in Adolescents with Sickle Cell Disease**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Novel or Improved Approaches To Treating Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Young Adult, Study Population

Monday, December 3, 2018: 8:00 AM; Room 28D (San Diego Convention Center)

Clark Brown¹, Carolyn Hoppe, MD², Adlette Inati³, Miguel R. Abboud⁴, Winfred Wang, MD⁵, Robert Liem, MD⁶, Gerald Woods⁷, Lewis L. Hsu⁸, Victor R. Gordeuk, MD⁸, Connie Piccone⁹, Richard A. Drachtman¹⁰, Erica Fong^{11}, Sandra Dixon^{11*}, Margaret Tonda, PharmD^{11*}, Carla Washington^{11*} and Joshua Lehr-Grauer¹¹*

¹Children's Healthcare of Atlanta, Atlanta, GA

²UCSF Benioff Children's Hospital, Oakland, CA

³Rafik Hariri University Hospital, Beirut, Lebanon

⁴American University of Beirut Medical Center, Beirut, Lebanon

⁵St. Jude Children's Research Hospital, Memphis, TN

⁶Ann and Robert Lurie Children's Hospital of Chicago, Chicago, IL

⁷Children's Mercy Hospital, Kansas City, Kansas City, MO

⁸University of Illinois at Chicago, Chicago, IL

⁹UH Rainbow Babies and Children's Hospital, Cleveland, OH

¹⁰Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

¹¹Global Blood Therapeutics, South San Francisco, CA

516 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Program: Oral and Poster Abstracts

Type: Oral

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: B and T Cell Biology

Hematology Disease Topics & Pathways: Leukemia, Diseases, LGLL, Lymphoid Malignancies

Monday, December 3, 2018: 8:15 AM; Room 8 (San Diego Convention Center)

Cassandra M. Hirsch^{1*}, Michael Clemente, MS^{2*}, Peter Chomczynski^{2*}, Bartłomiej P. Przychodzen^{3*}, Yasunobu Nagata^{4*}, Vera Adema, PhD^{5*}, Louis Williams, MD, MBA¹, Valeria Visconte, PhD², Alan Lichtin, MD⁶, Satu Mustjoki, MD, PhD⁷, Mikkael A. Sekeres, MD, MS⁸ and Jaroslaw P. Maciejewski^{1,9}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

537 Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Acquired Bone Marrow Failure and Somatic Genetics

Hematology Disease Topics & Pathways: Diseases, Anemias, Adult, aplastic anemia, Bone Marrow Failure, Elderly, Biological Processes, Technology and Procedures, Study Population, immune mechanism, NGS, pathogenesis

Monday, December 3, 2018: 7:30 AM; Grand Ballroom 2 (Marriott Marquis San Diego Marina)

Sofie Lundgren, BMed^{1*}, Jani Huuhtanen, BMed^{1,2*}, Mikko A Keränen, MD, PhD^{1*}, Cassandra M. Hirsch^{3*}, Emmi Jokinen, MSc^{2*}, Markus Heinonen, PhD^{2,4*}, Paula Savola, MD^{1*}, Tiina Kelkka, PhD^{1*}, Freja Ebeling, MD, PhD^{5*}, Jaroslaw P. Maciejewski³, Eva Hellstrom Lindberg, MD, PhD⁶, Harri Lähdesmäki, PhD^{2*} and Satu Mustjoki, MD, PhD^{1,7}

¹Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

²Department of Computer Science, Aalto University School of Science, Espoo, Finland

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Helsinki Institute for Information Technology, Helsinki, Finland

⁵Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

⁶Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

⁷Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

564 Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Targeted Therapy
Hematology Disease Topics & Pathways: Adult, Diseases, AML, Therapies, Non-Biological, Study
Population, Myeloid Malignancies, pharmacology

Monday, December 3, 2018: 8:15 AM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

Keith W. Pratz, MD¹, Mohamad Cherry, MD, MS², Jessica K. Altman, MD³, **Brenda Cooper, MD⁴**, Jose Carlos Cruz, MD⁵, Joseph G. Jurcic, MD⁶, Mark J. Levis, MD⁷, Tara L Lin, MD^{8,9}, Alexander E. Perl, MD¹⁰, Nikolai A. Podoltsev, MD, PhD¹¹, Gary J. Schiller, MD¹², Chaofeng Liu, PhD, MBA^{13*} and Erkut Bahceci, MD¹³

¹John Hopkins University, Baltimore, MD

²Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

³Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

⁴Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Methodist Physician Practices, San Antonio, TX

⁶Columbia University Medical Center, New York, NY

⁷Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁸University of Kansas Medical Center, Kansas City, KS

⁹Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS

¹⁰Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA

¹¹Yale School of Medicine, New Haven, CT

¹²David Geffen School of Medicine at UCLA, Los Angeles, CA

¹³Astellas Pharma Global Development, Northbrook, IL

575 Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes Of Lymphoma In The Elderly

Hematology Disease Topics & Pathways: Diseases, Adult, Lymphoma (any), Elderly, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018: 8:00 AM; Pacific Ballroom 18 (Marriott Marquis San Diego Marina)

Madison Keenan^{1*}, Kirsten Marie Boughan, DO², **Brenda Cooper, MD²**, **Molly M Gallogly, MD, PhD²**, **Stanton L. Gerson, MD³**, **Hillard M Lazarus, MD²**, **Ehsan Malek, MD⁴**, **Leland Metheny, MD²**, **Folashade Otegbeye, MBBChir, MPH²**, Benjamin K. Tomlinson, MD², Erika Moore, MD^{5*}, Kwadwo Asare Oduro, MD, PhD⁵, **Rose Beck, MD, PhD^{5*}**, **Howard Meyerson, MD^{5*}**, **Marcos de Lima, MD²** and **Paolo F Caimi, MD⁶**

¹Case Western Reserve University, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁵Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

697 Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Program: Oral and Poster Abstracts

Type: Oral

Session: 703. Adoptive Immunotherapy: In Vitro, Correlative, and Early Phase Studies to Improve Safety and Efficacy of CAR-T Cells

Hematology Disease Topics & Pathways: Biological, Diseases, bioengineering, Therapies, CAR-Ts, Non-

Hodgkin Lymphoma, Technology and Procedures, B-Cell Lymphoma, gene therapy, immunotherapy, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 10:30 AM; San Diego Ballroom B (Marriott Marquis San Diego Marina)

Jennifer Brudno, MD¹, Steven Hartman^{2}, Norris Lam, BS^{3*}, David F. Stroncek⁴, John M. Rossi, MS^{5*}, Yueh-wei Shen^{5*}, Allen Xue, PhD^{5*}, Adrian Bot, MD, PhD^{5*}, Jennifer A Kanakry, MD^{3*}, Steven Z. Pavletic, MD⁶, Lekha Mikkilineni, MD^{7*}, Mark Roschewski, MD⁸, **Robert M. Dean, MD⁹**, Jeremy J. Rose, MS^{3*}, Rashmika Patel^{2*}, Brenna Hansen^{2*}, Steve A. Rosenberg^{10*}, Ronald E. Gress, MD¹¹ and James N. Kochenderfer, MD¹²*

¹Experimental Transplantation and Immunology Branch, NIH, NCI, Bethesda, MD

²NIH, NCI, Bethesda

³Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

⁴National Institutes of Health, Clinical Center, Transfusion Medicine Department, Bethesda, MD

⁵Kite, a Gilead Company, Santa Monica, CA

⁶Experimental Transplantation and Immunology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD

⁷National Institutes of Health Clinical Center, Bethesda, MD

⁸Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁰Surgery Branch, National Institutes of Health Clinical Center, Bethesda, MD

¹¹Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

¹²Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

704 Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse

Hematology Disease Topics & Pathways: Diseases, Biological, CML, Therapies, Clinically relevant, Myeloid Malignancies, transplantation, TKI

Monday, December 3, 2018: 10:45 AM; Grand Hall B (Manchester Grand Hyatt San Diego)

Sarah Ann Schmidt, PharmD^{1}, Jennifer Holter Chakrabarty, MD^{2*}, Ying Liu, PhD^{3,4*}, Zhen-Huan Hu, MPH^{3*}, Kirsten M. Williams, MD⁵, Edwin P. Alyea III, MD⁶, Uday Popat, MD⁷, **Ronald Sobecks, MD⁸**, Bart L Scott, MD⁹ and Wael Saber, MD, MS^{3*}*

¹University of Oklahoma, Oklahoma City, OK

²Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee

⁵CETI, Children's National Medical Center, Washington, DC

⁶Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA

⁷Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research

Hematology Disease Topics & Pathways: Quality Improvement

Monday, December 3, 2018: 11:15 AM; Room 24B (San Diego Convention Center)

Madeline Waldron, PharmD^{1}, Caitlin Siebenaller, PharmD^{2*}, Marc Earl, PharmD^{2*}, **Hetty E. Carraway, MD, MBA^{3,4}**, Anjali S. Advani, MD⁵, Aziz Nazha, MD⁶, Aaron T. Gerds, MD, MS³, Betty K. Hamilton, MD³, Ronald Sobecks, MD⁷, Matt Kalaycio, MD⁷, Barb Tripp, CNS^{8*}, Brian P. Hobbs, PhD^{9*}, Sudipto Mukherjee, MD, PhD, MPH¹⁰ and Mikkael A. Sekeres, MD, MS¹¹*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pharmacy, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Cleveland Clinic, Cleveland, OH

⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

714 Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research

Hematology Disease Topics & Pathways: Pediatric, Study Population, Quality Improvement

Monday, December 3, 2018: 11:45 AM; Room 24B (San Diego Convention Center)

Kira O Bona, MD, MPH^{1}, Ruta Brazauskas, PhD^{2,3*}, Naya He^{3*}, Leslie E. Lehmann, MD⁴, Joanne Wolfe, MD, MPH^{5*}, Jignesh Dalal, MD⁶, Shahrukh K. Hashmi, MD, MPH^{7,8}, Theresa E. Hahn, PhD⁹, Nandita Khera, MD¹⁰, William A. Wood, MD, MPH¹¹, Christine Duncan, MD¹² and Wael Saber, MD, MS^{3*}*

¹Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

²Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Dana-Farber/Boston Children's Cancer & Blood Disorders Center, Boston, MA

⁵Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

⁶Rainbow Babies & Children's Hospital, Cleveland, OH

⁷Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁸Department of Internal Medicine, Mayo Clinic, Rochester, MN

⁹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁰Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

¹¹Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC

¹²Dana-Farber Cancer Institute, Boston, MA

853 A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Pain and Pain Management in Sickle Cell Disease

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant

Monday, December 3, 2018: 4:30 PM; Room 25B (San Diego Convention Center)

Sophie Lanzkron, MD¹, Jane Little, MD^{2,3}, Joshua J. Field, MD⁴, Carlton Haywood Jr., PhD, MA^{5}, Ravi Varadhan, PhD^{6*}, Mustapha Saheed, MD^{7*}, Marc Proudford^{8*}, Derek Robertson, MBA, JD^{9*}, Adrienne Kincaid^{10*}, Lorri Burgess, BS^{11*}, Charles Green^{12*}, Hang Wang, PhD^{13*}, Rebecca Seufert, BS^{14,15*}, Jasmine Brooks, BA^{13*}, Allie Piehet, BS^{16*}, Brandi Griffin, BSN, RN^{17*}, Nicole Arnold^{18*}, Steven Frymark^{19*}, Chiung-Yu Huang, PhD^{20*}, Marcus Wallace, MD^{21*}, Nebras Abu Al Hamayel, MBBS, MPH^{22*} and Jodi Segal, MD^{23*}*

¹Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

²CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH

³Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

⁵The Johns Hopkins University, Baltimore, MD

⁶Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD

⁷Johns Hopkins University, School of Medicine, Baltimore, MD

⁸Johns Hopkins Community Based Organization Partner, Baltimore

⁹Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia

¹⁰Community Based Organization Partner, Kincaid's Kindred Spirits, Euclid

¹¹Community Based Organization Partner, Lady of the Lake Regional Medical Center, Baton Rouge, LA

¹²Community Based Organization Partner, Blood Center of Wisconsin, Milwaukee

¹³Johns Hopkins University, School of Medicine, Baltimore, MD

¹⁴Johns Hopkins School of Medicine, Baltimore, MD

¹⁵School of Medicine, Johns Hopkins University, Baltimore, MD

¹⁶Our Lady of the Lake Hospital, Baton Rouge

¹⁷Case Western Reserve University Hospital, Cleveland

¹⁸Case Western Reserve University Hospital, Cl, OH

¹⁹Blood Center of Wisconsin, Milwaukee, WI

²⁰University of California San Francisco, San Francisco, CA

²¹Louisiana Health Care Connection, Baton Rouge, LA

²²Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

²³School of Medicine, Johns Hopkins School of Medicine, Baltimore, MD

900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Program: Oral and Poster Abstracts

Type: Oral

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy
Hematology Disease Topics & Pathways: Adult, ALL, Leukemia, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Pediatric, Young Adult, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 5:45 PM; Room 6A (San Diego Convention Center)

Remco J Molenaar, MD PhD^{1,2*}, Tomas Radivoyevitch^{3*}, Aaron T. Gerds, MD, MS⁴, Aziz Nazha, MD⁵, Hetty E. Carraway, MD, MBA^{5,6}, Anjali S. Advani, MD⁶, Matt Kalaycio, MD⁷, Navneet S. Majhail, MD, MS⁸, Jaroslaw P. Maciejewski⁹, Mikkael A. Sekeres, MD, MS¹⁰ and Sudipto Mukherjee, MD, PhD, MPH¹¹

¹Academic Medical Center, Amsterdam, Netherlands

²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁴Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

928 Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Study Population, Lymphoid Malignancies

Monday, December 3, 2018: 5:15 PM; Room 6F (San Diego Convention Center)

Mehdi Hamadani, MD¹, Graham P. Collins, MB BS DPhil^{2*}, Felipe Samaniego, MD³, Alexander I Spira, MD^{4*}, Andrew Davies, MD^{5*}, John Radford, MD, FRCP^{6*}, Paolo Caimi, MD⁷, Tobias Menne, MD, PhD^{8*}, Joseph Boni, PhD^{9*}, Hans Cruz, PhD¹⁰, Jay Feingold, MD, PhD^{11*}, Shui He, PhD^{9*}, Jens Wuerthner^{10*} and Steven M. Horwitz, MD¹²

¹Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

²Oxford University Hospitals, NHS Trust, Oxford, United Kingdom

³Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Virginia Cancer Specialists Research Institute, Fairfax, VA

⁵Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom

⁶Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

⁷Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

⁸The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom

⁹ADC Therapeutics, Inc., Murray Hill, NJ

¹⁰ADC Therapeutics, Switzerland, Switzerland

¹¹ADC Therapeutics, Inc, Murray Hill, NJ

929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Hodgkin Lymphoma, chemotherapy, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 5:30 PM; Room 6F (San Diego Convention Center)

Deborah M. Stephens¹, Hongli Li, MS^{2*}, Heiko Schoder, MD^{3*}, David J. Straus, MD⁴, Craig H. Moskowitz, MD^{3*}, Michael L. Leblanc, PhD^{2*}, Lisa M. Rimsza, MD⁵, Nancy L. Bartlett, MD⁶, Andrew M. Evens, DO, MSc⁷, Ann S. LaCasce, MD, MSc⁸, Paul Barr, MD⁹, Michael V. Knopp^{10*}, Eric D. Hsi, MD¹¹, John P. Leonard, MD¹², Brad S Kahl, MD¹³, Sonali M. Smith, MD¹⁴ and Jonathan W. Friedberg, MD¹⁵

¹Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

²SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

³Memorial Sloan Kettering Cancer Center, New York, NY

⁴Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

⁵Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ

⁶Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

⁷Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

⁸Dana-Farber Cancer Institute, Partners CancerCare, Boston, MA

⁹University of Rochester, Rochester, NY

¹⁰The Ohio State University, Columbus, OH

¹¹Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

¹²Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

¹³Department of Medicine, Washington University School of Medicine, Saint Louis, MO

¹⁴University of Chicago, Chicago, IL

¹⁵Wilmot Cancer Institute, University of Rochester, Rochester, NY

971 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results I

Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, MDS, Myeloid Malignancies, transplantation

Monday, December 3, 2018: 5:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Betul Oran, MD, MS¹, Marcos de Lima, MD², Guillermo Garcia-Manero, MD³, Peter F Thall^{4*}, Ruitao Lin^{4*}, Amin M. Alousi, MD⁵, Chitra Hosing, MD⁶, Partow Kebriaei, MD¹, Uday Popat, MD¹, Sergio Giralt, MD⁷, Sairah Ahmed, MD⁵, Elizabeth J. Shpall, MD⁵, Borje S Andersson, MD, PhD⁶, Qaiser Bashir, MBBS⁶, Stefan O. Ciurea¹, Katy Rezvani, MD, PhD¹, Glenda Woodworth, BSN, OCN, RN^{1*} and Richard E Champlin, MD¹

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁴Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

⁵Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

⁶The University of Texas MD Anderson Cancer Center, Houston, TX

⁷Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

988 Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 332. Antithrombotic Therapy: New Drugs and Technology

Hematology Disease Topics & Pathways: Adult, Diseases, bioengineering, Hemostasis, Bleeding and clotting, Technology and Procedures, Study Population, Clinically relevant

Monday, December 3, 2018: 7:00 PM; Room 29C (San Diego Convention Center)

Aman Opneja, MBBS^{1,2}, Debnath Maji, M.Tech^{3*}, Pedram Mohseni, PhD^{3*}, Michael A Suster, PhD^{3*} and Evi X Stavrou, MD^{4,5}

¹Division of Hematology Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, BALTIMORE, MD

²Division of Hematology Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH

³Case Western Reserve University, Cleveland, OH

⁴Division of Hematology-Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH

⁵Case Western Reserve University/, Cleveland, OH

1015 T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute

Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy

Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, AML, Biological, Adult, Therapies, MDS, Study Population, Lymphoid Malignancies, Myeloid Malignancies, transplantation

Monday, December 3, 2018: 6:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Scott R Solomon, MD¹, Andrew St. Martin, MS^{2*}, Nirav N Shah, MD³, Giancarlo Fatobene, MD^{4*}, Monzr Al Malki, MD⁵, Karen K. Ballen, MD^{6*}, Asad Bashey, MD, PhD⁷, Nelli Bejanyan, MD⁸, Javier Bolaños-Meade, MD⁹, Claudio G Brunstein, MD, PhD¹⁰, Zachariah Defilipp, MD¹¹, Richard E Champlin, MD¹², Ephraim J. Fuchs, MD, MBA⁹, Mehdi Hamadani, MD¹³, Peiman Hematti, MD¹⁴, Christopher G. Kanakry, MD^{15*}, Joseph P. McGuirk, DO¹⁶, Ian K. McNiece, PhD^{17*}, Stefan O. Ciurea¹⁸, Marcelo C. Pasquini, MD¹⁹, Vanderson Rocha, MD, PhD^{20*}, Rizwan Romee, MD²¹, Sagar S. Patel, MD²², Sumithira Vasu, MD, MBBS²³, Edmund K. Waller, MD²⁴, John R. Wingard, MD²⁵, Mei-Jie Zhang, PhD^{26*} and Mary Eapen, MBBS, MS²

¹Blood and Marrow Transplant Program, BMT Group of Georgia, Atlanta, GA

²Medical College of Wisconsin, Milwaukee, WI

³Department of Medicine, Medical College of Wisconsin, Brookfield, WI

⁴Médico do Centro de Oncologia do Hospital Sírio-Libanês, Sao Paulo, Brazil

⁵Department of Hematology/HCT, City of Hope, Duarte, CA

⁶Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA

⁷Blood and Marrow Transplant Group of Georgia, BMT Group of Georgia, Atlanta, GA

⁸H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁰Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹¹Department of Hematology and Medical Oncology, Winship Cancer Institute, Massachusetts General Hospital, Boston, MA

¹²The University of Texas MD Anderson Cancer Center, Houston, TX

¹³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

¹⁴Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI

¹⁵Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

¹⁶Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

¹⁷CellMED Consulting, Miami, FL

¹⁸Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

¹⁹CIBMTR and Medical College of Wisconsin, Milwaukee, WI

²⁰Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil

²¹Department of Medicine, Division of Oncology, Dana Farber Cancer Institute, Boston, MA

²²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²³Hematology, The Ohio State University, Columbus, OH

²⁴Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

²⁵University of Florida Department of Medicine/Division of Hematology Oncology, Gainesville, FL

²⁶CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

1017 Targeted Conditioning of Iomab-B (¹³¹I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy
Hematology Disease Topics & Pathways: Diseases, AML, Biological, antibodies, Adult, Therapies, bone marrow, Elderly, Biological Processes, Technology and Procedures, immunotherapy, Study Population, Clinically relevant, Myeloid Malignancies, transplantation, stem cells

Monday, December 3, 2018: 6:45 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Edward Agura, MD¹, **Boglarka Gyurkocza, MD²**, **Rajneesh Nath, MD³**, **Mark R. Litzow, MD⁴**, **Benjamin K. Tomlinson, MD⁵**, **Sunil Abhyankar, MD⁶**, **Stuart Seropian, MD^{7*}**, **Patrick J. Stiff, MD⁸**, **Hannah K. Choe, MD⁹**, **Partow Kebriaei, MD¹⁰**, **James M. Foran, MD¹¹**, **George Chen, MD¹²**, **Moshe Yair Levy, MD¹**, **Hillard M Lazarus, MD¹³**, **Sergio Giralt, MD²**, **Mark S. Berger, MD¹⁴**, **Vijay Reddy, MD, PhD¹⁴** and **John M. Pagel, MD, PhD¹⁵**

¹Baylor University Medical Center at Dallas, Dallas, TX

²Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

³Banner MD Anderson Cancer Center, Gilbert, AZ

⁴Division of Hematology, Mayo Clinic, Rochester, MN

⁵University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

⁷Yale University School of Medicine, New Haven, CT

⁸Loyola Univ. Med. Ctr., Maywood, IL

⁹The Ohio State University Comprehensive Cancer Center, Columbus

¹⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

¹¹Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

¹²Medicine, Roswell Park Cancer Institute, Buffalo, NY

¹³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁴Actinium Pharmaceuticals, New York, NY

¹⁵Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

POSTER PRESENTATIONS

1038 Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I

Hematology Disease Topics & Pathways:

Diseases, Anemias, Bleeding and clotting, Thrombosis, PNH

Saturday, December 1, 2018, 6:15 PM-8:15 PM

Hall GH (San Diego Convention Center)

Regis Peffault De Latour^{1,2*}, **Jaroslav P. Maciejewski³**, **Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPath^{4*}**, **Loree Larratt, MD, FRCPath(C)^{5*}**, **Ronald S. Go, MD⁶**, **David Dingli, MD, PhD⁶**, **Amanda Wilson, PhD^{7*}**, **Philippe Gustovic, MD^{8*}** and **Aleksandr Kulagin^{9*}**

¹Université Paris Diderot, Paris, France

²French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Haematological Medicine, King's College Hospital, NIHR/Wellcome King's Clinical Research Facility, London, United Kingdom

⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷Alexion Pharmaceuticals, Inc., Lexington, MA

⁸Alexion Pharma GmbH, Zürich, Switzerland

⁹Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation

[**1054 The LSD1 Inhibitor RN-1Â Increases Î³-GlobinÂ ExpressionÂ in BaboonsÂ By Targeting an Early EventÂ Responsible forÂ Î³-Globin Repression**](#)

Program: Oral and Poster Abstracts

Session: 112. Thalassemia and Globin Gene Regulation: Poster I

Hematology Disease Topics & Pathways:

Anemias, Diseases, Non-Biological, Therapies, Biological Processes, epigenetics, erythropoiesis, pharmacology

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Kestis Vaitkus^{1}, Vinzon Ibanez, B.S.^{1*}, Maria Armila Ruiz, B.S.^{1*}, Ramasamy Jagadeeswaran, PhD.^{2*}, **Yogenthiran Sauntharajah, MD³**, James Douglas Engel, PhD⁴, Joseph DeSimone, PhD^{1*}, Angela Rivers, MD² and Donald Lavelle, PhD¹*

¹Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

²Department of Pediatrics, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

³Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

⁴Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI

[**1095 Clinical Testing of Hemechip in Nigeria for Point-of-Care Screening of Sickle Cell Disease**](#)

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, sickle cell disease, Pediatric, Technology and Procedures, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, newborn screening

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Muhammad Noman Hasan, MS^{1}, Arwa Fraiwan, PhD^{1*}, Priyaleela Thota, MD^{2*}, Tolulope Oginni, BS^{3*}, Grace Mfon Olanipekun^{4*}, Fatimah Hassan-Hanga, MD^{5*}, Jane Little, MD^{1,6,7}, Stephen K. Obaro, MD, PhD^{4,8*} and Umut A. Gurkan, PhD¹*

¹Case Western Reserve University, Cleveland, OH

²Hemex Health Inc., Portland, OR

³eHealth Africa, Kano, Nigeria

⁴International Foundation Against Infectious Disease in Nigeria, Abuja, Nigeria

⁵Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria

⁶Division of Hematology/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

⁸Division of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE

[**1116 Human Bone Marrow Derived Mesenchymal Stromal Cells Enhance the Number and Function of Umbilical Cord Blood Peripheral Tregs during IL-2 Driven Ex Vivo Expansion**](#)

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

*Jeong-Su Do, PhD¹, **Alex Y. Huang, MD, PhD^{2*}**, Daniel Zwick, PhD^{1*}, Fei Zhong, MD^{1*}, David Askew, PhD^{2*}, Wouter van't Hof, PhD^{3*}, Marcie Finney, MS^{3*} and Mary Laughlin, MD³*

¹Research & Development, Cleveland Cord Blood Center, Cleveland, OH

²Case Western Reserve University, Cleveland, OH

³Cleveland Cord Blood Center, Cleveland, OH

[**1226 Expression of Recombinant ß2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome**](#)

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster I

Hematology Disease Topics & Pathways:

cellular interactions, Biological Processes, Technology and Procedures, immune mechanism, inflammation, pathogenesis, signal transduction

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Ravi Kumar Alluri, PhD^{1*}, Suman Kundu, MBA^{1*}, Jack Su, PhD^{2*}, Sekhar Kambakam^{2*}, Edward Yu, PhD^{2*} and Keith R. McCrae, MD^{1,3}

¹Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

²Department of Pharmacology, Case Western Reserve University, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1237 Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster I

Hematology Disease Topics & Pathways:

anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Clinically relevant, Thromboembolism

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Deborah Y. Park, BS^{1*}, Shyam K. Poudel, MD^{2*}, Xuefei Jia, MS^{3*}, Mailey Lynn Wilks, CNP, MSN, APRN^{2*}, Vicki Pinkava, MSBS, PA-C^{2*}, Meghan O'Brien, MS, ANP-BC^{2*}, Barbara Tripp, CNS, AOCN^{2*}, Jung-Min Song, RN, CNS^{2*}, Keith R. McCrae, MD², Dana E. Angelini, MD² and Alok A. Khorana²

¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

1242 Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster I

Hematology Disease Topics & Pathways:

Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Thrombosis, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Shafia Rahman, MD¹, Fahrettin Covut, MD¹, Yihong Zhou, MD^{1*}, Shab E Gul Rahim, MD^{1*}, Sudha Amarnath, MD^{2*} and Alok A. Khorana³

¹Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

²Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

1302 Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways:

Diseases, Anemias, aplastic anemia, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions, Biological Processes, hematopoiesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Sergei Vatolin, PhD^{1*} and Jaroslaw P. Maciejewski²

¹Lerner research institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1303 Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways:

Anemias, Diseases, aplastic anemia, Bone Marrow Failure, Biological Processes, Technology and Procedures, PNH, Clinically relevant, Quality Improvement, flow cytometry, pathogenesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Amy C Graham, BS, MS^{1}, Alexey Efanov, PhD^{2*}, Bartłomiej P. Przychodzen^{3*}, Cassandra M. Hirsch^{4*}, Vera Adema, PhD^{3*}, Valeria Visconte, PhD³ and Jaroslaw P. Maciejewski¹*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

1388 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Mohamed L. Sorror, MD, MSc^{1,2}, Barry E. Storer, PhD^{3,4}, Aaron T. Gerds, MD, MS⁵, Bruno C. Medeiros, MD⁶, Paul J Shami, MD⁷, John P. Galvin, MD, MS, MPH⁸, Kehinde U. Adekola, MBBS, MS⁹, Selina Luger, MD¹⁰, Maria R. Baer, MD¹¹, David A. Rizzieri, MD¹², Tanya M. Wildes, MD, MSCI¹³, Eunice S. Wang, MD¹⁴, Stefan Faderl, MD¹⁵, Jamie L. Koprivnikar, MD¹⁵, Mikkael A. Sekeres, MD, MS⁵, Sudipto Mukherjee, MD, PhD, MPH⁵, Julie Smith, MD^{16*}, Mitchell Garrison, MD^{16*}, Kiarash Kojouri, MD^{17*}, Jennifer E. Nyland, PhD^{1*}, Rachelle R. Moore, BS^{1*}, Sophie L. Fleuret, BS^{1*}, Ylinne Lynch, MD^{1,18*}, Pamela S. Becker, MD^{1,19}, Mary-Elizabeth M. Percival, MD^{1,19}, Brenda M. Sandmaier, MD^{1,2}, Frederick R. Appelbaum, MD^{1,2} and Elihu H. Estey, MD^{1,19}*

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

²Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

³Department of Biostatistics, University of Washington School of Public Health, Seattle, WA

⁴Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

⁶Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA

⁷Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

⁸Feinberg School of Medicine, Northwestern University, Chicago, IL

⁹Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL

¹⁰Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA

¹¹University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

¹²Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

¹³Division of Oncology, Washington University School of Medicine, St Louis, MO

¹⁴Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁵John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁶Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA

¹⁷Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA

¹⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA

¹⁹Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, Non-Biological, Therapies, chemotherapy, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Swapna Thota, MD¹, Bhumika J. Patel, MD², Hetty E. Carraway, MD, MBA^{3,4}, Elizabeth A. Griffiths, MD⁵, Amanda Przespolewski, DO¹, James E. Thompson, MD¹, Teodora Kuzmanovic^{6}, Aziz Nazha, MD², Shimoli Vipul Barot, MD⁷, Cassandra M. Hirsch^{8*}, Bartlomiej P. Przychodzen^{6*}, Sudipto Mukherjee, MD, PhD, MPH², Meghan Scully, NP^{9*}, Aaron T. Gerds, MD, MS¹⁰, Anjali S. Advani, MD⁴, Mikkael A. Sekeres, MD, MS¹¹, Manja Meggendorfer, PhD¹², Eunice S. Wang, MD¹³ and Jaroslaw P. Maciejewski⁸*

¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁵Roswell Park Comprehensive Cancer Center, Buffalo, NY

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Leukemia, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Cleveland Clinic, Cleveland

¹⁰Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹¹Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

¹²MLL Munich Leukemia Laboratory, Munich, Germany

¹³Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

1404 Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Study Population, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Evan Field^{1*}, Paolo F Caimi, MD², Brenda Cooper, MD³, Jane Little, MD^{4,5}, Ehsan Malek, MD⁶, Leland Metheny, MD³, Marcos de Lima, MD^{3,7}, Pingfu Fu^{8*} and Ben Tomlinson, MD³

¹Case Western Reserve University School of Medicine, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

⁵Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

⁷Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁸Case Western Reserve University, Cleveland, OH

1428 Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

AML, Diseases, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Maximilian Stahl, MD¹, Wei Wei, MD, PhD^{2*}, Pau Fernandez^{3*}, Etienne Lengline, MD^{4*}, Rory M Shallis, MD¹, Judith Neukirchen, MD^{5*}, Vijaya R. Bhatt, MD⁶, Mikkael A. Sekeres, MD, MS⁷, Amir T. Fathi, MD⁸, Heiko Konig, MD, PhD⁹, Selina Luger, MD¹⁰, Irum Khan, MBBS¹¹, Gail J. Roboz, MD¹², Thomas Cluzeau, MD, PhD^{13*}, David Martínez-Cuadron, MD^{3*}, Emmanuel Raffoux, MD^{4*}, Ulrich Germing, MD^{5*}, Jayadev Manikkam Umakanthan, MBBS⁶, Sudipto Mukherjee, MD, PhD, MPH⁷, Andrew M. Brunner, MD¹⁴, Adam M. Miller, BS, MD^{9*}, Christine M. McMahon, MD¹⁰, Ellen K. Ritchie, MD¹², Rebeca Rodríguez-Veiga, MD^{3*}, Raphael Itzykson, MD, PhD⁴, Blanca Boluda, MD^{3*}, Florence Rabian, MD^{4*}, Mar Tormo, MD^{15*}, Evelyn Gloria Acuna Cruz, MD^{3*}, Emma Rabinovich, MD^{11*}, Brendan Yoo^{10*}, Nikolai A. Podoltsev, MD, PhD¹, Steven D. Gore, MD¹ and Amer M. Zeidan, MBBS, MHS^{1*}

¹Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

²Department of Biostatistics, Yale School of Public Health, New Haven, CT

³Hospital Universitari i Politècnic La Fe, Valencia, Spain

⁴Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

⁵Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

⁶University of Nebraska Medical Center, Omaha, NE

⁷Leukemia Program, Cleveland Clinic, Cleveland, OH

⁸Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA

⁹Indiana University Simon Cancer Center, Indianapolis, IN

¹⁰Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹¹University of Illinois, Chicago, IL

¹²Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹³Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

¹⁴Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

¹⁵University Clinical Hospital, INCLIVA, Valencia, Spain, Valencia, Spain

1491 Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways:

Biological, AML, Adult, Diseases, Elderly, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Olga K Weinberg, MD^{1*}, Robert P. Hasserjian, MD², Ezra Baraban, MD^{3*}, Chi Young Ok, MD⁴, Julia T Geyer, MD^{5*}, John KSS Philip, MD^{6*}, Jason H. Kurzer, MD, PhD⁷, Heesun J. Rogers, MD, PhD⁸, Valentina Nardi, MD², Richard M. Stone, MD^{9,10}, Jacqueline S. Garcia⁹, Eric D. Hsi, MD¹¹, Adam Bagg, MD¹², Sa A. Wang, MD^{13*}, Attilio Orazi, MD^{14*} and Daniel A. Arber, MD¹⁵

¹Harvard Medical school, Boston Children's Hospital, Newton, MA

²Department of Pathology, Massachusetts General Hospital, Boston, MA

³University of Pennsylvania, Philadelphia, PA

⁴Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Pearland, TX

⁵Pathology, Weill Cornell, New York, NY

⁶Pathology, University of Chicago, Chicago, NY

⁷Stanford University Medical School, Stanford, CA

⁸Department of Hematopathology, Cleveland Clinic, Cleveland

⁹Dana-Farber Cancer Institute, Boston, MA

¹⁰Harvard Medical School, Boston, MA

¹¹Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

¹²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

¹³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

¹⁴Weill Cornell Medical College, New York, NY

¹⁵University of Chicago, Chicago, IL

1527 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways:

Diseases, AML, Biological Processes, Myeloid Malignancies, genomics

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Rachel Hu, MD¹, Aziz Nazha, MD², Xuefei Jia, MS^{3*}, Brian P. Hobbs, PhD^{4*}, Hetty E. Carraway, MD, MBA^{2,5}, Sudipto Mukherjee, MD, PhD, MPH⁶, Aaron T. Gerds, MD, MS⁷, Anjali S. Advani, MD⁸, Yasunobu Nagata^{9*}, Cassandra M. Hirsch^{9*}, Bartłomiej P. Przychodzen^{9*}, Babal K. Jha^{10*}, Jaroslaw P. Maciejewski⁹ and Mikkael A. Sekeres, MD, MS¹¹

¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

²Cleveland Clinic, Cleveland, OH

³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁴Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Cleveland Clinic, Cleveland, OH

1591 The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth

Program: Oral and Poster Abstracts

Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Non-Hodgkin Lymphoma, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Huseyin Halil Erdemir, MD¹, Meenal Shukla, PhD^{2*} and Keith R. McCrae, MD^{2,3}

¹Department of Pediatric Hematology/Oncology and BMT, Cleveland Clinic Children's Hospital, Cleveland, OH

²Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1648 Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Adult, CLL, Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Deborah M. Stephens¹, Ken Boucher, PhD^{2*}, Elizabeth Kander, MD³, Sameer A. Parikh, MD⁴, Erin Parry, MD, PhD^{5*}, Mazyar Shadman, MD, MPH⁶, John M. Pagel, MD, PhD⁷, Jennifer Cooperrider, BA^{8*}, Joanna Rhodes, MD⁹, Anthony R. Mato, MD MSCE¹⁰, Allison M. Winter, MD¹¹, Brian T. Hill, MD, PhD^{12,13}, Sameh Gaballa, MD^{14*}, Alexey V Danilov, MD, PhD¹⁵, Tycel J. Phillips, MD¹⁶, Danielle M. Brander, MD¹⁷, Sonali M. Smith, MD⁸, Matthew S Davids¹⁸, Kerry A. Rogers, MD¹⁹, Martha Glenn, MD¹ and John C. Byrd, MD^{3,20}

¹Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT

²Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

³Division of Hematology, The Ohio State University, Columbus, OH

⁴Mayo Clinic, Rochester, MN

⁵Dana-Farber Cancer Institute, Boston, MA

⁶Fred Hutchinson Cancer Research Center, Seattle, WA

⁷Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

⁸University of Chicago, Chicago, IL

⁹Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

¹⁰CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

¹¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁴Thomas Jefferson University, Philadelphia, PA

¹⁵Knight Cancer Institute, Oregon Health and Science University, Portland, OR

¹⁶University of Michigan Cancer Center, Dexter, MI

¹⁷Duke Cancer Institute, Duke University Health System, Durham, NC

¹⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

¹⁹Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

²⁰Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

1675 Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells

Program: Oral and Poster Abstracts

Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, CAR-Ts

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Ashish Sharma^{1*}, Anne Roe^{1*}, Filipa Blasco Lopes^{1*}, Ruifu Liu^{1*}, Jane Reese^{2*}, Susan Pereira Ribeiro^{1*}, Rafick-Pierre Sekaly, PhD^{1*}, Marcos de Lima, MD³ and David Wald, MD, PhD^{4*}

¹Case Western Reserve University, Cleveland

²University Hospitals Seidman Cancer Center, Adult Hematologic Malignancies & Stem Cell Transplant Section, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Department of Clinical Pathology, Case Western Reserve University, Cleveland, OH

1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways:

Adult, Diseases, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Marie Maerevoet, MD^{1*}, Joost Vermaat, MD, PhD², Miguel A. Canales³, René-Olivier Casasnovas, MD^{4*}, Eric Van Den Neste^{5*}, Andre Goy, MD^{6*}, Brian T. Hill, MD, PhD^{7,8}, Catherine Thieblemont, MD, PhD^{9*}, Maria De Fatima De La Cruz^{10*}, Federica Cavallo, MD, PhD^{11*}, George Follows, MD^{12*}, Sylvain Choquet, MD^{13*}, Ronit Gurion, MD^{14*}, Reda Bouabdallah, MD^{15*}, Ulrich Jaeger, MD¹⁶, Agnes Nagy, MD^{17*}, John Kuruvilla, MD¹⁸, Krzysztof Warzocha, MD^{19*}, Nagesh Kalakonda, MD^{20*}, **Paolo Caimi, MD²¹, Sameer Bakshi, MD^{22*}, Matthew Ku, MBBS, FRACP, FRCPA^{23*}, Nada Hamad, MD^{24*}, Hendrik Veelken, MD, PhD², Ewa Matczak, MD^{25*}, Xiwen Ma^{25*}, Jean-Richard Saint-Martin^{25*}, Jatin J. Shah, MD^{25*}, Michael G. Kauffman, MD, PhD²⁵, Sharon Shacham, PhD, MBA^{25*} and Josée M Zijlstra, MD^{26*}**

¹Institute Jules Bordet, Brussels, Belgium

²Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

³Hospital Univesitario La Paz, Madrid, Spain

⁴CHU Dijon, Dijon, FRA

⁵Cliniques universitaires Saint-Luc, Brussels, BEL

⁶John Theurer Cancer Center at Hackensack-UMC, Hackensack, NJ

⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Hopital St Louis, Paris, France

¹⁰Hospital University Virgen del Rocio, Sevilla, Spain

¹¹University of Torino, Department of Molecular Biotechnologies and Health Sciences, Turin, Italy

¹²Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom

¹³Hopital Pitie Salpetriere, Paris, France

¹⁴Rabin Medical Center, Petah Tikva, ISR

¹⁵Institut Paoli Calmettes, Department of Hematology, Marseille, France

¹⁶Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, Austria

¹⁷University of Pécs, ÁOK, Pécs, Hungary

¹⁸Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

¹⁹Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

²⁰Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom

²¹Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

²²Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

²³Department of Haematology, St. Vincent's Hospital, Melbourne, Australia

²⁴St. Vincent's Hospital, Sydney, Australia

²⁵Karyopharm Therapeutics, Newton, MA

²⁶Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

1692 Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, chemotherapy, Biological Processes, B-Cell Lymphoma, Lymphoid Malignancies, Clinically relevant, signal transduction

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Brian T. Hill, MD, PhD^{1,2}, Robert M. Dean, MD³, Deepa Jagadeesh, MD, MPH³, Alex V. Mejia Garcia, MD³, Brad Pohlman, MD⁴, Allison M. Winter, MD³, Ethan Krauspe, BA^{5*}, Patrick Collier, MD, PhD^{6*}, Christopher D'Andrea, PA-C^{3*}, Ashley Morrison, RN^{3*}, Sarah Lehmann, RN^{3*}, Benjamin K. Tomlinson, MD⁷, Brenda Cooper, MD⁸, Marcos de Lima, MD⁷, Sarah L. Ondrejka, DO⁹, Eric D. Hsi, MD⁹ and Paolo Caimi, MD⁷

¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵School of Medicine, Case Western Reserve University, Cleveland, OH

⁶Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

⁷University Hospitals of Cleveland, Cleveland, OH

⁸Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁹Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

[**1737 Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-2004**](#)

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Therapy: Poster I

Hematology Disease Topics & Pathways:

Biological, Adult, Diseases, Therapies, CML, Study Population, Clinically relevant, Myeloid Malignancies, TKI

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Qian Wang, MD, MPH¹, Yaning Zhang, MD^{2*}, Bing Yue, MD^{1*}, Yu Zhang, MD^{3*}, Changchuan Jiang, MD MPH^{1*}, Stuthi Perimbeti, MD, MPH^{1*} and Michael J. Mauro, MD⁴

¹Department of Medicine, Icahn School of Medicine at Mount Sinai St. Luke's and West, New York, NY

²Department of General Surgery, Cleveland Clinic, Cleveland, OH

³Department of Hematology, 307 Hospital of People's Liberation Army (PLA) of China, Beijing, China

⁴Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

[**1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del\(5q\) Myelodysplastic Syndromes**](#)

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Yazan F. Madanat, MD¹, Mikkael A. Sekeres, MD, MS², Sudipto Mukherjee, MD, PhD, MPH³, Cassandra M. Hirsch^{4*}, Yihong Guan^{5*}, Yasunobu Nagata^{4*}, Vera Adema, PhD^{6*}, Metis Hasipek, PhD^{4*}, Aaron T. Gerds, MD, MS⁷, Hetty E. Carraway, MD, MBA^{1,8}, Anjali S. Advani, MD¹, Bartlomiej P. Przychodzen^{6*}, Valeria Santini⁹, Jaroslaw P. Maciejewski⁶, Babal K. Jha^{6*} and Aziz Nazha, MD⁸

¹Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸Cleveland Clinic, Cleveland, OH

⁹MDS Unit, AOU Careggi-University of Florence, Florence, Italy

1801 Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, AML, CMML, MDS, Biological Processes, MPN, Technology and Procedures, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Kiyomi Morita, MD^{1,2}, Feng Wang, PhD^{3*}, Hideki Makishima, MD, PhD⁴, Yuanqing Yan, PhD^{5*}, Tetsuichi Yoshizato, MD, PhD⁶, Kenichi Yoshida, MD, PhD^{6*}, Bartłomiej P. Przychodzen^{7*}, Keyur Patel, MD, PhD^{8*}, Carlos E. Bueso-Ramos, MD, PhD⁸, Curtis Gumbs^{3*}, Latasha Little^{3*}, Samantha Tippen^{3*}, Jianhua Zhang, PhD^{3*}, Xingzhi Song, PhD^{3*}, Tapan M. Kadia, MD⁹, Naval G. Daver, MD¹, Naveen Pemmaraju, MD¹, Courtney D. DiNardo, MD, MSc¹, Farhad Ravandi, MBBS¹, Srdan Verstovsek, MD, PhD⁹, Elias J. Jabbour, MD¹, Jorge E. Cortes, MD¹, Hagop M. Kantarjian, MD⁹, Guillermo Garcia-Manero, MD¹, **Jaroslav P. Maciejewski⁷, Seishi Ogawa, MD, PhD¹⁰, P Andrew Futreal, PhD^{3*} and Koichi Takahashi, MD^{3,11}**

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Department of Hematology and Oncology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

³Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

⁵Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX

⁶Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

⁹Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

¹⁰Department of Pathology and Tumor Biology, Kyoto University, Sakyo, Japan

¹¹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

1802 Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, AML, Diseases, MDS, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Deepak Singhal, MBBS, MD, FRACP, FRCPA^{1,2}, Christopher N. Hahn, PhD^{3,4*}, Cassandra M. Hirsch^{5*}, Amilia Wee, BSc (Hons)^{6*}, Monika M Kutyna, MSc^{1*}, Milena Babic, BMPharBio (Hons)^{3*}, Rakchha Chhetri, MBBS^{6*}, Smita Hiwase, PhD^{7*}, Wendy Parker, PhD^{3,8*}, Jinghua Feng, PhD^{9*}, Andreas Schreiber, PhD^{8,10*}, Joel Goeghegan, MSc^{8*}, Peer Arts, PhD^{3*}, Nimit Singhal, MBBS MD DM FRACP^{1,11*}, Karin Kassahn, PhD, FFSc (RCPA)^{12,13*}, Susan Branford, PhD^{3,14}, Anna L. Brown, PhD, BSc^{3,15}, Ian D Lewis, MBBS, PhD¹⁶, Richard D'Andrea, PhD⁴, Hamish S. Scott, PhD^{3,13,17}, **Jaroslav P. Maciejewski⁵ and Devendra K Hiwase, MBBS, MD, FRACP, FRCPA, PhD^{1,18,19}**

¹School of Medicine, University of Adelaide, Adelaide, Australia

²Royal Adelaide Hospital, Adelaide, SA, Australia

³Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia

⁴Centre for Cancer Biology, University of South Australia, Adelaide, Australia

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Department of Haematology, Central Adelaide Local Health Network, Adelaide, Australia

⁷Central Adelaide Local Health Network, Adelaide, AUS

⁸ACRF Cancer Genomics Facility, SA Pathology, Adelaide, Australia

⁹School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

¹⁰School of Molecular and Biological Sciences, University of Adelaide, Adelaide, Australia

¹¹Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia

¹²Technology Advancement Unit, SA Pathology, Adelaide, Australia

¹³School of Biological Sciences, University of Adelaide, Adelaide, Australia

¹⁴Centre for Cancer Biology, SA Pathology, Adelaide, Australia

¹⁵Centre For Cancer Biology, SA Genomics Health Alliance, Adelaide, SA, Australia

¹⁶Adelaide Oncology and Haematology, North Adelaide, Australia

¹⁷Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

¹⁸Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

¹⁹Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

1805 Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, Biological Processes, genomics, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Hassan Awada, MD¹, Yasunobu Nagata^{1*}, Abhinav Goyal^{1*}, Mohammad Fahad B. Asad¹, Bhumika J. Patel, MD², Cassandra M. Hirsch^{1*}, Teodora Kuzmanovic^{1*}, Vera Adema, PhD^{1*}, Mai Aly^{1*}, Bartlomiej P. Przychodzen^{1*}, Yihong Guan^{1*}, Wenyi Shen, MD^{3*}, Louis Williams, MD, MBA¹, **Aziz Nazha, MD², Mohamed Abazeed^{1*}, Mikkael A. Sekeres, MD, MS², Tomas Radvovoyevitch^{4*}, Torsten Haferlach, MD⁵, Babal K. Jha^{1*}, Valeria Visconte, PhD¹ and Jaroslaw P. Maciejewski^{1,2}**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

⁴Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁵MLL Munchner Leukamie Labor GmbH, Munchen, Germany

1813 Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, CMML, Biological Processes, MDS, Technology and Procedures, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

C. Beau Hilton, BA^{1,2}, Mikkael A. Sekeres, MD, MS², Manja Meggendorfer, PhD³, Wencke Walter, PhD^{3*}, Stephan Hutter, PhD^{3*}, Eric Padron, MD⁴, Michael R. Savona, MD⁵, Aaron T. Gerds, MD, MS⁶, Yihong Guan^{7*}, David A Sallman, MD⁸, **Sudipto Mukherjee, MD, PhD, MPH², Mrinal M. Patnaik, MD, MBBS⁹, Brianna Smith, MD^{10*}, Yasunobu Nagata^{7*}, Vera Adema, PhD^{11*}, Metis Hasipek, PhD^{7*}, Cassandra M. Hirsch^{7*}, Bartlomiej P. Przychodzen^{11*}, Rami S. Komrokji, MD¹², Babal K. Jha^{11*}, Claudia Haferlach, MD³, **Jaroslaw P. Maciejewski⁷, Torsten Haferlach, MD³ and Aziz Nazha, MD²****

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³MLL Munich Leukemia Laboratory, Munich, Germany

⁴H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

⁵Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

⁶Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

⁹Division of Hematology, Mayo Clinic, Rochester, MN

¹⁰Vanderbilt University Medical Center, Nashville, TN

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹²Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

1824 Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, Clinically relevant, Myeloid Malignancies, molecular interactions, pathogenesis

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Abhinav Goyal^{1*}, Inom Mirzaev^{1*}, Mohammad Fahad B. Asad¹, Hassan Awada, MD¹, Cassandra M. Hirsch^{1*}, Hideki Makishima, MD, PhD², Kenichi Yoshida, MD, PhD^{2*}, Bartłomiej P. Przychodzen^{1*}, Aziz Nazha, MD³, Sudipto Mukherjee, MD, PhD, MPH³, Mikkael A. Sekeres, MD, MS³, Seishi Ogawa, MD, PhD⁴, Tomas Radivoyevitch, PhD^{5*}, Jacob Scott, MD^{1*}, Jaroslaw P. Maciejewski¹ and Yasunobu Nagata^{5*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Pathology and Tumor Biology, Kyoto University, Graduate School of Medicine, Kyoto, Japan

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1825 Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, MDS, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Alexander B Pine, MD, PhD¹, Nora B Chokr, MD^{2*}, Maximilian Stahl, MD³, David P. Steensma, MD⁴, Mikkael A. Sekeres, MD, MS⁵, Mark R. Litzow, MD⁶, Selina Luger, MD⁷, Richard M. Stone, MD⁴, Peter L Greenberg, M.D.⁸, Rafael Bejar, MD, PhD⁹, Steven D. Gore, MD¹⁰ and Amer M. Zeidan, MBBS, MHS³

¹Department of Medicine, Section of Hematology, Yale School of Medicine, Branford, CT

²Department of Medicine, Yale School of Medicine/Waterbury Hospital, Waterbury, CT

³Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

⁴Dana-Farber Cancer Institute, Boston, MA

⁵Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

⁸Stanford University Cancer Center, Stanford, CA

⁹Moore's Cancer Center, University of California, San Diego, La Jolla, CA

¹⁰Yale Cancer Center, Yale University School of Medicine, New Haven, CT

1875 A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, Leukemia, Adult, CLL, Therapies, Non-Biological, chemical interactions, Elderly, Biological Processes, cellular interactions, Technology and Procedures, Study Population, Lymphoid Malignancies, Clinically relevant, pharmacology, flow cytometry, inflammation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Basem M. William, MRCP, MD¹, Kaylee Brillhart^{2*}, Manuel Afable, MD³, Kristen Bakalarz, CNP^{4*}, Brenda Cooper, MD⁵, Hillard M Lazarus, MD⁶, Stanton L. Gerson, MD⁷, Richard Creger, PharmD^{8*}, Kalyanam Nagabhushanam, PhD^{9*}, James Grote, MD^{10*}, Pingfu Fu^{11*}, Sandeep Kunati, PhD^{12*}, Shuming Yang, PhD^{11*}, Yan Xu, PhD^{11*}, Philip Woost, PhD^{13*}, James Jacobberger, PhD^{13*}, Marcos de Lima, MD⁵ and Paolo Caimi, MD^{14*}

¹Division of Hematology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

²University Hospitals Cleveland Medical Center, Cleveland, OH

³Eli Lilly and Company, Indianapolis, IN

⁴University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁸Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

⁹Sabinsa Corporation, East Windsor, NJ

¹⁰BTR Group, Inc., Pittsfield, IL

¹¹Case Western Reserve University, Cleveland, OH

¹²Cleveland State University, Cleveland, OH

¹³Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland

¹⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Case Western Reserve University - University Hospitals Case Medical Center, Cleveland, OH

1899 Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Rajsheshkar Chakraborty, MBBS¹, Hien D. Liu, MD^{2*}, Lisa Rybicki, MS^{3*}, Robert M. Dean, MD⁴, Beth M. Faiman, PhD, CNP⁵, Matt Kalaycio, MD⁶, Jack Khouri, MD⁵, Christy J. Samaras, DO⁵, Navneet S. Majhail, MD, MS⁶ and Jason Valent, MD⁷

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Motfitt Cancer Center, Tampa, FL

³Cleveland Clinic Foundation, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁷Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Eastlake, OH

1918 Vactosertib, a TGF- β Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

Program: Oral and Poster Abstracts

Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological, Therapies, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Byung-Gyu Kim, PhD, DVM^{1,2*}, Sung Hee Choi, PhD^{1,2*}, George Luo^{1,2*}, Olga Sergeeva, PhD^{3*}, Zhenghong Lee, PhD^{3*}, James Driscoll, MD, PhD⁴, Marcos de Lima, MD^{5,6}, Rose Beck, MD, PhD^{7*}, Seong-Jin Kim, PhD^{8,9*}, John Letterio, MD^{1,2*} and Ehsan Malek, MD^{6,10}

¹Department of Pediatrics, Case Western Reserve University, Cleveland, OH

²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

³Department of Radiology, Case Western Reserve University, Cleveland, OH

⁴Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁵Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

⁶Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH

⁷Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH

⁸Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)

⁹MedPacto Inc., Suwon, Korea, Republic of (South)

¹⁰Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

1948 Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Faiza Jamil, MD¹, Madeeha Shafqat¹, Ali Younas Khan, MD¹, Seren Durer, MD¹, Ceren Durer, MD¹, Zunairah Shah, MBBS¹, Anum Qureshi¹, Muhammad Abu Zar, MD¹, Ahmad Kamal, MD¹, Malik Qistas Ahmad, MD, MBBS¹, Chaudhry Saad Sohail, MD¹, Insija Ilyas Selene, MBBS¹, Mustafa Nadeem Malik, MD¹, Abdul Rafae, MD¹ and Faiz Anwer, MD^{1,2}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1949 Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, multiple myeloma, Diseases, antibodies, Therapies, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Zunairah Shah, MBBS¹, Madeeha Shafqat¹, Faiza Jamil, MD¹, Mustafa Nadeem Malik, MD¹, Abdul Rafae, MD¹, Shehroz Aslam, MD¹, Anum Qureshi¹, Maryam Sadiq, MBBS¹, Muhammad Abu Zar, MD¹, Ahmad Kamal, MD¹, Insija Ilyas Selene, MBBS¹, Sharoon Samuel, MBBS¹, Rida Riaz, MBBS¹, Midhat Lakhani, MD¹ and Faiz Anwer, MD^{2,3}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²University of Arizona, Tucson, AZ

³Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1950 Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, apoptosis, Therapies, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Shehroz Aslam, MD¹, Mustafa Nadeem Malik, MD¹, Abdul Rafae, MD¹, Rida Riaz, MBBS¹, Muhammad Jahanzeb Khalil, MD¹, Faisal Mahfooz, MD², Madeeha Shafqat¹, Anum Qureshi¹, Insija Ilyas Selene, MBBS¹, Syed Shabee Hassan, MD¹, Muhammad Junaid Tariq, MD¹, Muhammad Yasir, MD¹, Sharoon Samuel, MBBS¹, Maryam Sadiq, MBBS¹ and Faiz Anwer, MD^{1,3}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Nawaz Sharif Medical College, University of Gujrat, Gujrat, Pakistan

³Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1951 Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, stem cells

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Jemin Aby Jose, MD^{1}, Insija Ilyas Selene, MBBS^{1*}, Mustafa Nadeem Malik, MD^{1*}, Anum Qureshi^{1*}, Abdul Rafae, MD^{1*}, Hafiz Muhammad Fazeel, MD^{1*}, Muhammad Abu Zar, MD^{1*}, Ahmad Kamal, MD^{1*}, Saad Ullah Malik, MD^{1*}, Ceren Durer, MD^{1*}, Seren Durer, MD^{1*}, Faiza Jamil, MD^{1*}, Madeeha Shafqat^{1*}, Muhammad Usman, MD^{2*}, Giyth Mithim Mahdi^{3*} and Faiz Anwer, MD^{4,5}*

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²uni, Tucson, AZ

³Department of Medicine, Division of Hematology and Oncology, University of Arizona, University of Arizona, Tucson, AZ

⁴Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

⁵Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1952 Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Therapies, Non-Biological, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Anum Qureshi^{1}, Muhammad Junaid Tariq, MD^{1*}, Zunairah Shah, MBBS^{1*}, Muhammad Abu Zar, MD^{1*}, Shehroz Aslam, MD^{1*}, Abdul Rafae, MD^{1*}, Mustafa Nadeem Malik, MD^{1*}, Ahmad Kamal, MD^{1*}, Jemin Aby Jose, MD^{1*}, Insija Ilyas Selene, MBBS^{1*}, Madeeha Shafqat^{1*}, Faiza Jamil, MD^{1*}, Seren Durer, MD^{1*}, Ceren Durer, MD^{1*} and Faiz Anwer, MD^{1,2}*

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1962 Preclinical Studies and a Phase I Trial of the TGF- β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, immune mechanism

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Ehsan Malek, MD¹, Byung-Gyu Kim, PhD, DVM^{2}, Jason Valent, MD³, James Driscoll, MD, PhD⁴, Paolo Caimi, MD⁵, Seong-Jin Kim, PhD^{6,7*}, Marcos de Lima, MD⁸ and John Letterio, MD^{9*}*

¹Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH

²Department of Pediatrics, Case Western Reserve University, Solon, OH

³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁵University Hospitals of Cleveland, Cleveland, OH

⁶MedPacto Inc., Suwon, Korea, Republic of (South)

⁷Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)

⁸Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

⁹Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

1992 Longer Term Follow up of the A Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological, Adult, Therapies, Elderly, enzyme inhibitors, Plasma Cell Disorders, immunotherapy, Study Population, Lymphoid Malignancies, Clinically relevant, Quality Improvement

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Brian GM Durie, MD¹, Antje Hoering, PhD^{2*}, Rachael Sexton, PhD^{2*}, Muneer H. Abidi, MD³, Joshua Epstein, DSc⁴, S. Vincent Rajkumar, MD⁵, Angela Dispenzieri, MD⁵, Stephen P. Kahanic, MD^{6*}, Mohan C. Thakuri, MD⁷, **Frederic J. Reu, MD⁸, Christopher M. Reynolds, MD^{9*}, Robert Z. Orlowski, MD, PhD¹⁰ and Bart Barlogie, MD, PhD¹¹**

¹Cedars Sinai Cancer Center, Los Angeles, CA

²SWOG Statistical Center, Seattle, WA

³Michigan State University/Spectrum Health Cancer Center, Grand Rapids, MI

⁴Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

⁵Division of Hematology, Mayo Clinic, Rochester, MN

⁶Sanford NCORP of the North Central Plains/ Siouland Regional Cancer Center, Sioux City, IA

⁷Cancer Care Western NC, Asheville, NC

⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Michigan Cancer Research Consortium NCORP, St. Joseph Mercy Hospital, Ann Arbor, MI

¹⁰Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

¹¹Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

2009 Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Diseases, Biological, Adult, antibodies, multiple myeloma, Therapies, chemotherapy, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Sarah S Lee, MD, Nathaniel Rosko, PharmD^{*}, Bhumika J. Patel, MD, Madeline Waldron, PharmD^{*}, Jackie Tomer, MPH^{*}, Roman Goldman, CNP^{*}, Mary Ann Karam, RN^{*}, Janice Reed, RN^{*}, Beth M. Faiman, PhD, CNP, Kimberly Hamilton, APRN/PA^{*}, Saveta Mathur, CNP^{*}, Christy J. Samaras, DO and Jason Valent, MD
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2012 Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Adult, Diseases, Technology and Procedures, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, flow cytometry

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

William E. Pierceall¹, Nizar Bahlis, MD², David S Siegel, MD, PhD³, Gary J. Schiller, MD⁴, Christy J. Samaras, DO⁵, Michael Sebag, MD, PhD⁶, Jesus G. Berdeja, MD⁷, Siddhartha Ganguly, MD^{8*}, Jeffrey V Matous, MD⁹, Kevin Song, MD¹⁰, Christopher S. Seet, MD¹¹, Giampaolo Talamo^{12*}, Shanti Srinivas^{13,14*}, Mirelis Acosta-Rivera^{15*}, Michael Bar^{16*}, Donald P. Quick, MD¹⁷, Bertrand Anz^{18*}, Gustavo Fonseca^{19*}, Donna Reece^{20*}, Weiyuan Chang^{1*}, Natalya Serbina^{1*}, Faiza Zafar, MPAS^{1*}, Amit Agarwal, MD, PhD¹ and Anjan Thakurta, PhD^{1*}

¹Celgene Corporation, Summit, NJ

²University of Calgary, Calgary, AB, Canada

³John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

⁴UCLA School of Medicine, Los Angeles, CA

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶McGill University Health Centre, Montreal, QC, Canada

⁷Sarah Cannon Research Institute, Nashville, TN

⁸University of Kansas Medical Center, Westwood, KS

⁹Colorado Blood Cancer Institute, Denver, CO

¹⁰The Vancouver General Hospital, Vancouver, BC, CAN

¹¹David Geffen School of Medicine at UCLA, Los Angeles, CA

¹²Penn State Hershey Cancer Institute, Hershey, PA

¹³Veterans Affairs NJ Health Care System, East Orange, NJ

¹⁴Rutgers-New Jersey Medical School, Newark, NJ

¹⁵Fundacion de Investigacion, San Juan, Puerto Rico

¹⁶Stamford Hospital, Stamford, CT

¹⁷Joe Arrington Cancer Research Treatment Center, Lubbock, TX

¹⁸Tennessee Oncology, Chattanooga, TN

¹⁹Florida Cancer Specialists, St. Petersburg, FL

²⁰Princess Margaret Cancer Centre, Toronto, Canada

2022 Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Adeela Mushtaq, MD^{1*}, Ahmad Iftikhar, MD^{2*}, Midhat Lakhani, MD^{3*}, Fnu Sagar, MD^{3*}, Ahmad Kamal, MD^{3*}, Umar Zahid, MD, MPH^{4,5*}, Hamza Hassan, MD^{6*}, Zeeshan Ali, MD^{3*}, Faryal Razzaq, MBBS^{3*}, Saad Ullah Malik, MD^{3*}, Syeda Fatima Hassan, MBBS^{3*}, Muhammad Abu Zar, MD^{3*}, Mohammad Bilal Chaudhary, MD^{7*}, Ahmad Safdar^{3*}, Mohamed Mokhtar Bakr, MD^{8*} and Faiz Anwer, MD^{3,9}

¹Department of Medicine, University of Pittsburgh Medical Center, McKeesport, PA

²Department of Medicine, University of Arizona, Tucson, AZ

³Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

⁴Johns Hopkins University, Baltimore, MD

⁵Jersey Shore Medical University, Tucson, AZ

⁶Department of Medicine, Rochester General Hospital, Rochester, NY

⁷Elmhurst Hospital Center, Queens, NY

⁸Jersey Shore University Medical Center, New Jersey

⁹Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

2025 Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

antibodies, Biological, Leukemia, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Muhammad Aadil Rahman, MD^{1*}, Ali Younas Khan, MD^{1*}, Awais Ijaz, MD^{2*}, Muhammad Junaid Tariq, MD^{1*}, Muhammad Usman, MD^{1*}, Muhammad Jahanzeb Khalil, MD^{1*}, Muhammad Asad Fraz, MD^{3*}, Faiza Jamil, MD^{1*}, Abdul Rafae, MD^{1*}, Mustafa Nadeem Malik, MD^{1*}, Insija Ilyas Selene, MBBS^{1*}, Jemin Aby Jose, MD^{1*}, Ahmad Safdar, BS^{4*}, Ali McBride, PharmD, MS⁵ and Faiz Anwer, MD^{1,6}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Medicine, Division of Hematology and Oncology, University of Arizona, TUCSON, AZ

³Department of Medicine, Division of Hematology and Oncology, University of Arizona, Buford, GA

⁴Department of Medicine, University of Arizona, Tucson

⁵Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ

⁶Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Therapies, Non-Biological, Biological Processes, chemotherapy, Technology and

Procedures, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, immune mechanism, NGS

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD¹, Betty K. Hamilton, MD¹, Lisa Rybicki, MS^{2*}, Dawn Thomas^{3*}, Arden Emrick^{1*}, Aziz Nazha, MD⁴, Sudipto Mukherjee, MD, PhD, MPH⁴, Anjali S. Advani, MD⁴, Hetty E. Carraway, MD, MBA^{4,5}, Brad Pohlman, MD⁶, Brian J. Bolwell, MD¹, Robert M. Dean, MD¹, Aaron T. Gerds, MD, MS¹, Rabi Hanna, MD⁷, Matt Kalaycio, MD¹, Aiwen Zhang, PhD^{8*}, Mikkael A. Sekeres, MD, MS⁴, Jaroslaw P. Maciejewski⁹, Navneet S. Majhail, MD, MS¹, Medhat Askar, MD, PhD^{10*} and Ronald Sobecks, MD¹

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Allogen Laboratories, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

⁸Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, TX

2123 Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I

Hematology Disease Topics & Pathways:

AML, ALL, Leukemia, Biological, Diseases, CML, Therapies, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies, transplantation, stem cells

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Jaap Jan Boelens, MD, PhD^{1,2}, Coco de Koning^{3*}, Mitchell E. Horwitz, MD⁴, Guillermo Sanz, MD, PhD⁵, Madan Jagasia, MD, MS⁶, John E. Wagner, MD⁷, Patrick J. Stiff, MD⁸, Rabi Hanna, MD⁹, Daniela Cilloni, MD, PhD^{10*} and Stefan Nierkens, PhD^{1*}

¹Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands

²Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands

³University Medical Center Utrecht, Utrecht, Netherlands

⁴Duke University School of Medicine, Durham, NC

⁵Hematology Department, Hospital Universitario La Fe, Valencia, Spain

⁶Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

⁷Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN

⁸Loyola Univ. Med. Ctr., Maywood, IL

⁹Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

¹⁰University of Turin, Orbassano, Italy

2081 The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, Biological Processes, Clinically relevant, NK cells, transplantation

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Lucy Li^{1*}, Merle Kolk^{2*}, Kirsten Marie Boughan, DO², Paolo F Caimi, MD², Molly M Gallogly, MD, PhD², Jane Little, MD³, Ehsan Malek, MD⁴, Leland Metheny, MD², Ben Tomlinson, MD², Brenda Cooper, MD², Marcos de Lima, MD² and Folashade Otegbeye, MBBChir, MPH⁵

¹Case Western Reserve University School of Medicine, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

2130 Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

Hematology Disease Topics & Pathways:

Biological, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Petra Martin^{1*}, Rebecca Ye, BA², Merle Kolk^{3*}, Nicole Ferrari^{4*}, Paolo Caimi, MD⁵, Leland Metheny, MD³, James Driscoll, MD, PhD⁶, Marcos de Lima, MD³ and Ehsan Malek, MD⁷

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²New York University, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴University Hospitals Seidman Cancer Center, Cleveland, OH

⁵University Hospitals of Cleveland, Cleveland, OH

⁶Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

2170 Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster I

Hematology Disease Topics & Pathways:

Therapies, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Celalettin Ustun, MD¹, Jennifer Le-Rademacher, PhD^{2*}, Hai-Lin Wang, MPH^{3*}, Megan Othus^{4*}, Zhuoxin Sun, PhD^{5*}, Brittny Major^{6*}, Mei-Jie Zhang, PhD^{3*}, Elizabeth Storricks^{7*}, Jacqueline M Lafky^{8*}, Selina Chow^{9*}, Krzysztof Mrózek, MD, PhD¹⁰, Eyal C. Attar, MD^{11,12*}, Clara D. Bloomfield, MD¹³, Larry D Cripe, MD^{14*}, Richard A. Larson, MD¹⁵, Guido Marcucci, MD¹⁶, Gail J. Roboz, MD¹⁷, Geoffrey L. Uy, MD¹⁸, Richard M. Stone, MD^{19*}, Aminah Jatoi^{8*}, Thomas C. Shea, MD²⁰, Marcos de Lima, MD²¹, James M. Foran, MD²², Brenda M. Sandmaier, MD^{23,24,25}, Mark R. Litow, MD²⁶, Harry P. Erba, MD, PhD²⁷, Arti Hurria, MD^{28*}, Daniel J. Weisdorf, MD²⁹ and Andrew S. Artz, MD^{30,31}

¹Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

²Dept of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle

⁵Harvard T.H. Chan School of Public Health, Boston

⁶Department of Health Sciences Research, Mayo Clinic, Rochester

⁷Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

⁸Mayo Clinic, Rochester

⁹University of Chicago Comprehensive Cancer Center, Chicago

¹⁰The Ohio State University Comprehensive Cancer Center, Columbus, OH

¹¹Massachusetts General Hospital, Boston

¹²Agios Pharmaceuticals, Inc., Cambridge, MA

¹³Comprehensive Cancer Center, The Ohio State University, Columbus, OH

¹⁴Indiana University Simon Cancer Center, Indianapolis

¹⁵Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL

¹⁶Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA

¹⁷Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹⁸Washington University School of Medicine, Saint Louis, MO

¹⁹Dana-Farber Cancer Institute, Boston, MA

²⁰Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

²¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²²Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

²³Fred Hutchinson Cancer Research Center, Seattle, WA

²⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

²⁵Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

²⁶Division of Hematology, Mayo Clinic, Rochester, MN

²⁷Duke University, Durham

²⁸City of Hope, Duarte, CA

²⁹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

³⁰Department of Medicine, Section of Hematology/Oncology, University of Chicago Hospital, Chicago, IL

³¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

2194 Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases

Program: Oral and Poster Abstracts

Session: 801. Gene Therapy and Transfer: Poster I

Hematology Disease Topics & Pathways:

Biological, sickle cell disease, Diseases, Therapies, thalassemia, Hemoglobinopathies, gene therapy
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Hafiz Muhammad Fazeel, MD^{1*}, Muhammad Abu Zar, MD^{1*}, Saad Ullah Malik, MD^{1*}, Ahmad Kamal, MD^{1*}, Mustafa Nadeem Malik, MD^{1*}, Syed Shabee Hassan, MD^{1*}, Syeda Sabeeka Batool, MD^{2*}, Ceren Durer, MD^{1*}, Seren Durer, MD^{1*}, Shehroz Aslam, MD^{1*}, Madeeha Shafqat^{1*}, Faiqa Ijaz, MBBS^{1*}, Faiz Anwer, MD^{1,3} and Shahrukh K. Hashmi, MD, MPH⁴

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Internal Medicine, University of Alabama, Huntsville, AL

³Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology, Mayo Clinic, Rochester, MN

2245 Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Adult, Elderly, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Kah Poh Loh, MBBCHBAO¹, Jian Liang Tan^{2*}, Colin M. McHugh, MD^{1*}, Jane L. Liesveld, MD¹, Kristen M. O'Dwyer, MD^{1*}, Michael W. Becker, MD¹, Jason H. Mendler, MD, PhD¹, Omar S. Aljitawi, MD¹, Heidi D. Klepin, MD³, Wendy Stock, MD⁴, Tanya Wildes, MD⁵, Andrew S. Artz, MD^{4,6}, Areej El-Jawahri, MD⁷ and Navneet S. Majhail, MD, MS⁸

¹Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

²Department of Medicine, Crozer-Chester Medical Center, Chester, PA

³Wake Forest University School of Medicine, Winston Salem, NC

⁴Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

⁵Washington University, Saint Louis, MO

⁶Department of Medicine, Section of Hematology/Oncology, University of Chicago Hospital, Chicago, IL

⁷Massachusetts General Hospital, Allston, MA

⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

2246 Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Elderly, Study Population, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Kah Poh Loh, MBBCHBAO¹, Sindhuja Kadambi, MD^{2*}, Supriya G. Mohile, MD, MS^{1*}, Jason H. Mendler, MD, PhD¹, Jane L. Liesveld, MD¹, Kristen M. O'Dwyer, MD^{1*}, Michael W. Becker, MD¹, Colin M. McHugh,

MD^{1*}, Marsha Wittink, MD, MBE^{3*}, Wendy Stock, MD⁴, Navneet S. Majhail, MD, MS⁵, Tanya Wildes, MD⁶, Paul Duberstein, PhD^{3*} and Heidi D. Klepin, MD⁷

¹Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

²Division of Geriatrics and Aging, University of Rochester Medical Center, Rochester, NY

³Department of Psychiatry, University of Rochester Medical Center, Rochester, NY

⁴Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Washington University, Saint Louis, MO

⁷Wake Forest University School of Medicine, Winston Salem, NC

2259 Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster I

Hematology Disease Topics & Pathways:

Diseases, Adult, MPN, Polycythemia vera, Study Population, Myeloid Malignancies, Quality Improvement

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Ivy Altomare, MD^{1*}, Aaron T. Gerds, MD, MS², David Lessen, MD³, Philomena Colucci, DO, MS^{4*}, Shreekanth Parasuraman, BPharm, PhD^{4*}, Dilan Chamikara Paranagama, PhD^{4*} and Ruben A. Mesa, MD, FACP⁵

¹Duke University Medical Center, Durham, NC

²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Southeast Florida Hem-Onc Group, Fort Lauderdale, FL

⁴Incyte Corporation, Wilmington, DE

⁵University of Texas Health Science Center, San Antonio, TX

2273 Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH)

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster I

Hematology Disease Topics & Pathways:

Diseases, autoimmune disorders, Bleeding and clotting, ITP, Immune Disorders

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Caroline Kruse^{1*}, Alexandra Kruse^{1*}, Shirley Watson^{2*}, Mervyn Morgan^{2*}, Nichola Cooper, MRCP³, Waleed Ghanima⁴, Andrew Provan^{5*}, Donald M. Arnold, MD, MSc, FRCPC⁶, Cristina Santoro^{7*}, Ming Hou, MD^{8*}, Yoshiaki Tomiyama, MD⁹, Serge Laborde^{10*}, Barbara Lovrencic^{11*}, John Waller, PhD, BSc^{12*}, Gavin Taylor-Stokes^{12*}, Tom Bailey^{12*}, Miona Stankovic^{13*} and James B. Bussell, MD¹⁴

¹Platelet Disorder Support Association, Cleveland

²ITP Support Association, Bolnhurst, United Kingdom

³Hammersmith Hospital, Imperial College London, London, United Kingdom

⁴Department of Medicine, Ostfold Hospital Trust, Kalnes, Norway

⁵Barts and The London School of Medicine and Dentistry, London, United Kingdom

⁶Department of Medicine, McMaster University, Hamilton, ON, Canada

⁷Department of Cellular Biotechnologies & Haematology, 'Sapienza' University of Rome, Rome, Italy

⁸Department of Hematology, Shandong University, Jinan, China

⁹Osaka University Hospital, Osaka, Japan

¹⁰O'Cyto, Saint Loubes, France

¹¹Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy

¹²Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom

¹³Novartis Pharma AG, Basel, Switzerland

¹⁴Division of Hematology/Oncology, Weill Cornell Medical College, New York

2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster I

Hematology Disease Topics & Pathways:

Adult, AML, Diseases, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Raffi Tchekmedyian, BS¹, Tomas Radivoyevitch, PhD^{2,3*}, Aaron T. Gerds, MD, MS⁴, Aziz Nazha, MD⁵, Hetty E. Carraway, MD, MBA^{6,7}, Anjali S. Advani, MD⁷, Jaroslav P. Maciejewski³, Matt Kalaycio, MD⁸, Navneet S. Majhail, MD, MS⁸, Mikhael A. Sekeres, MD, MS⁹ and Sudipto Mukherjee, MD, PhD, MPH⁹

¹Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2330 A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

Hematology Disease Topics & Pathways:

Diseases, Anemias, PNH

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Robert A. Brodsky, MD¹, Regis Peffault De Latour^{2,3*}, Scott T. Rottinghaus, MD^{4*}, Alexander Röth, MD⁵, Antonio M. Risitano, MD, PhD⁶, Ilene C. Weitz, MD^{7*}, Peter Hillmen, MB ChB, PhD, FRCP, FRCPATH⁸, Jaroslav P. Maciejewski⁹, Jeffrey Szer, MBBS¹⁰, Jong-Wook Lee, MD, PhD¹¹, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPATH^{12*}, Lori Volles, MD^{4*}, Andrew I. Damokosh, PhD^{4*}, Stephan Ortiz, RPh, PhD^{4*}, Lori Shafner, PhD^{4*}, Anita Hill, MD, PhD^{13*} and Hubert Schrezenmeier, MD^{14,15}

¹Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

²Université Paris Diderot, Paris, France

³French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

⁴Alexion Pharmaceuticals, Inc., New Haven, CT

⁵Department of Hematology, University Hospital Essen, Essen, Germany

⁶Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy

⁷Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA

⁸Department of Haematology, St James's University Hospital, Leeds, United Kingdom

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia

¹¹Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

¹²Department of Haematological Medicine, King's College Hospital, NIHR/Wellcome King's Clinical Research Facility, London, United Kingdom

¹³Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom

¹⁴Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany

¹⁵Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

2383 Mean Platelet Volume Predicts Mortality in Sickle Cell Disease

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:

Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Aravind Thavamani, MBBS, MD^{1*}, Regi Ramanathan, MBBS^{2*} and Mammen Puliyeel, MD, MBBS^{3,4}

¹Department of Pediatrics, Metrohealth Medical Center, Cleveland, OH

²Metrohealth Medical Center, Cleveland, OH

³Department of Pediatrics, Case Western Reserve University, Cleveland, OH

⁴Metro Health Medical Center, Cleveland, OH

2386 Red Blood Cell Adhesion in Adult Patients with Sickle Cell Disease, at Baseline and with Pain, Measured on SCD Biochip Microfluidic Assay

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:

Adult, Diseases, sickle cell disease, bioengineering, Technology and Procedures, Hemoglobinopathies, Study Population, Clinically relevant, flow cytometry, serologic tests

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Alexandra Boye-Doe¹ and Jane Little, MD²

¹Case Western Reserve University School of Medicine, Cleveland

²Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

2387 Red Blood Cell Adhesion Is Increased in the Young Adult Population with Sickle Cell Disease

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, Hemoglobinopathies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Erina Quinn^{1}, Charlotte Yuan, BA^{2*}, Sargam Kapoor, MD³, Karen Ireland, RN^{4*}, Janine Keenan, RN^{4*}, Deepa Manwani, MD⁵, Umut A. Gurkan, PhD² and Jane Little, MD³*

¹Case Western Reserve University, Bradenton, FL

²Case Western Reserve University, Cleveland, OH

³Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Division of Hematology/ Oncology, The Children's Hospital at Montefiore, Bronx, NY

⁵Children's Hospital at Montefiore, Bronx, NY

2475 A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

Hematology Disease Topics & Pathways:

Diseases, Hemophilia, Bleeding and clotting, Technology and Procedures, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael A Suster, PhD^{1}, Debnath Maji, M.Tech^{1*}, Lalitha V. Nayak, MD², Christina Jenkins, MSN-PNP, RN^{3*}, Susan Hunter, BSN, RN-BC^{3*}, Alvin H. Schmaier, MD¹, Pedram Mohseni, PhD^{1*} and Sanjay Ahuja⁴*

¹Case Western Reserve University, Cleveland, OH

²University Hospitals Cleveland Medical Center, Cleveland, OH

³University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

⁴University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

2500 Real-World Data of Immune Tolerance Induction Using rFVIII-Fc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Program: Oral and Poster Abstracts

Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

Hematology Disease Topics & Pathways:

Adult, Biological, Diseases, Bleeding and clotting, Therapies, Pediatric, Study Population, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Manuel Carcao¹, Amy Shapiro², Nina Hwang^{3}, Steven Pipe⁴, Sanjay Ahuja⁵, Kenneth Lieuw, MD, PhD⁶, Janice Staber⁷, Haowei Linda Sun^{8*}, Hilda Ding^{9*}, Michael Wang, MD¹⁰, Macgregor Steele^{11*}, Elisa Tsao^{12*}, Jing Feng^{12*}, Zahra Al-Khateeb^{13*}, Jennifer Dumont¹² and Nisha Jain^{12*}*

¹Hospital for Sick Children, Toronto, ON, CAN

²Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, IN

³Center for Inherited Blood Disorders, Orange, CA

⁴Pediatrics and Pathology, University of Michigan, Ann Arbor, MI

⁵University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

⁶Walter Reed National Military Medical Center, Bethesda, MD

⁷University of Iowa Stead Family Children's Hospital, Iowa City, IA

⁸University of Alberta Hospital, Edmonton, AB, Canada

⁹Rady Children's Hospital San Diego, San Diego, CA

¹⁰Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO

¹¹Alberta Children's Hospital, Edmonton, AB, Canada

¹²Bioverativ, a Sanofi company, Waltham, MA

¹³Trinity Partners LLC, Waltham, MA

2510 Venous Thromboembolism in Cancer Patients Receiving Immunotherapy

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Bleeding and clotting, Therapies, immunotherapy, Thromboembolism, Clinically relevant, Quality Improvement

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Joanna Roopkumar, MBBS, MPH^{1*}, Ann S. Kim, BA², Thapa Bicky, MD^{3*}, Brian P. Hobbs, PhD^{4*} and Alok A. Khorana¹

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Cleveland Clinic, Cleveland, OH

³Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH

⁴Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2523 Safety of Apixaban in Patients with CKD Stage V and ESRD with Venous Thromboembolism

Program: Oral and Poster Abstracts

Session: 332. Antithrombotic Therapy: Poster II

Hematology Disease Topics & Pathways:

Therapies, Non-Biological

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jahnvi Gollamudi, MD^{1*}, Sadeer Al-Kindi, M.D.^{2*}, Petra Martin^{3*} and Lalitha V. Nayak, MD³

¹Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH

²Division of Cardiology, Case Western Reserve University, Cleveland

³University Hospitals Cleveland Medical Center, Cleveland, OH

2572 Distinct Features of Chip-Derived and De Novo MDS

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yasunobu Nagata^{1*}, Hideki Makishima, MD, PhD², Cassandra M. Hirsch^{1*}, Hassan Awada, MD¹, Abhinav Goyal^{1*}, Teodora Kuzmanovic, BA^{1*}, Bartłomiej P. Przychodzen^{1*}, Tetsuichi Yoshizato, MD, PhD², Kenichi Yoshida, MD, PhD^{2*}, Kenichi Chiba, PhD^{3*}, Hiroko Tanaka, BA^{3*}, Yuichi Shiraishi, PhD^{3*}, Satoru Miyano, PhD^{3*}, Sudipto Mukherjee, MD, PhD, MPH⁴, Tomas Radivoyevitch, PhD^{1*}, Thomas Laframboise, PhD^{5*}, Aziz Nazha, MD⁶, Mikkael A. Sekeres, MD, MS⁴, Torsten Haferlach, MD⁷, Seishi Ogawa, MD, PhD⁸ and Jaroslaw P. Maciejewski¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁶Cleveland Clinic, Cleveland, OH

⁷MLL Munich Leukemia Laboratory, Munich, Germany

⁸Department of Pathology and Tumor Biology, Kyoto University, Sakyo, Japan

2583 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Wenyi Shen, MD*^{1,2*}, *Cassandra M. Hirsch*^{3*}, *Bartlomiej P. Przychodzen*^{4*}, *Hideki Makishima, MD, PhD*⁵, *Louis Williams, MD, MBA*⁶, *Sudipto Mukherjee, MD, PhD, MPH*⁷, *Hetty E. Carraway, MD, MBA*^{8,9}, *Mikael A. Sekeres, MD, MS*¹⁰ and *Jaroslav P. Maciejewski*^{7,11}**

¹The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

²Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁶NYU, New York, NY

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Cleveland Clinic, Cleveland, OH

⁹Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

***Bhumika J. Patel, MD*¹, *Shimoli Vipul Barot, MD*², *Teodora Kuzmanovic, BA*^{3*}, *Bartlomiej P. Przychodzen*^{3*}, *Cassandra M. Hirsch*^{4*}, *Hassan Awada, MD*⁵, *Metis Hasipek, PhD*^{4*}, *Swapna Thota, MD*⁶, *Tomas Radivoyevitch, PhD*^{4*}, *Anjali S. Advani, MD*⁷, *Matt Kalaycio, MD*⁸, *Mikael A. Sekeres, MD, MS*⁹, *Hetty E. Carraway, MD, MBA*^{7,10} and *Jaroslav P. Maciejewski*⁴**

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Internal Medicine, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

⁶Department of Medicine, Roswell Park, Buffalo, NY

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

¹⁰Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

2647 Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMG632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II

Hematology Disease Topics & Pathways:

apoptosis, antibodies, AML, Diseases, Non-Biological, Therapies, Biological Processes, DNA repair, Myeloid Malignancies, pharmacology

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Claire Fritz^{1,2*}, Scott M. Portwood, MS, MBA^{3*}, Julie Adams, BS^{3*}, Tara Cronin, BA^{3*}, Linda Lutgen-Dunckley^{3*}, Brandon L Martens, BS^{3*}, Callum M. Sloss, PhD⁴, Krystal Watkins^{4*}, Yelena Kovtun, PhD⁴, Sharlene Adams, PhD^{4*} and Eunice S. Wang, MD⁵

¹Department of Medicine, Case Western Reserve University, Buffalo, NY

²Case Western Reserve University, Cleveland, OH

³Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

⁴ImmunoGen, Inc., Waltham, MA

⁵Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

2699 Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Hagop M. Kantarjian, MD¹, Wendy Stock, MD², Ryan D. Cassaday, MD³, Daniel J. DeAngelo, MD⁴, Elias J. Jabbour, MD⁵, Susan M. O'Brien, MD⁶, Matthias Stelljes, MD⁷, Tao Wang^{8*}, Katherine F Liao^{9*}, Kevin Nguyen^{10*}, Barbara Sleight^{8*}, Erik Vandendries, MD, PhD^{11*}, Alexander Neuhoof, MD^{12*}, A. Douglas Laird^{9*} and Anjali S. Advani, MD¹³

¹Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

²Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

³UW/FHCRC, Seattle, WA

⁴Dana-Farber Cancer Inst., Boston, MA

⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

⁶UCI Cancer Center, Orange, CA

⁷Universitätsklinikum Münster, Münster, Germany

⁸Pfizer Inc, Groton, CT

⁹Pfizer Inc, San Diego, CA

¹⁰Navigate BioPharma Services (formerly Genoptix BioPharma Services), a Novartis subsidiary, Carlsbad, CA

¹¹Pfizer Inc, Cambridge, MA

¹²Pfizer Pharma GmbH, Berlin, Germany

¹³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

2732 Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Therapies, enzyme inhibitors, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jorge E. Cortes, MD¹, Cristina Papayannidis², Catriona Jamieson, MD, PhD^{3,4}, Gary J. Schiller, MD⁵, Anna Candoni, MD^{6*}, Brian Leber, MD⁷, Claudia D. Baldus, MD⁸, José A. Pérez-Simón, MD, PhD⁹, Weidong Wendy Ma^{10*}, Corrado Gallo Stampino^{10*}, Ashleigh O'Connell^{10*}, Mirjana Zeremski, MD^{11*}, Geoffrey Chan, MD¹² and Mikkael A. Sekeres, MD, MS¹³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy

³Sanford Stem Cell Clinical Center, University California, San Diego, La Jolla, CA

⁴Moore's Cancer Center, University of California, San Diego, La Jolla, CA

⁵Ronald Regan University of California Los Angeles Medical Center, Santa Monica, CA

⁶Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

⁷Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

⁸Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Germany

⁹Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain

¹⁰Pfizer Inc, New York, NY

¹¹Pfizer Canada Inc., Kirkland, QC, CAN

¹²Pfizer Oncology, Collegeville, PA

¹³Leukemia Program, Cleveland Clinic, Cleveland, OH

2735 Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

AML, Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rachel J. Cook, MD¹, **Tamara Moyo, MD, PhD^{2*}**, **Jane L. Liesveld, MD³**, **David A. Rizzieri, MD⁴**, **Eytan M. Stein, MD⁵**, **Stephane De Botton, MD, PhD^{6*}**, **Gail J. Roboz, MD⁷**, **Mikael A. Sekeres, MD, MS⁸**, **Joseph G. Jurcic, MD⁹**, **Azra Raza, MD¹⁰**, **Robert L. Redner, MD¹¹**, **Dale L. Bixby, MD, PhD^{12*}**, **Jorge E. Cortes, MD¹³**, **Kristin Stephens^{14*}**, **Angela Volkert^{14*}**, **Qing Kang, PhD^{14*}**, **Emmanuelle Di Tomaso, PhD^{14*}**, **David A. Roth, MD¹⁴** and **Carlos E Vigil, MD¹⁵**

¹Knight Cancer Institute, Oregon Health and Science University, Portland, OR

²Vanderbilt University, Nashville, TN

³Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

⁴Dept. of Medicine, Div. of Hematological Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC

⁵Division of Hematologic Oncology, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁶Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

⁷Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

⁹Columbia University Medical Center, New York, NY

¹⁰Myelodysplastic Syndrome Center, Columbia University Medical Center, New York, NY

¹¹UPMC Hillman Cancer Center, Pittsburgh, PA

¹²Internal Medicine, University of Michigan, Ann Arbor, MI

¹³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

¹⁴Syros Pharmaceuticals, Cambridge, MA

¹⁵Division of Hematology, Oncology, and Blood & Marrow Transplantation, The University of Iowa, Iowa City, IA

2809 Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Aziz Nazha, MD¹, **Manja Meggendorfer, PhD²**, **Sudipto Mukherjee, MD, PhD, MPH¹**, **Wencke Walter, PhD^{2*}**, **Stephan Hutter, PhD^{2*}**, **Ahed Makhoul, MD^{3*}**, **Cassandra M. Hirsch^{4*}**, **Bartlomiej P. Przychodzen^{5*}**, **Hetty E. Carraway, MD, MBA^{6,7}**, **Yasunobu Nagata^{4*}**, **Yihong Guan^{8*}**, **Teodora Kuzmanovic, BA^{5*}**, **Metis Hasipek, PhD^{4*}**, **Babal K. Jha^{5*}**, **Jaroslav P. Maciejewski⁵**, **Claudia Haferlach, MD²**, **Mikael A. Sekeres, MD, MS⁹** and **Torsten Haferlach, MD²**

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Germany

³Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2874 Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Follicular Lymphoma, Diseases, Biological, Adult, Therapies, Mantle Cell Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Paolo Caimi, MD¹, Brad S. Kahl, MD^{2*}, Mehdi Hamadani, MD³, Carmelo Carlo-Stella, MD⁴, Shui He, PhD^{5*}, David Ungar, MD^{6*}, Jay Feingold, MD, PhD^{7*}, Kirit M. Ardeshtna, MA MD FRCP FRCPath⁸, John Radford, MD, FRCP^{9*}, Melhem Solh, MD¹⁰, Leonard Heffner, MD^{11*} and Owen A. O'Connor, M.D., Ph.D.¹²

¹Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH

²Siteman Cancer Center, Washington University, St Louis, MO

³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

⁴Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

⁵ADC Therapeutics, Inc., Murray Hill, NJ

⁶ADC Therapeutics America, Inc, Murray Hill

⁷ADC Therapeutics, Inc, Murray Hill, NJ

⁸Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

⁹The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

¹⁰Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

¹¹Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory

¹²Center for Lymphoid Malignancies, Department of Medicine, Columbia University, New York, NY

2878 Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Matthew J Maurer, MS^{1,2}, Amy S. Ruppert, MAS, PhD^{3*}, Brian K. Link, MD⁴, Lawrence D Kaplan, MD⁵, David J Inwards, MD^{6*}, Andrew L. Feldman, MD⁷, Eric D. Hsi, MD⁸, Adam Pettinger^{9*}, Jonathon B. Cohen, MD, MS¹⁰, Peter Martin, FRCP, MD, MS¹¹, Brad S Kahl, MD¹², Nancy L. Bartlett, MD¹³, James R. Cerhan, MD, PhD¹⁴, John P. Leonard, MD¹⁵ and Thomas M. Habermann, MD¹⁴

¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN

²Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

³Division of Hematology, The Ohio State University, Columbus, OH

⁴Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

⁵Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

⁸Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁹Alliance Statistical and Data Center, Mayo Clinic, Rochester, MN

¹⁰Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹¹Division of Hematology and Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

¹²Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

¹³Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

¹⁴Mayo Clinic, Rochester, MN

¹⁵Weill Medical College of Cornell University, New York, NY

2893 Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Follicular Lymphoma, Leukemia, Diseases, Adult, Non-Biological, Therapies, CLL, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Andrew D. Zelenetz, MD, PhD¹, Jacob D. Soumerai, MD², Deepa Jagadeesh, MD, MPH³, Nishitha Reddy, MD⁴, Anastasios Stathis, MD^{5*}, Adam S. Asch, MD⁶, Huda S. Salman, MD⁷, Vaishalee P. Kenkre, MD⁸, Haresh Jhangiani, MD, MBA^{9*}, Alexia Iasonos, PhD^{10*}, Patel Krish, MD^{11*}, Richard G Ghalie, MD, MBA¹² and John M. Pagel, MD, PhD¹³

¹Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY

²Center for Lymphoma, Massachusetts General Hospital, Boston, MA

³Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

⁵Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

⁶Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

⁷Stony Brook University, Stony Brook, NY

⁸Division of Hematology/Oncology, University of Wisconsin, Madison, WI

⁹Compassionate Care Research Group, Fountain Valley, CA

¹⁰Memorial Sloan-Kettering Cancer Center, New York, NY

¹¹Swedish Cancer Institute, Seattle, WA

¹²MEI Pharma, San Diego, CA

¹³Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

2914 The Predictive Value of PET/CT for Post-Transplant Outcomes in T Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, Non-Biological, Therapies, Biological Processes, chemotherapy, Technology and Procedures, T-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement, imaging

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nancy Kaddis, MD, MPH¹, Eric D Jacobsen, MD², Ailbhe O'Neill, MD^{3*}, Nikhil Ramaiya, MD^{4*} and Robert A. Redd, MS^{5*}

¹Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

³Department of Radiology, St Vincent's University Hospital, Dublin 4, Ireland

⁴Department of Radiology, Case Western Reserve Hospitals, Cleveland, OH

⁵Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

2925 Pooled Safety Analysis and Efficacy of Tenufovir (RP6530), a PI3K δ / γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Therapies, Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Swami P. Iyer, MD¹, Auris Huen, MD^{2*}, Andres J M Ferreri, MD³, Brad M. Haverkos, MD, MPH, MS⁴, Jasmine M. Zain, MD⁵, Radhakrishnan Ramchandren, MD⁶, Mary Jo Lechowicz, MD⁷, Sumana Devata, MD⁸, Neil Korman, MD^{9*}, Lauren C. Pinter-Brown, MD¹⁰, Richard Delarue, MD¹¹, Kasi Viswanath V Routhu, PhD^{12*}, Prajak Barde, MD^{13*}, Ajit M Nair, PhD^{13*} and Carmelo Carlo-Stella, MD¹⁴

¹The Methodist Cancer Center, Houston, TX

²The University of Texas MD Anderson Cancer Center, Houston, TX

³Unit of Lymphoid Malignancies, IRCCS San Raffaele Scientific Institute, Milano, Italy

⁴University of Colorado, Denver, CO

⁵Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

⁶Department of Oncology, Karmanos Cancer Institute, Detroit, MI

⁷Emory University, Atlanta, GA

⁸Internal Medicine/Hematology/Oncology, University of Michigan, Ann Arbor, MI

⁹Department of Dermatology at Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

¹⁰University of California, Irvine, Beverly Hills, CA

¹¹Hematology Department / Hemophilia Center, Necker University Hospital, AP-HP, Paris, France

¹²Rhizen Pharmaceuticals S.A., Hyderabad, Telangana, India

¹³Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds,, Switzerland

¹⁴Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy

2927 Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Chul S. Ha, MD¹, Hongli Li, MS^{2*}, Heiko Schoder, MD^{3*}, Chelsea C Pinnix, MD^{4*}, Elizabeth Brem, MD⁵, Nancy L. Bartlett, MD⁶, Andrew M. Evens, DO, MSc⁷, Eric D. Hsi, MD⁸, Lisa M. Rimsza, MD⁹, John P. Leonard, MD¹⁰, Brad S Kahl, MD¹¹, Michael L. Leblanc, PhD^{2*}, Sonali M. Smith, MD¹², Louis S. Constine, MD¹³ and Jonathan W. Friedberg, MD¹³

¹University of Texas Health Science Center At San Antonio, San Antonio, TX

²SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

³Memorial Sloan Kettering Cancer Center, New York, NY

⁴Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston

⁵Division of Hematology/Oncology, Dept. of Medicine, University of California at Irvine School of Medicine, Huntington Beach, CA

⁶Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

⁷Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

⁸Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁹Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ

¹⁰Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

¹¹Department of Medicine, Washington University School of Medicine, Saint Louis, MO

¹²University of Chicago, Chicago, IL

¹³Wilmot Cancer Institute, University of Rochester, Rochester, NY

2967 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

Hematology Disease Topics & Pathways:

Diseases, Biological, Lymphoma (any), Therapies, CAR-Ts, Non-Hodgkin Lymphoma, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sattva S. Neelapu, MD¹, Armin Ghobadi, MD^{2*}, Caron A. Jacobson, MD, MMSc^{3*}, David B. Miklos, MD, PhD⁴, Lazaros J. Lekakis, MD^{5*}, Olalekan O. Oluwole, MBBS, MPH⁶, Yi Lin, MD, PhD⁷, Ira Braunschweig, MD^{8*}, Brian T. Hill, MD, PhD^{9,10}, John M. Timmerman, MD¹¹, Abhinav Deol, MD¹², Patrick M. Reagan, MD¹³, Patrick J. Stiff, MD¹⁴, Ian W. Flinn, MD, PhD¹⁵, Umar Farooq, MD¹⁶, Andre Goy, MD¹⁷, Peter A. McSweeney, MD^{18*}, Javier Munoz, MD¹⁹, Tanya Siddiqi, MD²⁰, Julio C. Chavez, MD²¹, Alex F. Herrera, MD²², Allen Xue, PhD^{23*}, Yizhou Jiang, PhD^{23*}, Adrian Bot, MD, PhD^{23*}, John M. Rossi, MS^{23*}, Jenny J. Kim, MD, MS^{23*}, William Y. Go, MD, PhD²³ and Frederick L. Locke, MD²⁴

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

²Washington University School of Medicine, St. Louis, MO

³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

⁴Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

⁵University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL

⁶Vanderbilt-Ingram Cancer Center, Nashville, TN

⁷Division of Hematology, Mayo Clinic, Rochester, MN

⁸Department of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹UCLA David Geffen School of Medicine, Los Angeles, CA

¹²Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹³Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

¹⁴Loyola University Medical Center, Maywood, IL

¹⁵Sarah Cannon Research Institute, Nashville, TN

¹⁶Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

¹⁷John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

¹⁸Colorado Blood Cancer Institute, Denver, CO

¹⁹Banner MD Anderson Cancer Center, Gilbert, AZ

²⁰City of Hope National Medical Center, Duarte, CA

²¹H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

²²Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

²³Kite, a Gilead Company, Santa Monica, CA

²⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

3027 Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Adult, Therapies, Non-Biological, Biological Processes, MPN, epigenetics, Study Population, Clinically relevant, Myeloid Malignancies, TKI, signal transduction

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Raajit K. Rampal, MD, PhD¹, John Mascarenhas, MD², Heidi E. Kosiorek, MS^{3*}, Rupali Bhawe, M.D.^{4*}, Elizabeth O. Hexner, MD, MS⁵, Eunice S. Wang, MD⁶, Aaron T. Gerds, MD, MS⁷, Mark L Heaney, MD, PhD⁸, Camille N Abboud, MD⁹, Marina Kremyanskaya, MD, PhD^{10*}, Dmitriy Berenzon, MD^{11*}, Olatoyosi Odenike, MD¹², Elizabeth Virtgaym^{13*}, Lonette Sandy^{10*}, Rona Singer Weinberg, PhD¹⁴, Vesna Najfeld, PhD¹⁵, Mohamed E. Salama, MD¹⁶, Ross L. Levine, MD¹⁷, Ruben A. Mesa, MD, FACP¹⁸, Amylou C. Dueck, PhD¹⁹ and Ronald Hoffman, MD¹⁰

¹Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY

²Icahn School of Medicine at Mount Sinai, New York, NY

³Department of Biostatistics, Mayo Clinic, Scottsdale, AZ

⁴Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC

⁵Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

⁶Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

⁷Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸Columbia University Medical Center, New York, NY

⁹Division of Oncology, Washington University School of Medicine, Saint Louis, MO

¹⁰Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

¹¹Comprehensive Cancer Center, Wake Forest Baptist Health, Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC

¹²Section of Hematology/Oncology, University of Chicago, Chicago, IL

¹³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

¹⁴New York Blood Center, New York, NY

¹⁵Division of Hematology/Medical Oncology/Pathology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY

¹⁶Mayo Medical Laboratories, Rochester, MN

¹⁷Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

¹⁸UT Health San Antonio Cancer Center, San Antonio, TX

¹⁹Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ

3073 LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS, RNA sequencing

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Courtney Hershberger, BS^{1*}, James Hiznay^{1*}, Rosemary Dietrich^{1*}, Xiaorong Gu, PhD^{2*}, Cassandra M. Hirsch^{3*}, Amy Graham, BS, MS^{3*}, Bartłomiej P. Przychodzen^{3*}, Valeria Visconte, PhD³, Vera Adema, PhD^{4*},

Yvonne Parker^{5*}, Hetty E. Carraway, MD, MBA^{6,7}, Tomas Radivoyevitch, PhD^{3*}, Mikkael A. Sekeres, MD, MS⁸, Yogenthiran Sauntharajah, MD⁹, Jaroslaw P. Maciejewski¹³ and Richard A Padgett^{1*}

¹Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland
Cleveland Clinic, Cleveland

⁵Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

3074 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Cassandra M. Hirsch^{1*}, Wenyi Shen, MD^{2*}, Bartlomiej P. Przychodzen^{1*}, Yasunobu Nagata^{3*}, Vera Adema, PhD^{4*}, Teodora Kuzmanovic, BA^{1*}, Louis Williams, MD, MBA¹, Aziz Nazha, MD⁵, Valeria Visconte, PhD⁶, Hetty E. Carraway, MD, MBA⁷, Mikkael A. Sekeres, MD, MS⁸ and Jaroslaw P. Maciejewski^{1,9}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, OH

⁵Cleveland Clinic, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, CMML, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Teodora Kuzmanovic^{1*}, Bhumika J. Patel, MD², Srinivasa Reddy Sanikommu, MD³, Yasunobu Nagata^{4*}, Hassan Awada, MD⁵, Cassandra M. Hirsch^{4*}, Bartlomiej P. Przychodzen^{1*}, Remco J Molenaar, MD PhD^{6,7*}, Babal K. Jha^{1*}, Sudipto Mukherjee, MD, PhD, MPH², Anjali S. Advani, MD⁸, Aziz Nazha, MD², Aaron T. Gerds, MD, MS⁹, Hetty E. Carraway, MD, MBA^{8,10}, Mikkael A. Sekeres, MD, MS¹¹, Jaroslaw P. Maciejewski^{4,12} and Tomas Radivoyevitch, PhD^{4,13*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium health, Charlotte, NC

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

⁶Academic Medical Center, Amsterdam, Netherlands

⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹²Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, apoptosis, Non-Biological, Therapies, MDS, Biological Processes, chemotherapy, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David A Sallman, MD¹, Amy E. DeZern, MD², David P. Steensma, MD³, Kendra L. Sweet, MD¹, Thomas Cluzeau, MD, PhD^{4*}, Mikkael A. Sekeres, MD, MS⁵, Guillermo Garcia-Manero, MD⁶, Gail J. Roboz, MD⁷, Amy F McLemore, M.S.^{1*}, Kathy L McGraw, PhD¹, John Puskas, PhD^{1*}, Ling Zhang, MD¹, Chirag K Bhagat, PharmD^{8*}, Jiqiang Yao, PhD^{9*}, Najla Al Ali, M.Sc^{10*}, Eric Padron, MD¹, Roger Tell, MD, PhD^{11*}, Jeffrey E. Lancet, MD¹, Pierre Fenaux, MD, PhD^{12*}, Alan F. List, MD¹ and Rami S. Komrokji, MD¹

¹Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁴Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

⁵Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁶Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁷Weill Cornell Medical College, New York, NY

⁸Genoptix, Inc, Carlsbad, CA

⁹Cancer Informatics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa

¹⁰H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹¹Apria Therapeutics, Solna, Sweden

¹²Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France

3095 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sudipto Mukherjee, MD, PhD, MPH^{1,2}, Tomas Radivoyevitch, PhD^{3,4*}, Brian P. Hobbs, PhD^{5*}, Xuefei Jia, MS^{3*}, Rami S. Komrokji, MD⁶, David P. Steensma, MD⁷, Amy E. DeZern, MD⁸, Gail J. Roboz, MD⁹, Guillermo Garcia-Manero, MD¹⁰, Jaroslaw P. Maciejewski⁴, Aziz Nazha, MD¹ and Mikkael A. Sekeres, MD, MS^{11,12}

¹Cleveland Clinic, Cleveland, OH

²Leukemia Program, Cleveland Clinic, Cleveland, OH

³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

⁷Dana-Farber Cancer Institute, Boston, MA

⁸Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁹Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹⁰Department of Leukemia, MD Anderson Cancer Center, Houston, TX

¹¹Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

3096 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, MDS, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sudipto Mukherjee, MD, PhD, MPH¹, David P. Steensma, MD², Rami S. Komrokji, MD³, Amy E. DeZern, MD⁴, Gail J. Roboz, MD⁵, Guillermo Garcia-Manero, MD⁶, **Aziz Nazha, MD⁷**, **Jaroslav P. Maciejewski⁸**, **Mikkael A. Sekeres, MD, MS⁹**, **Brian P. Hobbs, PhD^{10*}** and Xuefei Jia, MS^{11*}

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Dana-Farber Cancer Institute, Boston, MA

³Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁵Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

⁶Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁷Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

3098 What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rami S. Komrokji, MD¹, **Najla Al Ali, MSc^{2*}**, David A Sallman, MD³, Eric Padron, MD¹, **Aziz Nazha, MD⁴**, David P. Steensma⁵, Amy E. DeZern, MD⁶, Gail J. Roboz, MD⁷, Guillermo Garcia-Manero, MD⁸, **Mikkael A. Sekeres, MD, MS⁴**, Jeffrey E. Lancet, MD¹ and Alan F. List, MD⁹

¹Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

²Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

³Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Dana-Farber Cancer Institute, Boston, MA

⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁷Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York

⁸Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁹H. Lee Moffitt Cancer Center, Tampa, FL

3103 Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:

Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Andrea Kuendgen, MD^{1*}, Meritxell Nomdedeu^{2*}, Heinz Tuechler^{3*}, Guillermo Garcia-Manero, MD⁴, Rami S. Komrokji, MD⁵, **Mikkael A. Sekeres, MD, MS⁶**, Matteo Giovanni Della Porta^{7*}, Alan F. List, MD⁸, Mario Cazzola⁹, Amy E. DeZern, MD¹⁰, Gail J. Roboz, MD¹¹, David P. Steensma, MD¹², Arjan A. Van de Loosdrecht, MD, PhD¹³, Hartmut Döhner, MD¹⁴, Xavier Calvo, MD^{15*}, Sabine Blum^{16*}, Arturo Pereira, MD, PhD^{17*}, Peter Valent¹⁸, Dolors Costa^{19*}, Aristoteles Giagounidis²⁰, Luis Benlloch^{21*}, Uwe Platzbecker, MD²², Carme Pedro, MD^{23*}, Michael Lübbert²⁴, Itziar Ojartzabal^{25*}, Javier Grau^{26*}, Maria Díez-Campelo^{27*}, María Teresa Cedena^{28*}, Sigrid Machherndl-Spandl, MD^{29*}, Maria López-Pavía^{30*}, Claudia D. Baldus, MD³¹, Montserrat Martínez-de-Sola^{32*}, Reinhard Stauder, MD, MSc³³, Brayan Merchan^{34*}, Christina Ganster³⁵, Thomas Schroeder^{36*}, Barbara Hildebrandt^{37*}, Jordi Esteve, MD, PhD³⁸, Benet Nomdedeu^{39*}, Francesc Cobo^{40*}, Francesc Sole, PhD⁴¹, Rainer Haas, MD^{42*}, Ulrich Germing, MD^{43*}, Peter L Greenberg, M.D.⁴⁴, Detlef Haase, MD, PhD^{35*} and Guillermo Sanz, MD, PhD⁴⁵

- ¹Department of Hematology, Oncology, and Clinical Immunology, Duesseldorf, DEU
²Hospital Clinic, Spanish MDS Cooperative Group, Barcelona, ESP
³Boltzmann Institute for Leukemia Research, Hanusch Hospital, Vienna, Austria
⁴Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁵Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁷Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University, Rozzano - Milan, Italy
⁸H. Lee Moffitt Cancer Center, Tampa, FL
⁹Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
¹⁰Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
¹¹Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
¹²Dana-Farber Cancer Institute, Boston, MA
¹³Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
¹⁴Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
¹⁵Laboratori de Citologia Hematològica i Citogenètica, servei de Patologia, Hospital del Mar. GRETNHE - Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
¹⁶Service of Hematology, University Hospital Lausanne, Lausanne, Switzerland
¹⁷Hemotherapy and Hemostasis Department, Hospital Clinic, Barcelona, Spain
¹⁸Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
¹⁹Hospital Clínic-IDIBAPS, Barcelona, Spain
²⁰Department of Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany
²¹Spanish Cooperative Group, Valencia, Spain
²²University Hospital Dresden, Dresden, Germany
²³Hospital del Mar, Barcelona, Spain
²⁴Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
²⁵Hospital Universitario Araba, Vitoria-Gasteiz, Spain
²⁶Department of Laboratory Hematology, University Hospital Germans Trias i Pujol. ICO Josep Carreras Leukemia Research Institute, Badalona, Spain
²⁷Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain
²⁸Hospital Universitario 12 de Octubre, Madrid, Spain
²⁹1st. Internal Department – Hematology with stem cell transplants, hemostaseology and medical oncology, Elisabethinen Hospital, Linz, Austria
³⁰Hospital General Universitari de València, Hematology Service, Valencia, Spain
³¹Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Germany
³²Hospital Parc Taulí, Sabadell, Spain
³³Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
³⁴Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
³⁵Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
³⁶Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
³⁷Institute of Human Genetics, University Duesseldorf, duesseldorf, Germany
³⁸Hematology Department, Hospital Clínic, Barcelona, Spain
³⁹Hospital Clínic i Provincial, Barcelona, Spain
⁴⁰Hospital Quirón Teknon, Barcelona, Spain
⁴¹MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
⁴²Department for Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Duesseldorf, Germany
⁴³Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
⁴⁴Stanford University Cancer Center, Stanford, CA
⁴⁵Hematology Department, Hospital Universitario La Fe, Valencia, Spain

3142 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Anthony R. Mato, MD MSCE¹, Lindsey E. Roeker, MD¹, Toby A. Eyre^{2*}, Chadi Nabhan, MD³, Nicole Lamanna, MD⁴, Brian T. Hill, MD, PhD^{5,6}, Danielle M. Brander, MD⁷, Paul Barr, MD^{8,9}, Frederick Lansigan, MD¹⁰, Bruce Cheson, MD¹¹, Arun K Singavi, MD¹², Maryam Yazdy, MD¹³, Nirav N Shah, MD¹⁴, John N. Allan, MD¹⁵, Erica B Bhavsar, BS^{16*}, Joanna Rhodes, MD¹⁷, Kaitlin Kennard, RN, BSN^{18*}, Stephen J. Schuster, MD¹⁹, Annalynn M Williams, MS²⁰, Alan P Skarbnik, MD²¹, Andre Goy, MD²², Catherine C. Coombs, MD²³, Hande H. Tuncer, MD²⁴, Chaitra S. Ujjani, MD²⁵, Ryan Jacobs, MD²⁶, Allison M. Winter,

MD²⁷, John M. Pagel, MD, PhD²⁸, Neil Bailey, MSc^{28*}, Anna Schuh, MD²⁹, Mazyar Shadman, MD, MPH²⁵, Andrea Sitlinger, MD³⁰, Hanna Weissbrot, BS^{31*}, Sivraj Muralikrishnan, MD¹⁰, Amy A Kirkwood, MSc^{32*} and Christopher P. Fox, MD, PhD^{33*}

¹CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

²Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom

³Cardinal Health Specialty Solutions, Deerfield, IL

⁴Herbert Irving Comprehensive Cancer Center (New York-Presbyterian Columbia University Medical Center), New York, NY

⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Duke Cancer Institute, Duke University Health System, Durham, NC

⁸Willmot Cancer Institute, University of Rochester, Rochester, NY

⁹University of Rochester, Rochester, NY

¹⁰Dartmouth-Hitchcock Medical Center, Lebanon, NH

¹¹Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

¹²Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

¹³Department of hematology and oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

¹⁴Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

¹⁵Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

¹⁶CLL Research Center, Weill Cornell Medicine, New York, NY

¹⁷Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

¹⁸Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹⁹Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

²⁰University of Rochester Medical Center, Rochester, NY

²¹John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

²²John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

²³Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

²⁴Tufts Medical Center, Boston, MA

²⁵Fred Hutchinson Cancer Research Center, Seattle, WA

²⁶Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

²⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

²⁸Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

²⁹Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

³⁰Department of Medicine, Duke University Medical Center, Durham, NC

³¹Columbia University Medical Center, New York, NY

³²Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom

³³Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

3233 Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

antibodies, Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Ujjawal H Gandhi, PhD, MBBS¹, Arjun Lakshman, MD, MRCP^{2*}, Zhubin Gahvari, MD³, Elizabeth McGehee, MD^{4*}, Megan Helena Jagosky, MD^{5*}, Ridhi Gupta, MBBS^{6*}, William Varnado, MD^{7*}, Saurabh Chhabra, MD⁸, Mark A. Fiala, BS^{9*}, **Ehsan Malek, MD¹⁰**, Joshua Mansour, MD¹¹, Barry Paul, MD^{12*}, Alyssa Barnstead^{13*}, Saranya Kodali, MD¹⁴, Amarendra K. Neppalli, MD¹⁵, Michaela Liedtke, MD⁶, Kelly N. Godby, MD^{7*}, Yubin Kang, MD¹⁶, Ankit Kansagra, MD⁴, Emma C. Scott, MD¹⁷, Elvira Umyarova, MD¹⁴, Parameswaran Hari, MBBS, MD¹⁸, Ravi Vij, MBBS¹⁹, Saad Z. Usmani, MD²⁰, Natalie Scott Callander, MD²¹, Robert Frank Cornell, MD²², Shaji K. Kumar, MD²³ and Luciano J Costa, MD, PhD²⁴

¹Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN

²Division of Hematology, Mayo Clinic, Rochester, MN

³University of Wisconsin, Madison, WI

⁴University of Texas Southwestern Medical Center, Dallas, TX

⁵Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC

⁶Stanford Cancer Institute, Stanford, CA

⁷University of Alabama at Birmingham, Birmingham, AL

⁸Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

⁹Washington University School of Medicine, Saint Louis, MO

¹⁰Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

¹¹Medical University of South Carolina, Charleston, SC

¹²Department of Medicine, Duke University School of Medicine, Durham, NC

¹³Oregon Health & Science University, Portland, OR

¹⁴University of Vermont, College of Medicine, Burlington, VT

¹⁵Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

¹⁶Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

¹⁷Knight Cancer Institute, Oregon Health & Science University, Portland, OR

¹⁸CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

¹⁹Section of Stem Cell Transplant and Leukemia, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

²⁰Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC

²¹Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI

²²Department of Medicine, Division of Hematology & Oncology, Vanderbilt Univ. Medical Center, Nashville, TN

²³Department of Hematology, Mayo Clinic, Rochester, MN

²⁴Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

3239 Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Muhammad Usman, MD^{1*}, Warda Faridi, MD^{1*}, Muhammad Asad Fraz, MD^{1*}, Muhammad Junaid Tariq, MD^{1*}, Saad Ullah Malik, MD^{1*}, Fnu Sagar, MD^{1*}, Awais Ijaz, MD^{1*}, Abid Hussain, MD^{1*}, Malik Qistas Ahmad, MD, MBBS^{1*}, Muhammad Jahanzeb Khalil, MD^{1*}, Amna Khalid, MD^{1*}, Midhat Lakhani, MD^{1*}, Ceren Durer, MD^{1*}, Seren Durer, MD^{1*} and Faiz Anwer, MD^{1,2}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3271 Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David S Siegel, MD, PhD¹, Gary J. Schiller, MD², Christy J. Samaras, DO³, Michael Sebag, MD, PhD⁴, Jesus G. Berdeja, MD⁵, Siddhartha Ganguly, MD^{6*}, Jeffrey V Matous, MD⁷, Kevin Song, MD⁸, Christopher S. Seet, MD⁹, Giampaolo Talamo^{10*}, Mirelis Acosta-Rivera^{11*}, Michael Bar^{12*}, Donald P. Quick, MD¹³, Bertrand Anz, MD^{14*}, Gustavo Fonseca^{15*}, Donna Reece^{16*}, Amit Agarwal, MD, PhD¹⁷, Weiyuan Chung^{17*}, Faiza Zafar, MPAS^{17*} and Nizar Bahlis, MD¹⁸

¹John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ

²David Geffen School of Medicine at UCLA, Los Angeles, CA

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴McGill University Health Centre, Montreal, QC, Canada

⁵Sarah Cannon Research Institute, Nashville, TN

⁶The University of Kansas Cancer Center, Fairway, KS

⁷Colorado Blood Cancer Institute, Denver, CO

⁸The Vancouver General Hospital, Vancouver, BC, CAN

⁹UCLA Medical Center, Los Angeles, CA

¹⁰Penn State Hershey Cancer Institute, Hershey, PA

¹¹Fundacion de Investigacion, San Juan, Puerto Rico

¹²Stamford Hospital, Stamford, CT

¹³Joe Arrington Cancer Research Treatment Center, Lubbock, TX

¹⁴Tennessee Oncology, Chattanooga, TN

¹⁵Florida Cancer Specialists, St. Petersburg, FL

¹⁶Princess Margaret Cancer Centre, Toronto, Canada

¹⁷Celgene Corporation, Summit, NJ

¹⁸University of Calgary, Calgary, AB, Canada

3292 Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Muhammad Abu Zar, MD^{1*}, Ahmad Kamal, MD^{1*}, Ali Younas Khan, MD^{1*}, Saad Ullah Malik, MD^{1*}, Mustafa Nadeem Malik, MD^{1*}, Abdul Rafae, MD^{1*}, Ceren Durer, MD^{1*}, Seren Durer, MD^{1*}, Insija Ilyas Selene, MBBS^{1*}, Anum Qureshi^{1*}, Jemin Aby Jose, MD^{1*}, Hafiz Muhammad Fazeel, MD^{1*}, Zunairah Shah, MBBS^{1*}, Muhammad Adil Rehman, MBBS^{1*} and Faiz Anwer, MD^{1,2}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3303 Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, multiple myeloma, Diseases, Therapies, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

William Varnado, MD^{1,2}, Megan Helena Jagosky, MD^{3*}, Zhubin Gahvari, MD⁴, Saurabh Chhabra, MD⁵, Ujjawal H Gandhi, PhD, MBBS⁶, Arjun Lakshman, MD, MRCP^{7*}, Elizabeth McGehee, MD^{8*}, Ridhi Gupta, MBBS^{9*}, Ehsan Malek, MD¹⁰, Mark A. Fiala, BS^{11*}, Joshua Mansour, MD¹², Barry Paul, MD^{13*}, Alyssa Barnstead^{14*}, Saranya Kodali, MD¹⁵, Neppalli Amarendra, MD^{16*}, Michaela Liedtke, MD¹⁷, Kelly N. Godby, MD^{1*}, Yubin Kang, MD¹⁸, Ankit Kansgra, MD^{19*}, Emma C. Scott, MD²⁰, Elvira Umyarova, MD¹⁵, Parameswaran Hari, MBBS, MD²¹, Ravi Vij²², Saad Z. Usmani, MD²³, Robert Frank Cornell, MD²⁴, Shaji K. Kumar, MD²⁵, Natalie Scott Callander, MD²⁶ and Luciano J Costa, MD, PhD²⁷

¹University of Alabama at Birmingham, Birmingham, AL

²University of Alabama in Birmingham, Birmingham

³Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC

⁴University of Wisconsin, Madison, WI

⁵Medical College of Wisconsin, Milwaukee, WI

⁶Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN

⁷Division of Hematology, Mayo Clinic, Rochester, MN

⁸University of Texas Southwestern Medical Center, Dallas, TX

⁹Stanford Cancer Institute, Stanford, CA

¹⁰University of Cincinnati, Cleveland, OH

¹¹Washington University School of Medicine, Saint Louis, MO

¹²Medical University of South Carolina, Charleston, SC

¹³Department of Medicine, Duke University School of Medicine, Durham, NC

¹⁴Oregon Health & Science University, Portland, OR

¹⁵University of Vermont, College of Medicine, Burlington, VT

¹⁶Medical University of South Carolina, Charleston

¹⁷Stanford University Cancer Center, Stanford, CA

¹⁸Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

¹⁹UT Southwestern Medical Center, Dallas, TX

²⁰Knight Cancer Institute, Oregon Health & Science University, Portland, OR

²¹Department of Medicine, Medical College of Wisconsin, Menomonee Falls, WI

²²Washington University School of Medicine at St. Louis, St Louis, MO

²³Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC

²⁴Department of Medicine, Division of Hematology & Oncology, Vanderbilt Univ. Medical Center, Nashville, TN

²⁵Department of Hematology, Mayo Clinic, Rochester, MN

²⁶Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health,, Madison, WI

²⁷Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

3309 Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

Non-Biological, Therapies, chemotherapy

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Insija Ilyas Selene, MBBS¹, Jemin Aby Jose, MD¹, Muhammad Jahanzeb Khalil, MD¹, Muhammad Junaid Tariq, MD¹, Seren Durer, MD¹, Ceren Durer, MD¹, Madeeha Shafqat¹, Shehroz Aslam, MD¹, Zunairah Shah, MBBS¹, Anum Qureshi¹, Faiza Jamil, MD¹, Mustafa Nadeem Malik, MD¹, Abdul Rafae, MD¹, Muhammad Masab, MD² and Faiz Anwer, MD^{3,4}

¹Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

²West Virginia University, west virginia

³Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

⁴Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3365 Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways:

AML, Adult, Diseases, Non-Biological, Therapies, chemotherapy, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Quality Improvement , Myeloid Malignancies, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD¹, Lisa Rybicki, MS², Arden Emrick¹, Victoria Winslow, RN¹, Jamie Starn, RN¹, Jamie Elbersen, RN¹, Brittany Hodgeman, RN¹, Brad Pohlman, MD³, Brian J. Bolwell, MD¹, Aaron T. Gerds, MD, MS¹, Betty K. Hamilton, MD¹, Rabi Hanna, MD⁴, Matt Kalaycio, MD¹, Navneet S. Majhail, MD, MS¹ and Ronald Sobecks, MD¹

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

3379 Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways:

Biological, Adult, Therapies, Bone Marrow Failure, Biological Processes, Technology and Procedures, cell expansion, Study Population, Clinically relevant, hematopoiesis, transplantation

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Hillard M Lazarus, MD¹, Leland Metheny, MD^{2,3}, Tsila Zuckerman, MD^{4,5}, Carolina Escobar, MD⁶, Joseph P. McGuirk, DO⁷, Yael Rosen, MD⁸ and Jacob M. Rowe, MD⁹

¹Case Western Reserve University School of Medicine, Cleveland, OH

²Case Western Reserve University, Cleveland, OH

³Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Cleveland, OH

⁴Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

⁵The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

⁶Texas Oncology-Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, Dallas, TX

⁷Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

⁸Pluristem Ltd., Haifa, Israel

⁹Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

3456 Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Hematology Disease Topics & Pathways:

Diseases, AML, Biological, Therapies, Myeloid Malignancies, transplantation

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rajneesh Nath, MD¹, Zheng Zhou, MD, PhD², Jan Cerny, MD, PhD³, Hai-Lin Wang, MPH^{4*}, Khalid Bo-Subait^{4*}, Zartash Guth^{5*}, Gulrayz Ahmed^{6*}, Muhammad Wagas Khan^{7*}, Gerhard Carl Hildebrandt, MD⁸, Hassan B. Alkhateeb, MD^{9*}, Moussab Damla, MD^{10*}, Mrinal M. Patnaik, MD, MBBS⁹, Brenda M. Sandmaier, MD^{11,12,13}, Daniel J. Weisdorf, MD¹⁴, Marcos de Lima, MD¹⁵, Mark R. Litzow, MD⁹ and Wael Saber, MD, MS^{4*}

¹Banner MD Anderson Cancer Center, Gilbert, AZ

²Lahey Hospital and Medical Center, Burlington, MA

³Division of Stem Cell Transplantation, UMass Memorial Medical Center, Worcester, MA

⁴CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵University of Cincinnati, Cincinnati, OH

⁶Mount Auburn Hospital-Harvard Medical School, Boston, MA

⁷University of Kentucky, Lexington, KY

⁸Department of Internal Medicine, Division of Hematology/BMT, University of Kentucky, Lexington, KY

⁹Division of Hematology, Mayo Clinic, Rochester, MN

¹⁰McGill, Montreal, QC, Canada

¹¹Fred Hutchinson Cancer Research Center, Seattle, WA

¹²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹³Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

¹⁴Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹⁵Case Western Reserve University, Cleveland, OH

3562 The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S Nationwide Study

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster II

Hematology Disease Topics & Pathways:

Diseases, Clinically relevant, Quality Improvement

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Mohamed Mokhtar Bakr, MD^{1*}, Umar Zahid, MD, MPH^{1,2*}, Pavan Tenneti, MD^{3*}, Rehan Farooqi, MD^{4*} and Faiz Anwer, MD^{5,6}

¹Jersey Shore University Medical Center, Neptune, NJ

²Johns Hopkins University, Baltimore, MD

³University of Arizona, Tucson, AZ

⁴Internal Medicine, MedStar Health, Baltimore, MD

⁵Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁶Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

3570 Deaths Due to Thrombotic Versus Bleeding Events within 90 Days of Cancer Associated Thrombosis

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster II

Hematology Disease Topics & Pathways:

Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Mailey L Wilks, MSN, APRN, NP-C^{1*}, Shyam K. Poudel, MD^{2*}, Deborah Y. Park, BS^{3*}, Xuefei Jia, MS^{4*}, Vicki Pinkava, MSBS, PA-C^{2*}, Meghan O'Brien, MS, ANP-BC^{2*}, Barb Tripp, CNS^{1*}, Jung-Min Song, RN, CNS^{2*}, Keith R. McCrae, MD⁵, Alok A. Khorana⁶ and Dana E. Angelini, MD²

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

⁴Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

3600 Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster II

Hematology Disease Topics & Pathways:

Adult, Study Population, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sanghee Hong¹, Lisa Rybicki, MS^{2*}, Jane Dabney, LISW-S^{3*}, Christine Lawrence, LISW-S^{4*}, Betty K. Hamilton, MD⁵, Matt Kalaycio, MD⁶, Linda McLellan, LISW^{6*}, Ronald Sobecks, MD⁶, Stephanie J. Lee, MD, MPH⁷ and Navneet S. Majhail, MD, MS⁶

¹University of Washington, Seattle, WA

²Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

³Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

⁶Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁷Fred Hutchinson Cancer Research Center, Seattle, WA

3671 Heterogeneous Hypoxia-Mediated Neutrophil and Red Blood Cell Adhesion to E-Selectin in Microscale Flow

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, cellular interactions, Biological Processes, Hemoglobinopathies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yuncheng Man^{1*}, Erdem Kucukal, MS^{1*}, Shichen Liu^{1*}, Deepa Manwani, MD^{2,3}, Jane Little, MD^{1,4} and Umut A. Gurkan, PhD¹

¹Case Western Reserve University, Cleveland, OH

²Children's Hospital at Montefiore, Bronx, NY

³Albert Einstein College of Medicine, Bronx

⁴Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

3672 Hypoxia Enhanced Red Cell Adhesion in Vitro May Identify Patients at Risk for Vasculopathy

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III

Hematology Disease Topics & Pathways:

sickle cell disease, Diseases, Hemoglobinopathies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Charlotte Yuan, BA^{1*}, Erina Quinn^{1*}, Sargam Kapoor, MD², Myeongseop Kim, MS^{1*}, Erdem Kucukal, MS^{1*}, Umut A. Gurkan, PhD¹ and Jane Little, MD²

¹Case Western Reserve University, Cleveland, OH

²Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

3798 The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Thrombosis, Thromboembolism

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Alok A. Khorana¹, Nicole M. Kuderer², **Keith R. McCrae, MD**³, Dejan Milentijevic, PhD^{4*}, Guillaume Germain, MA^{5*}, François Laliberté, MA^{5*}, Nguyen Le, BSc^{6*}, Patrick Lefebvre, MA^{7*}, Gary H. Lyman⁸ and Michael B. Streiff⁹

¹Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

²University of Washington, Seattle, WA

³Cleveland Clinic, Cleveland, OH

⁴Janssen Scientific Affairs, LLC, Titusville, NJ

⁵Groupe d'analyse, Ltée, Montréal, QC, Canada

⁶Analysis Group, Inc., Boston

⁷Analysis Group, Inc, Montreal, QC, Canada

⁸Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁹Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

3799 Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Thrombosis, Thromboembolism

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael B. Streiff¹, **Keith R. McCrae, MD**², Nicole M. Kuderer³, Dejan Milentijevic, PhD^{4*}, Guillaume Germain, MA^{5*}, François Laliberté, MA^{5*}, Nguyen Le, BSc^{6*}, Patrick Lefebvre, MA^{7*}, Gary H. Lyman⁸ and **Alok A. Khorana**⁹

¹Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³University of Washington, Seattle, WA

⁴Janssen Scientific Affairs, LLC, Titusville, NJ

⁵Groupe d'analyse, Ltée, Montréal, QC, Canada

⁶Analysis Group, Inc., Boston

⁷Analysis Group, Inc, Montreal, QC, Canada

⁸Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA

⁹Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

3800 Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways:

Biological Processes, cellular interactions, inflammation, molecular interactions, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Dewen You, PhD^{1,2*}, Suman Kundu, MBA^{3*}, **Alvin H. Schmaier, MD**⁴, **Alok A. Khorana**^{5,6} and **Keith R. McCrae, MD**^{3,7}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Department of Cellular and Molecular Medicine, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH

⁴Case Western Reserve University, Cleveland, OH

⁵Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

⁷Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3840 Targeting NAD⁺ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Biological, Animal models, Therapies, bone marrow, Bone Marrow Failure, chemical interactions, Biological Processes, Technology and Procedures, cell expansion, Xenograft models, Study Population, Clinically relevant, Quality Improvement, Myeloid Malignancies, pharmacology, hematopoiesis, transfusion, inflammation, stem cells, metabolomics

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Phillip J Maciejewski^{1*}, Yihong Guan^{2*}, Metis Hasipek, PhD^{2*}, Anand D. Tiwari, PhD.^{1*}, Dale Grabowski, BS^{2*}, James G Phillips, PhD^{2*}, Yogenthiran Sauntharajah, MD¹, Jaroslaw P. Maciejewski^{2,3} and Babal K. Jha^{1,4*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Cleveland Clinic Lerner College of Medicine, Cleveland

3866 Heterozygous CTC1 Variants in Acquired Bone Marrow Failure

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Wenxi Shen, MD^{1,2*}, Cassandra M. Hirsch^{3*}, Bartłomiej P. Przychodzen^{4*}, Reda Z. Mahfouz, MD, PhD^{5*}, Tomas Radivoyevitch^{6*}, Louis Williams, MD, MBA⁷, Mohammad Fahad B. Asad³ and Jaroslaw P. Maciejewski⁸

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

²Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁷NYU, New York, NY

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Bhumika J. Patel, MD¹, Shimoli Vipul Barot, MD², Bartłomiej P. Przychodzen^{3*}, Teodora Kuzmanovic, BA^{3*}, Michael Clemente, MS^{4*}, Cassandra M. Hirsch^{5*}, Valeria Visconte, PhD⁶, Roy Souaid, MD^{7*}, Marissa Versalle^{8*}, Sarah S Lee, MD⁹, Tomas Radivoyevitch^{10*}, Metis Haspiek^{8*}, Swapna Thota, MD¹¹, Aziz Nazha, MD¹², Matt Kalaycio, MD¹³, Anjali S. Advani, MD¹⁴, Hetty E. Carraway, MD, MBA^{14,15}, Mikkael A. Sekeres, MD, MS⁵ and Jaroslaw P. Maciejewski⁵

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Internal Medicine, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

⁷Thor, Cleveland

⁸Cleveland Clinic, Cleveland

⁹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

¹¹Department of Medicine, Roswell Park, Buffalo, NY

¹²Cleveland Clinic, Cleveland, OH

¹³Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁴Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

¹⁵Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

3871 The Shwachman-Diamond Syndrome Registry: Hematologic Complications

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bone Marrow Failure, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Kasiani C. Myers, MD¹, Elissa M. Furutani, MD², Sara Loveless, BSN^{3}, Maggie Malsch, MSN, RN^{4*}, Ashley Galvin^{5*}, Ellie Fratt^{5*}, Jordan Larson^{5*}, Jacob Cotton^{5*}, Leah Cheng^{5*}, Kelly McIntosh^{6*}, Joan Moore, RN^{6*}, Leann Mount, RN^{6*}, **Rabi Hanna, MD⁷**, Winfred Wang, MD⁸, Alison A. Bertuch, MD, PhD⁹, Stella M. Davies, PhD, MBBS, MRCP¹⁰ and Akiko Shimamura, MD, PhD¹¹*

¹Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital, Cincinnati, OH

²Cancer and Blood Disorders Center, Boston Children's Hospital, Boston, MA

³Cincinnati Children's Hospital Medical Center, Cincinnati, OH

⁴Boston Children's Hospital, Boston

⁵Cancer and Blood Disorders Center, Dana-Farber/Boston Children's, Boston

⁶Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati

⁷Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

⁸St. Jude Children's Research Hospital, Memphis, TN

⁹Texas Children's Hospital, Houston, TX

¹⁰Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

¹¹Dana-Farber/Boston Children's Cancer & Blood Disorders Center, Boston, MA

3995 FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

AML, Diseases, Elderly, Technology and Procedures, Study Population, Clinically relevant, genetic profiling, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

James M. Foran, MD¹, Zhuoxin Sun, PhD^{2}, Elisabeth Paietta, PhD³, Janis Racevskis, PhD^{3*}, David F. Claxton, MD⁴, **Hillard M Lazarus, MD⁵**, Daniel A. Arber, MD⁶, Jacob M. Rowe, MD⁷, John Godwin, MD⁸, Yanming Zhang, MD⁹, Martin S. Tallman, MD¹⁰, Mark R. Litzow, MD¹¹, Keith W. Pratz, MD¹² and Selina Luger, MD¹³*

¹Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL

²ECOG-ACRIN statistical center, Boston

³Cancer Center, Montefiore Medical Center, Bronx, NY

⁴Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁶University of Chicago, Chicago, IL

⁷The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

⁸Providence Portland Medical Center, Portland, OR

⁹Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

¹⁰Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

¹¹Division of Hematology, Mayo Clinic, Rochester, MN

¹²John Hopkins University, Baltimore, MD

¹³Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

3999 Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, AML, Adult, Study Population, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rory M Shallis, MD¹, Maximilian Stahl, MD², Wei Wei, MD, PhD^{3*}, Pau Fernandez^{4*}, Etienne Lengline, MD^{5*}, Judith Neukirchen, MD^{6*}, Vijaya R. Bhatt, MD⁷, **Mikael A. Sekeres, MD, MS⁸**, Amir T. Fathi, MD⁹, Heiko Konig, MD, PhD¹⁰, Selina Luger, MD¹¹, Irum Khan, MBBS¹², Gail J. Roboz, MD¹³, Thomas Cluzeau, MD, PhD^{14*}, David Martínez-Cuadron, MD^{15*}, Emmanuel Raffoux, MD^{16*}, Ulrich Germing, MD^{17*}, Jayadev Manikkam Umakanthan, MBBS¹⁸, **Sudipto Mukherjee, MD, PhD, MPH¹⁹**, Andrew M. Brunner, MD²⁰, Adam M. Miller, BS, MD^{10*}, Christine M. McMahon, MD¹¹, Ellen K. Ritchie, MD¹³, Rebeca Rodríguez-Veiga, MD^{15*}, Raphael Itzykson, MD, PhD²¹, Blanca Boluda, MD^{15*}, Florence Rabian, MD^{16*}, Mar Tormo, MD, PhD²², Evelyn Gloria Acuna Cruz, MD^{15*}, Nikolai Podoltsev, MD, PhD^{23,24}, Steven D. Gore, MD^{2,24} and Amer M. Zeidan, MBBS, MHS^{23,24*}

¹Department of Internal Medicine, Section of Hematology, Yale School of Medicine, West Haven, CT

²Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

³Department of Biostatistics, Yale School of Public Health, New Haven, CT

⁴Hospital Universitari i Politècnic La Fe, Valencia; CIBERONC, Instituto Carlos III, Madrid, Spain

⁵Hopital St. Louis, Paris, France

⁶Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Duesseldorf, Germany

⁷Department of Internal Medicine, Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA

¹⁰Indiana University Simon Cancer Center, Indianapolis, IN

¹¹Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹²University of Illinois, Chicago, IL

¹³Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹⁴Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

¹⁵Hospital Universitari i Politècnic La Fe, Valencia, Spain

¹⁶Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

¹⁷Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany

¹⁸University of Nebraska Medical Center, Omaha, NE

¹⁹Cleveland Clinic, Cleveland, OH

²⁰Dana-Farber Cancer Institute, Boston, MA

²¹Hématologie clinique, Hôpital Saint-Louis, Paris, France

²²Hematology Department, Hospital Clínico Universitario, Instituto de investigacion INCLIVA, Valencia, Valencia, Spain

²³Yale Cancer Center, Yale University School of Medicine, New Haven, CT

²⁴Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT

[**4031 Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study**](#)

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

Leukemia, Diseases, Biological, ALL, antibodies, Therapies, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Partow Kebriaei, MD¹, Daniel J. DeAngelo, MD², **Anjali S. Advani, MD³**, Susan M. O'Brien, MD⁴, David Marks⁵, Hagop M. Kantarjian, MD⁶, Elias J. Jabbour, MD⁶, Tao Wang^{7*}, Erik Vandendries, MD, PhD^{8*}, A. Douglas Laird, PhD^{9*}, Sonja Nick, MSc^{10*} and Matthias Stelljes, MD¹¹

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²Dana-Farber Cancer Inst., Boston, MA

³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁴University of California Irvine Medical Center, Orange, CA

⁵University Hospitals Bristol, Bristol, United Kingdom

⁶Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁷Pfizer Inc, Groton, CT

⁸Pfizer Inc, Cambridge, MA

⁹Pfizer Inc, San Diego, CA

¹⁰Pfizer AG, Zurich, Switzerland

¹¹Universitätsklinikum Münster, Münster, Germany

4040 Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

Diseases, AML, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Maximilian Stahl, MD¹, Wei Wei, MD, PhD^{2*}, Pau Fernandez^{3*}, Etienne Lengline, MD^{4*}, Rory M Shallis, MD¹, Judith Neukirchen, MD^{5*}, Vijaya R. Bhatt, MD⁶, **Mikhael A. Sekeres, MD, MS⁷**, Amir T. Fathi, MD⁸, Heiko Konig, MD, PhD⁹, Selina Luger, MD¹⁰, Irum Khan, MBBS¹¹, Gail J. Roboz, MD¹², Thomas Cluzeau, MD, PhD^{13*}, David Martínez-Cuadron, MD^{3*}, Emmanuel Raffoux, MD^{4*}, Ulrich Germing, MD^{5*}, Jayadev Manikkam Umakanthan, MBBS⁶, **Sudipto Mukherjee, MD, PhD, MPH⁷**, Andrew M. Brunner, MD¹⁴, Adam M. Miller, BS, MD^{9*}, Christine M. McMahon, MD¹⁰, Ellen K. Ritchie, MD¹², Rebeca Rodríguez-Veiga, MD^{3*}, Raphael Itzykson, MD, PhD⁴, Blanca Boluda, MD^{3*}, Florence Rabian, MD^{4*}, Mar Tormo, MD^{15*}, Evelyn Gloria Acuna Cruz, MD^{3*}, Emma Rabinovich, MD^{11*}, Brendan Yoo^{10*}, Nikolai A. Podoltsev, MD, PhD¹, Steven D. Gore, MD¹ and Amer M. Zeidan, MBBS, MHS^{1*}

¹Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

²Department of Biostatistics, Yale School of Public Health, New Haven, CT

³Hospital Universitari i Politècnic La Fe, Valencia, Spain

⁴Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

⁵Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

⁶University of Nebraska Medical Center, Omaha, NE

⁷Leukemia Program, Cleveland Clinic, Cleveland, OH

⁸Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA

⁹Indiana University Simon Cancer Center, Indianapolis, IN

¹⁰Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹¹University of Illinois, Chicago, IL

¹²Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

¹³Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France

¹⁴Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

¹⁵University Clinical Hospital, INCLIVA, Valencia, Spain, Valencia, Spain

4067 Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:

apoptosis, Diseases, AML, Therapies, Non-Biological, chemical interactions, cellular interactions, Biological Processes, Technology and Procedures, epigenetics, Clinically relevant, Quality Improvement, Myeloid Malignancies, hematopoiesis, flow cytometry, metabolomics, RNA sequencing, molecular interactions, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Metis Hasipek, PhD^{1*}, Dale Grabowski, BS^{1*}, Yihong Guan^{1*}, **James G Phillips, PhD^{1*}**, **Jaroslav P. Maciejewski¹**, **Hetty E. Carraway, MD, MBA^{2,3}** and Babal K. Jha^{4*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

³Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4146 Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:

Adult, Follicular Lymphoma, Diseases, Non-Hodgkin Lymphoma, Study Population, Lymphoid
Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Allison M. Winter, MD¹, Loretta J. Nastoupil, MD², Melody R. Becnel, MD², James R. Cerhan, MD, PhD³, Thomas M. Habermann, MD³, Brian K. Link, MD⁴, Matthew J. Maurer, MS³, Bita Fakhri, MD, MPH⁵, Prathima Reddy, MD^{6}, Stephen D. Smith, MD⁶, Dhruvika Mukhija, MD^{1*}, **Deepta Jagadeesh, MD, MPH¹**, Amrita Desai, MD^{7*}, Juan Pablo Alderuccio, MD⁷, Izidore S. Lossos, MD⁸, Pooja Mehra, MD^{9*}, Craig A. Portell, MD⁹, Christopher R. D'Angelo, MD^{10*}, Vaishalee P. Kenkre, MD¹⁰, Max L. Goldman, MD¹¹, Oscar Calzada, BS^{11*}, Jonathon B. Cohen, MD, MS¹¹, Mohammad Junaid Hussain, MD¹², Nilanjan Ghosh, MD, PhD¹², Yang Liu, MD^{13*}, Stefan Klaus Barta, MD, MRCP, MS¹⁴, **Paolo F Caimi, MD¹⁵**, Adam Kittai, MD¹⁶, Alexey V Danilov, MD, PhD¹⁶, Timothy Tiutan, MD^{17*}, Peter Martin, FRCPC, MD, MS¹⁷, Nathalie Danielson, MSN, RN, ACNP-BC^{18*}, Manali Kamdar, MD¹⁹, Abhigna Kodali, MD^{20*}, Andrew M. Evens, DO, MSc²¹, Brad S Kahl, MD⁵ and **Brian T. Hill, MD, PhD^{22,23}***

¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

²The University of Texas MD Anderson Cancer Center, Houston, TX

³Mayo Clinic, Rochester, MN

⁴Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

⁵Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO

⁶Seattle Cancer Care Alliance, University of Washington, Seattle, WA

⁷Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

⁸Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

⁹Division of Hematology and Oncology, University of Virginia, Charlottesville, VA

¹⁰Division of Hematology/Oncology, University of Wisconsin, Madison, WI

¹¹Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹²Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

¹³Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

¹⁴Fox Chase Cancer Center, Philadelphia, PA

¹⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁶Knight Cancer Institute, Oregon Health and Science University, Portland, OR

¹⁷Division of Hematology and Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

¹⁸Vanderbilt-Ingram Cancer Center, Nashville, TN

¹⁹Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Denver, CO

²⁰Tufts University School of Medicine and Cancer Center, Boston, MA

²¹Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

²²Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4153 Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:

Adult, Diseases, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant,
Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Krithika Shanmugasundaram, MD¹, Subir Goyal, MPH, MBBS^{2}, Jeffrey M. Switchenko, PhD, MS^{3*}, Oscar Calzada, BS^{4*}, Michael C Churnetski, BS^{5*}, Bhaskar Kolla, MBBS⁶, Veronika Bachanova, MD, PhD⁷, James Nathan Gerson, MD⁸, Stefan Klaus Barta, MD, MRCP, MS⁸, Max J. Gordon, MD⁹, Alexey V Danilov, MD, PhD¹⁰, Natalie S Grover, MD¹¹, Stephanie Mathews, MD^{12*}, Madelyn Burkart, MD^{13*}, Reem Karmali, MD¹⁴, Yazeed Sawalha, MD¹⁵, **Brian T. Hill, MD, PhD^{16,17}**, Nilanjan Ghosh, MD, PhD¹⁸, Steven I Park, MD¹⁹, Narendranath Epperla, MD, MS^{20,21}, David A. Bond, MD²², Talha Badar, MD²³, Kristie A. Blum, MD^{24,25},*

Mehdi Hamadani, MD²⁶, Timothy S. Fenske, MD²⁷, Mary Malacek, MD^{28}, Brad S. Kahl, MD^{29*}, Christopher R Flowers, MD, MS³⁰ and Jonathon B. Cohen, MD, MS²⁴*

¹Department of Hematology and Medical Oncology, Emory University Hospital, Atlanta, GA

²Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA

³Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA

⁴Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

⁵Winship Cancer Institute, Emory University, Atlanta, GA

⁶University of Minnesota, Minneapolis, MN

⁷Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁸Fox Chase Cancer Center, Philadelphia, PA

⁹Oregon Health and Science University, Portland, OR

¹⁰Knight Cancer Institute, Oregon Health and Science University, Portland, OR

¹¹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

¹²UNC, Chapel Hill, NC

¹³Northwestern University, Chicago, IL

¹⁴Division of Hematology, Northwestern University, Chicago, IL

¹⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁶Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁸Levine Cancer Institute, Charlotte, NC

¹⁹Levine Cancer Institute, Concord, NC

²⁰Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH

²¹Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

²²Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH

²³Division of Hematology and Oncology, Medical College of Wisconsin, Brookfield, WI

²⁴Emory University, Atlanta, GA

²⁵Division of Hematology, The Ohio State University, Columbus, OH

²⁶Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

²⁷Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

²⁸Siteman Cancer Center, Washington University, St. Louis, MO

²⁹Siteman Cancer Center, Washington University, St. Louis, MO

³⁰Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

4202 Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yazeed Sawalha, MD¹, John McMichael, PhD^{2*}, Lisa Rybicki, MS^{3*}, Tamara A. Sussman, MD^{1*}, Alex V. Mejia Garcia, MD¹, Robert M. Dean, MD¹, Brad Pohlman, MD¹, Brian T. Hill, MD, PhD^{4,5} and Deepa Jagadeesh, MD, MPH¹

¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

²Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland

³Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4274 Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Therapy: Poster III

Hematology Disease Topics & Pathways:

Diseases, Biological, Adult, CML, Therapies, immunotherapy, Study Population, Myeloid Malignancies, TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Tomas Radivoyevitch^{1*}, Brian P. Hobbs, PhD^{2*} and Jaroslaw P. Maciejewski³

¹Departments of Quantitative Health Sciences and Translational Hematology & Oncology Research, Quantitative Health Sciences, Cleveland, OH

²Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4282 Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Therapies, Non-Biological, Biological Processes, Study Population, Clinically relevant, erythropoiesis, Myeloid Malignancies, inflammation, iron metabolism, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Stephen T Oh, MD, PhD¹, Moshe Talpaz, MD², Aaron T. Gerds, MD, MS³, Vikas Gupta, MD, FRCP, FRCPATH⁴, Srdan Verstovsek, MD, PhD⁵, Ruben A. Mesa, MD, FACP⁶, Carole Brennan Miller, MD⁷, Candido E. Rivera, MD⁸, Angela Fleischman, MD, PhD⁹, Swati Goel^{10*}, Mark L Heaney, MD, PhD¹¹, Casey O'Connell, MD^{12*}, Murat Arcasoy, MD^{13*}, Yafeng Zhang, PhD, MD^{14*}, Jun Kawashima, MD^{15*}, Tomas Ganz, MD, PhD¹⁶ and Carrie Baker Brachmann^{17*}

¹Washington University School of Medicine, Saint Louis, MO

²Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI

³Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Princess Margaret Cancer Centre, Toronto, ON, Canada

⁵Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX

⁶Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

⁷Cancer Center, Ascension/St Agnes, Baltimore, MD

⁸Hematology, Mayo Clinic - Jacksonville, Jacksonville, FL

⁹University of California, Irvine, Irvine, CA

¹⁰Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

¹¹Columbia University Medical Center, New York, NY

¹²Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles, CA

¹³Duke Cancer Institute, Duke University School of Medicine, Durham, NC

¹⁴Biostatistics, Gilead Sciences, Inc., Foster City, CA

¹⁵Gilead Sciences, Inc., Foster City, CA

¹⁶Medicine, University of California, Los Angeles, Los Angeles, CA

¹⁷Gilead Science, Inc., Foster City, CA

4288 Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways:

Diseases, Biological, Therapies, Bone Marrow Failure, transplantation, TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Krisztina L. Gowin, DO¹, Karen K. Ballen, MD^{2*}, Kwang Woo Ahn, PhD^{3,4*}, Zhen-Huan Hu, MPH^{3*}, Ying Liu, PhD^{3,5*}, Lucia Masarova, MD^{6*}, Srdan Verstovsek, MD, PhD⁷, Maria Coakley^{8*}, Tania Jain, MBBS^{9*}, Andrew Kuykendall, MD^{10*}, Rami Komrokji, MD^{11*}, Martha Wadleigh, MD^{12*}, Sarah Patches^{12*}, Murat Arcasoy, MD^{13*}, Michael Green^{13*}, Malathi Kandarpa, PhD^{14*}, Moshe Talpaz, MD¹⁵, Haris Ali, MD¹⁶, Vikas Gupta, MD, FRCP, FRCPATH¹⁷, Rebecca Devlin^{18*}, Laura C. Michaelis, MD¹⁹, Gabriela S. Hobbs, MD²⁰, Brady Lee Stein, MD²¹, Ashley Pariser, MD^{22*}, Aaron T. Gerds, MD, MS²³, Kierstin Kuber^{24*}, Raajit Rampal^{25*}, Edwin P. Alyea III, MD²⁶, Uday Popat, MD²⁷, Ronald Sobecks, MD²⁸, Bart L Scott, MD²⁹, Ruben Mesa, MD^{9*} and Wael Saber, MD, MS^{3*}

¹Department of Hematology, University of Arizona, Tacoma, WA

²Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

⁵Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee

⁶Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

⁷Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

⁸Royal Marsden Hospital, Sutton, United Kingdom

⁹Mayo Clinic Arizona, Phoenix, AZ

¹⁰H. Lee Moffitt Cancer Center, Tampa, FL

¹¹H. Lee Moffitt Cancer Center, Houston, TX

¹²Dana Farber Cancer Institute, Boston, MA

¹³Duke University Medical Center, Durham, NC

¹⁴Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI

¹⁵The University of Michigan Health Systems, Ann Arbor, MI

¹⁶Department of Hematology/HCT, City of Hope Medical Center, Duarte, CA

¹⁷Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

¹⁸Harvard University, Cambridge, MA

¹⁹Medical College of Wisconsin, Milwaukee, WI

²⁰Massachusetts General Hospital, Boston, MA

²¹Dept. of Medicine, Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

²²Yale Smilow Cancer Center, New Haven, CT

²³Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²⁴Washington University, St. Louis, MO

²⁵Memorial Sloan Kettering Cancer Center, New York, NY

²⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

²⁷Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

²⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

²⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

4345 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemotherapy, Biological Processes, epigenetics

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yihong Guan^{1*}, Anand D. Tiwari, PhD^{1*}, Metis Hasipek, PhD^{2*}, Dale Grabowski, BS^{2*}, Yvonne Parker^{2*}, Cassandra M. Hirsch^{2*}, Amy C Graham, BS, MS^{2*}, Yasunobu Nagata^{2*}, Bartłomiej P. Przychodzen^{1*}, Aziz Nazha, MD², Daniel Lindner, MD, PhD^{2*}, Tomas Radivoyevitch, PhD^{2,3*}, James G Phillips, PhD^{2*}, Jaroslaw P. Maciejewski² and Babal K. Jha^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

4346 Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yihong Guan^{1*}, Edward F Greenberg, MD¹, Metis Hasipek, PhD^{1*}, Cassandra M. Hirsch^{1*}, Amy C Graham, BS, MS^{1*}, Tomas Radivoyevitch, PhD^{1,2*}, Shi Chen^{3*}, Xiaochen Liu^{3*}, Valeria Visconte, PhD⁴, Dewen You, PhD^{1*}, Eiju Negoro, MD, PhD^{1*}, Bartłomiej P. Przychodzen^{5*}, Hideki Makishima, MD, PhD^{1,6}, Aziz Nazha, MD¹, Daniel Gackowski, PhD^{7*}, Ewelina Zarakowska^{7*}, Mridul Mukherji, D.Phil.^{8*}, Mikkael A. Sekeres, MD, MS¹, Mingjiang Xu, MD, PhD³, Ryszard Ólinski, Professor^{7*}, Jaroslaw P. Maciejewski¹ and Babal K. Jha^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Biochemistry and Molecular Biology & Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

⁷Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁸School of Pharmacy, University of Missouri - Kansas City, Kansas City, MO

4350 SKI Controls MDS-Associated Chronic TGFb Signaling, Aberrant Splicing, and Stem Cell Fitness

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Animal models, MDS, Biological Processes, Technology and Procedures, Study Population, Myeloid Malignancies, genomics, hematopoiesis, flow cytometry, molecular testing, NGS, RNA sequencing, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David Muench, BS¹, Kyle Ferchen, BS^{2}, Chinavenmeni S. Velu, PhD^{3,4*}, Kith Pradhan, PhD^{5*}, Kashish Chetal, MS^{6*}, Clemencia Colmenares, PhD^{7*}, Amit Verma, MD⁸, Nathan Salomonis, PhD^{6*} and H. Leighton Grimes, PhD⁹*

¹Molecular and Developmental Biology Graduate Program, Cincinnati Children's Hospital Medical Center, Fort Wright, KY

²Department of Cancer Biology, University of Cincinnati, Cincinnati

³Cincinnati Children's Hosp. Med. Ctr., Cincinnati, OH

⁴Cincinnati Children's Hosp. Med. Ctr., Cincinnati

⁵Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

⁶Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

⁷Lerner Research Institute, Cleveland Clinic, Cleveland, OH

⁸Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY

⁹Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

4351 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, genomics, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yasunobu Nagata^{1}, Satoshi Narumi, MD, PhD^{2*}, Yihong Guan^{1*}, Bartłomiej P. Przychodzen^{1*}, Cassandra M. Hirsch^{1*}, Hideki Makishima, MD, PhD³, Hirohito Shima^{2*}, Victor Pastor Loyola, MSc^{4*}, Teodora Kuzmanovic, BA^{1*}, Tomas Radivoyevitch, PhD^{5*}, Vera Adema, PhD^{1*}, Hassan Awada, MD¹, Kenichi Yoshida, MD, PhD^{3*}, Francesc Sole, PhD⁶, Babal K. Jha^{1*}, Rabi Hanna, MD⁷, Thomas Laframboise, PhD^{8*}, Seishi Ogawa, MD, PhD⁹, Mikkael A. Sekeres, MD, MS¹⁰, Marcin W. Wlodarski, MD, PhD^{4,11}, Jorg Cammenga, MD^{12*} and Jaroslaw P. Maciejewski¹*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan

³Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁴Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

⁷Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

⁸Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁹Department of Pathology and Tumor Biology, Kyoto University, Sakyo, Japan

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Hematology, St. Jude Children's Research Hospital, Memphis, TN

¹²Linköping University, Department of Hematology, Linköping, SWE

4352 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, AML, MDS, Biological Processes, Technology and Procedures, DNA repair, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, genomics, NGS, pathogenesis

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Louis Williams, MD, MBA¹, Teodora Kuzmanovic, BA^{2}, Cassandra M. Hirsch^{2*}, Bartlomiej P. Przychodzen^{2*}, Yogenthiran Sauntharajah, MD³, Hassan Awada, MD², Vera Adema, PhD^{2*}, Amy C Graham, BS, MS^{2*}, Tomas Radivoyevitch, PhD^{2*}, Hetty E. Carraway, MD, MBA^{4,5}, Aziz Nazha, MD⁴, Mikkael A. Sekeres, MD, MS⁶ and Jaroslaw P. Maciejewski⁷*

¹NYU, New York, NY

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

⁴Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

AML, Diseases, CMML, MDS, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Teodora Kuzmanovic^{1}, Bhumika J. Patel, MD², Yasunobu Nagata^{3*}, Hassan Awada, MD⁴, Cassandra M. Hirsch^{3*}, Bartlomiej P. Przychodzen^{1*}, Srinivasa Reddy Sanikommu, MD⁵, Louis Williams, MD, MBA⁶, Sudipto Mukherjee, MD, PhD, MPH², Anjali S. Advani, MD⁷, Aziz Nazha, MD⁸, Aaron T. Gerds, MD, MS⁹, Tomas Radivoyevitch, PhD^{3*}, Hetty E. Carraway, MD, MBA^{7,10}, Mikkael A. Sekeres, MD, MS¹¹ and Jaroslaw P. Maciejewski³*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH

⁵Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium health, Charlotte, NC

⁶NYU, New York, NY

⁷Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁸Cleveland Clinic, Cleveland, OH

⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4362 Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, Non-Biological, Therapies, Biological Processes, chemotherapy, MDS, Study Population, epigenetics, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael K Keng, MD¹, Samer K. Khaled, MD², Brenda Cooper, MD³, Erica D. Warlick, MD⁴, David Ramies, MD^{5}, Silvia Mappa, MD^{6*} and Ehab L. Atallah, MD⁷*

¹Division of Hematology/ Oncology, University of Virginia Cancer Center, Charlottesville, VA

²Department of Hematology/HCT, City of Hope, Duarte, CA

³Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

⁴Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁵MEI Pharma, Inc., San Diego, CA

⁶Clinical Research and Development, Helsinn Healthcare, Lugano, Switzerland

⁷Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Ling Zhang, MD^{1*}, Donald M Stablein, PhD^{2*}, Pearlie Epling-Burnette, PhD, PharmD^{3*}, Alexandra M. Harrington, MD, MT(ASCP)⁴, Lynn C. Moscinski, MD⁵, Steven Kroft, MD^{4*}, Amy E. DeZern, MD⁶, Tareq Al Baghdadi, MD^{7*}, Jane Jijun Liu, MD^{8*}, Matthew J. Walter, MD⁹, Rafael Bejar, MD, PhD¹⁰, Edward J. Gorak, DO, MBA, MS¹¹, Rami S. Komrokji, MD¹², Gregory A. Abel, MD, MPH¹³, Bart L Scott, MD¹⁴, Steven D. Gore, MD¹⁵ and **Mikael A. Sekeres, MD, MS¹⁶**

¹University of South Florida, Moffitt Cancer Center, Tampa, FL

²The Emmes Corporation, Rockville, MD

³Moffitt Cancer Center & Research Institute/Immunology Program, Tampa, FL

⁴Medical College of Wisconsin, Milwaukee, WI

⁵H. Lee Moffitt Cancer Center, Tampa, FL

⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁷IHA Hematology Oncology Consultants, Ypsilanti, MI

⁸Illinois Cancer Care, P.C., Peoria, IL

⁹Department of Medicine, Division of Oncology, Washington University In St. Louis, Saint Louis, MO

¹⁰Moore's Cancer Center, University of California, San Diego, La Jolla, CA

¹¹Baptist MD Anderson Cancer Center, Jacksonville, FL

¹²Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹³Dana-Farber Cancer Institute, Boston, MA

¹⁴Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁵Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT

¹⁶Leukemia Program, Cleveland Clinic, Cleveland, OH

4374 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David P. Steensma, MD¹, Rami S. Komrokji, MD², Amy E. DeZern, MD³, Gail J. Roboz, MD⁴, Andrew M. Brunner, MD⁵, Richard M. Stone, MD¹, John Barnard, PhD^{6*} and **Mikael A. Sekeres, MD, MS⁷**

¹Dana-Farber Cancer Institute, Boston, MA

²Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁴Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY

⁵Massachusetts General Hospital, Boston, MA

⁶Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4389 Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, AML, CML, MDS, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Vera Adema, PhD^{1*}, Cassandra M. Hirsch^{1*}, Bartłomiej Przychodzen^{1*}, Yasunobu Nagata^{1*}, **Tomas Radivoyevitch^{2,3*}**, **Thomas Laframboise, PhD^{4*}**, Amy C Graham, BS, MS^{1*}, Louis Williams, MD, MBA¹, Hassan Awada, MD¹, Aziz Nazha, MD⁵, Hetty E. Carraway, MD, MBA^{5,6}, Valeria Santini⁷, Hrishikesh M

Mehta, PhD^{1,8,9*}, Francesc Sole, PhD¹⁰, Mikkael A. Sekeres, MD, MS⁵, Valeria Visconte, PhD¹, Rabi Hanna, MD⁹, Seth J. Corey, MD^{1,9,11} and Jaroslaw P. Maciejewski¹²

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁴Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷MDS Unit, AOU Careggi, University of Florence, Florence, Italy

⁸Division of Hematology-Oncology, Department of Pediatrics, Virginia Commonwealth University, Richmond

⁹Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

¹⁰MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

¹¹Departments of Pediatrics, Microbiology/Immunology, Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA

¹²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways:

Adult, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement , TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Lindsey E. Roeker, MD¹, Christopher P. Fox, MD, PhD^{2*}, Toby A. Eyre^{3*}, John N. Allan, MD⁴, Stephen J. Schuster, MD⁵, Chadi Nabhan, MD⁶, **Brian T. Hill, MD, PhD^{7,8}**, Nirav N Shah, MD⁹, Frederick Lansigan, MD¹⁰, Maryam Yazdy, MD¹¹, Nicole Lamanna, MD¹², Bruce Cheson, MD¹³, Arun K Singavi, MD⁹, Catherine C. Coombs, MD¹⁴, Paul Barr, MD¹⁵, Alan P Skarbnik, MD¹⁶, Mazyar Shadman, MD, MPH¹⁷, Hande H. Tuncer, MD¹⁸, Chaitra S. Ujjani, MD¹⁷, Allison M. Winter, MD¹⁹, Joanna Rhodes, MD⁵, Colleen Dorsey, BSN, RN^{1*}, Hannah Morse, BSN^{20*}, John M. Pagel, MD, PhD²¹, Annalynn M Williams, MS²², Ryan Jacobs, MD²³, Andre Goy, MD²⁴, Sivraj Muralikrishnan, MD¹⁰, Laurie Pearson, MD^{18*}, Andrea Sitlinger, MD²⁵, Neil Bailey, MSc^{21*}, Anna Schuh, MD²⁶, Danielle M. Brander, MD²⁷, Amy A Kirkwood, MSc^{28*} and Anthony R Mato, MD²⁰

¹CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

²Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

³Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom

⁴Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁶Cardinal Health Specialty Solutions, Deerfield, IL

⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

¹⁰Dartmouth-Hitchcock Medical Center, Lebanon, NH

¹¹Department of hematology and oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

¹²Hematology/Oncology Division, Columbia University Medical Center, New York, NY

¹³Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

¹⁴Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

¹⁵University of Rochester, Rochester, NY

¹⁶John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

¹⁷Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁸Tufts Medical Center, Boston, MA

¹⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

²⁰CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

²¹Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

²²University of Rochester Medical Center, Rochester, NY

²³Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

²⁴John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

²⁵Department of Medicine, Duke University Medical Center, Durham, NC

²⁶Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

²⁷Duke Cancer Institute, Duke University Health System, Durham, NC

²⁸Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom

4414 Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways:

Leukemia, Diseases, CLL, Clinically relevant, Lymphoid Malignancies, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Brian Koffman, MDCM, DCFP, DABFM, MS Ed^{1*}, Betsy Dennison, MS, RN^{2*}, Kaitlin Kennard, RN, BSN^{3*}, John C. Byrd, MD⁴, Richard R. Furman, MD⁵, John M. Pagel, MD, PhD⁶, Matthew S Davids⁷, Chadi Nabhan, MD⁸, Neil E. Kay, MD⁹, Tanya Siddiqi, MD¹⁰, Danielle M. Brander, MD¹¹, William G. Wierda, MD, PhD¹², Deborah M. Stephens¹³, **Brian T. Hill, MD, PhD^{14,15}**, Javier Pinilla Ibarz, MD¹⁶, Bruce Cheson, MD¹⁷, Steven T Rosen¹⁸, Farrukh T. Awan, MD^{19,20}, Michael Y. Choi, MD²¹, Thomas E Henry, MBA, RPh, CPh^{16*}, Lindsey E. Roeker, MD²² and Anthony R. Mato, MD MSCE²²

¹CLL Society, Claremont, CA

²Clarity Communications, Pompton Lakes, NJ

³Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁴Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

⁵Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

⁶Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

⁷Department of Medical Oncology, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA

⁸Cardinal Health Specialty Solutions, Dublin, OH

⁹Division of Hematology, Mayo Clinic, Rochester, MN

¹⁰City of Hope National Medical Center, Duarte, CA

¹¹Duke Cancer Institute, Duke University Health System, Durham, NC

¹²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

¹³University of Utah Huntsman Cancer Institute, Salt Lake City, UT

¹⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁶H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹⁷Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC

¹⁸Beckman Research Institute, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA

¹⁹The Ohio State University, Dallas, TX

²⁰Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX

²¹Moore Cancer Center, University of California San Diego, La Jolla, CA

²²CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

4603 Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Hematology Disease Topics & Pathways:

Adult, Diseases, AML, Therapies, Non-Biological, chemotherapy, Biological Processes, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, immune mechanism, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD¹, **Betty K. Hamilton, MD¹**, Lisa Rybicki, MS^{2*}, Dawn Thomas^{3*}, Arden Emrick^{1*}, **Aziz Nazha, MD⁴**, **Sudipto Mukherjee, MD, PhD, MPH⁴**, **Anjali S. Advani, MD⁴**, **Hetty E. Carraway, MD, MBA^{4,5}**, **Brad Pohlman, MD⁶**, **Brian J. Bolwell, MD¹**, **Robert M. Dean, MD¹**, **Aaron T. Gerds, MD, MS¹**, **Rabi Hanna, MD⁷**, **Matt Kalaycio, MD¹**, Aiwen Zhang, PhD^{8*}, **Mikael A. Sekeres, MD, MS⁴**, **Jaroslav P. Maciejewski⁹**, **Navneet S. Majhail, MD, MS¹**, Medhat Askar, MD, PhD^{10*} and **Ronald Sobecks, MD¹**

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Allogen Laboratories, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children's Hospital, Cleveland Clinic, Cleveland, OH

⁸Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, TX

4627 Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster III

Hematology Disease Topics & Pathways:

Diseases, multiple myeloma, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Najla H El Jurdi, MD¹, Ali Filali, PhD^{2*}, Iman Salem, MD^{2*}, Mauricio Retuerto, MS^{2*}, Nina Dambrosio, CNP^{3*}, Hillard M Lazarus, MD⁴, Paolo F Caimi, MD⁵, Richard Creger, PharmD^{3*}, Brenda Cooper, MD⁶, Ben Tomlinson, MD⁷, Leland Metheny, MD⁷, Ehsan Malek, MD⁸, Folashade Otegbeye, MBBChir, MPH⁹, Rafick-Pierre Sekaly, PhD^{2*}, Mahmoud Ghannoum, PhD^{2*} and Marcos de Lima, MD⁷

¹Hematology, Oncology and Transplantation, University of Minnesota, MINNEAPOLIS, MN

²Case Western Reserve University, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

⁴Case Western Reserve University School of Medicine, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

⁶Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁸Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

4695 National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Mohamed Mokhtar Bakr, MD^{1*}, Umar Zahid, MD, MPH^{2,3*}, Pavan Tenneti, MD^{4*}, Alsadiq Waleed Al-Hillan, MD^{5*} and Faiz Anwer, MD^{6,7}

¹Jersey Shore University Medical Center, New Jersey

²Jersey Shore University Medical Center, Neptune, NJ

³Johns Hopkins University, Baltimore, MD

⁴University of Arizona, Tucson, AZ

⁵Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ

⁶Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁷Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ

4709 Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Atin Jindal, MD^{1*}, Jan Kover, BPharm^{2*}, Vanja Raduka, PharmD, R.Ph^{3*} and Timothy E. O'Brien, MD⁴

¹Department of Medicine, Case Western Reserve University, MetroHealth Campus, Cleveland, OH

²Metrohealth Medical Center, Cleveland, OH

³MetroHealth Hospital, Cleveland, OH

⁴MetroHealth Medical Center/Case Western Reserve Univ School of Medicine, Cleveland, OH

4718 Identifying Neutropenic Fever Earlier: An Application of a Skin Patch for Continuous Temperature Monitoring

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nina Dambrosio, CNP^{1*}, Molly Porter, CNP^{2*}, Erica Bauer, RN^{2*}, Nathan Levitan, MD^{3*}, Deborah Liedtke, RN^{2*}, Marcos de Lima, MD⁴ and Ehsan Malek, MD⁵

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

²Seidman Cancer Center, Adult Stem Cell Transplant, Cleveland, OH

³University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect[®] MDS/AML Disease Registry

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Biological, Diseases, Therapies, Non-Biological, chemotherapy, MDS, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Christopher R. Cogle, MD¹, Guillermo Garcia-Manero, MD², David L. Grinblatt³, Rami S. Komrokji, MD⁴, Michael R. Savona, MD⁵, Bart L. Scott, MD⁶, Mikkael A. Sekeres, MD, MS⁷, Chrystal U. Louis^{8*}, E. Dawn Flick^{9*}, Melissa Nifenecker^{8*}, Pavel Kiselev^{8*}, Arlene S. Swern^{8*} and David P. Steensma¹⁰

¹University of Florida, Gainesville, FL

²MD Anderson Cancer Center, Houston, TX

³NorthShore University HealthSystem, Evanston, IL

⁴Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

⁵Vanderbilt-Ingram Cancer Center, Nashville, TN

⁶Fred Hutchinson Cancer Research Center, Seattle, WA

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Celgene Corporation, Summit, NJ

⁹Celgene Corporation, San Francisco, CA

¹⁰Dana-Farber Cancer Institute, Boston, MA

4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect[®] MDS/AML Disease Registry

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Biological, AML, Diseases, Therapies, Myeloid Malignancies, transfusion

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sudipto Mukherjee, MD, PhD, MPH¹, Mehrdad Abedi, MD², Harry P. Erba, MD, PhD³, Daniel A Pollyea, MD⁴, Gail J. Roboz, MD⁵, Michael A. Thompson, MD, PhD, FASCO⁶, Chrystal U. Louis^{7*}, E. Dawn Flick^{8*}, Melissa Nifenecker^{7*}, Pavel Kiselev^{7*}, Arlene S. Swern^{7*} and Christopher R. Cogle, MD⁹

¹Cleveland Clinic, Cleveland, OH

²University of California Davis Comprehensive Cancer Center, Sacramento, CA

³University of Alabama at Birmingham, Birmingham, AL

⁴University of Colorado, Denver, CO

⁵Weill Cornell Medical College, New York, NY

⁶Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI

⁷Celgene Corporation, Summit, NJ

⁸Celgene Corporation, San Francisco, CA

⁹University of Florida, Gainesville, FL

4755 Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Lymphoma (any), Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Shafia Rahman, MD¹, Lisa Rybicki, MS^{2*}, Eric Cober, MD^{3*}, Robert M. Dean, MD⁴, Betty K. Hamilton, MD⁵, Deepa Jagadeesh, MD, MPH⁴, Brian T. Hill, MD, PhD^{6,7}, Brad Pohlman, MD⁸, Ronald Sobecks, MD⁹, Matt Kalaycio, MD⁹, Sherif Mossad, MD^{3*} and Navneet S. Majhail, MD, MS⁹

¹Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Infectious Disease, Medicine Institute, Cleveland Clinic, Cleveland, OH

⁴Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

⁶Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Diseases, Leukemia, Therapies, Non-Biological, CLL, chemotherapy, Clinically relevant, Lymphoid Malignancies, pharmacology

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Anthony R Mato, MD¹, Maryam Sarraf Yazdy, MD^{2*}, Brian T. Hill, MD, PhD^{3,4}, Mazyar Shadman^{5*}, Hande Tuncer, MD^{6*}, Allison M. Winter, MD⁷, Kaitlin Kennard, RN, BSN^{8*}, John N. Allan, MD⁹, Chaitra S. Ujjani, MD¹⁰, Danielle M. Brander, MD¹¹, Chadi Nabhan, MD¹², Paul Barr, MD¹³, Jennifer R. Brown, MD, PhD¹⁴, Christopher P. Fox, MD, PhD^{15*}, Joanna Rhodes, MD¹⁶, Anna Schuh, MD¹⁷, Toby A. Eyre, MD^{18*}, Nicole Lamanna, MD^{19*}, Nitin Jain, MD²⁰, William G. Wierda, MD, PhD²¹, Alan P Skarbnik, MD²², Lindsey E. Roeker, MD²³, Rajat Bannerji, MD, PhD²⁴, Andrew M. Evens, MD^{25*}, Frederick Lansigan, MD²⁶, Jennifer C. Samp, MS, PharmD^{27*}, Jacqueline Nielsen, PhD^{28*}, James M. Pauff^{27*}, Thomas J. Kipps, MD, PhD²⁹, Stephen J. Schuster, MD³⁰, George A Follows, MD, PhD^{31*}, Bruce Cheson, MD³² and Barbara Eichhorst^{33*}

¹CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

²Division of Hematology, Medstar Georgetown University Hospital, Washington, DC

³Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁶Tufts Medical Center, Boston, MA

⁷Cleveland Clinic, Cleveland, OH

⁸Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁹Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

¹⁰Fred Hutchinson Cancer Research Center, Seattle, WA

¹¹Duke Cancer Institute, Duke University Health System, Durham, NC

¹²Cardinal Health Specialty Solutions, Deerfield, IL

¹³University of Rochester, Rochester, NY

¹⁴Dana-Farber Cancer Institute, Boston, MA

¹⁵Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

¹⁶Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA

¹⁷Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

¹⁸Churchill Hospital, Oxford University, Oxford, United Kingdom

- ¹⁹Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
²⁰Department of Leukemia, MD Anderson Cancer Center, Houston, TX
²¹Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
²²John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ
²³CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
²⁴Cancer Institute of New Jersey, New Brunswick, NJ
²⁵Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
²⁶Dartmouth-Hitchcock Medical Center, Lebanon, NH
²⁷AbbVie Inc., North Chicago, IL
²⁸AbbVie, Inc., North Chicago, IL
²⁹Moore Cancer Center, University of California School, San Diego, CA
³⁰Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
³¹Haematology, Cambridge University Hospitals NHS Foundation Trust (on behalf of the UK CLL forum), Cambridge, United Kingdom
³²Georgetown Univ. Hosp. Lombardi Cancer Ctr., Washington, DC
³³University Hospital Cologne, Cologne, Germany

4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Young Adult, Study Population

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Reema R Mathanda, MD^{1*}, Betty K. Hamilton, MD², Lisa Rybicki, MS^{3*}, Anjali S. Advani, MD⁴, Brian J. Bolwell, MD⁴, Amy Colver, LISW^{4*}, Jane Dabney, LISW-S^{4*}, Christina Ferraro, CNP^{4*}, Aron Flagg, MD^{1*}, Rabi Hanna, MD⁵, Matt Kalaycio, MD⁴, Christine Lawrence, LISW-S^{4*}, Linda McLellan, LISW^{4*}, Ronald Sobecks, MD⁴ and Navneet S. Majhail, MD, MS⁴

¹Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH

³Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

4788 The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Adult, Study Population, Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jason Tay, MD¹, Ruta Brazauskas, PhD^{2,3*}, Naya He^{3*}, Sara Beattie^{4*}, Christopher Bredeson, MD, FRCPC, MSc⁵, Jignesh Dalal, MD⁶, Shahrukh K. Hashmi, MD, MPH^{7,8}, Theresa E. Hahn, PhD⁹, Nandita Khera, MD¹⁰, William A. Wood, MD, MPH¹¹ and Wael Saber, MD, MS^{3*}

¹Univ. of Ottawa/Ottawa Hosp., Calgary, AB, Canada

²Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, AB, Canada

⁵Ottawa General Hospital, Ottawa, ON, CAN

⁶Rainbow Babies & Children's Hospital, Cleveland, OH

⁷Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁸Department of Internal Medicine, Mayo Clinic, Rochester, MN

⁹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁰Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

¹¹Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC

4802 Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Diseases: Poster III

Hematology Disease Topics & Pathways:

Adult, antibodies, Biological, multiple myeloma, Diseases, Therapies, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Pramod Pinnamaneni, MD, Craig Savage*, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO and Jason Valent, MD*

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4804 Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

autoimmune disorders, Diseases, Bleeding and clotting, ITP, Immune Disorders

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nichola Cooper, MRCP¹, Alexandra Kruse^{2}, Caroline Kruse^{2*}, Shirley Watson^{3*}, Mervyn Morgan^{3*}, James B. Bussel, MD⁴, Waleed Ghanima⁵, Donald M. Arnold, MD, MSc, FRCPC⁶, Cristina Santoro^{7*}, Ming Hou, MD^{8*}, Yoshiaki Tomiyama, MD⁹, Serge Laborde^{10*}, Barbara Lovrencic^{11*}, John Waller, PhD, BSc^{12*}, Tom Bailey^{12*}, Gavin Taylor-Stokes^{12*}, Miona Stankovic^{13*} and Andrew Provan^{14*}*

¹Hammersmith Hospital, Imperial College London, London, United Kingdom

²Platelet Disorder Support Association, Cleveland

³ITP Support Association, Bolnhurst, United Kingdom

⁴Division of Hematology/Oncology, Weill Cornell Medical College, New York

⁵Department of Medicine, Ostfold Hospital Trust, Kalnes, Norway

⁶Department of Medicine, McMaster University, Hamilton, Canada

⁷Department of Cellular Biotechnologies & Haematology, 'Sapienza' University of Rome, Rome, Italy

⁸Department of Hematology, Shandong University, Jinan, China

⁹Osaka University Hospital, Osaka, Japan

¹⁰O'Cyto, Saint Loubes, France

¹¹Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy

¹²Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom

¹³Novartis Pharma AG, Basel, Switzerland

¹⁴Barts and The London School of Medicine and Dentistry, London, United Kingdom

4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Madeline Waldron, PharmD^{1}, Caitlin Siebenaller, PharmD^{2*}, Brian P. Hobbs, PhD^{3*}, Marc Earl, PharmD^{2*}, Mary Schleicher^{4*}, Hetty E. Carraway, MD, MBA^{5,6}, Anjali S. Advani, MD⁷, Aziz Nazha, MD⁸, Aaron T. Gerds, MD, MS⁵, Betty K. Hamilton, MD⁵, Ronald Sobecks, MD⁹, Matt Kalaycio, MD⁹, Mikkael A. Sekeres, MD, MS¹⁰ and Sudipto Mukherjee, MD, PhD, MPH¹⁰*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pharmacy, Cleveland Clinic, Cleveland, OH

³Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Medical Library Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁸Cleveland Clinic, Cleveland, OH

⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4806 Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Madeline Waldron, PharmD^{1*}, Caitlin Siebenaller, PharmD^{2*}, Marc Earl, PharmD^{2*}, Xuefei Jia, MS^{3*}, **Hetty E. Carraway, MD, MBA^{4,5}**, **Anjali S. Advani, MD⁶**, **Aziz Nazha, MD⁷**, **Aaron T. Gerds, MD, MS⁸**, **Betty K. Hamilton, MD⁴**, **Ronald Sobecks, MD⁹**, **Matt Kalaycio, MD⁹**, Barb Tripp, CNS^{10*}, **Brian P. Hobbs, PhD^{3*}**, **Mikhael A. Sekeres, MD, MS¹¹** and **Sudipto Mukherjee, MD, PhD, MPH¹¹**

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pharmacy, Cleveland Clinic, Cleveland, OH

³Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

⁷Cleveland Clinic, Cleveland, OH

⁸Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4809 Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: The Cleveland Clinic Experience

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III

Hematology Disease Topics & Pathways:

Diseases, Bleeding and clotting, Clinically relevant, VTE

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Shyam K. Poudel, MD^{1*}, Xuefei Jia, MS^{2*}, Deborah Y. Park, BS^{3*}, Mailey Lynn Wilks, CNP, MSN, APRN^{1*}, Vicki Pinkava, MSBS, PA-C^{1*}, Meghan O'Brien, MS, ANP-BC^{1*}, Barbara Tripp, CNS, AOCN^{1*}, Jung-Min Song, RN, CNS^{1*}, **Keith R. McCrae, MD⁴**, **Alok A. Khorana¹** and **Dana E. Angelini, MD¹**

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

³Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4832 Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rajshekhar Chakraborty, MBBS¹, Lisa Rybicki, MS^{2*}, Christy J. Samaras, DO³, Beth M. Faiman, PhD, CNP³, **Jason Valent, MD¹** and **Navneet S. Majhail, MD, MS⁴**

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Cleveland Clinic Foundation, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

4834 Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Clinically relevant, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Megan Sturdy, MD^{1*}, Rebecca Ye, BA², Trevor L Jenkins, MD^{3*}, James Driscoll, MD, PhD⁴, Paolo Caimi, MD⁵, Leland Metheny, MD⁶, Rachel Zebrowski, RN^{7*}, Nicole Ferrari^{8*}, Merle Kolk^{9*}, Marcos de Lima, MD⁹ and Ehsan Malek, MD¹⁰

¹University Hospitals Richmond Medical Center, Cleveland, OH

²New York University, Cleveland, OH

³Harrington Heart & Vascular Institute, University Hospital Cleveland Medical Center, Cleveland, OH

⁴Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁵University Hospitals of Cleveland, Cleveland, OH

⁶Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Cleveland, OH

⁷University Hospitals Seidman Cancer Center, Cleveland, OH

⁸University Hospitals Seidman Cancer Center, Cleveland, OH

⁹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁰Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

4835 Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster III

Hematology Disease Topics & Pathways:

Diseases, Adult, multiple myeloma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rajshekh Chakraborty, MBBS¹, Saad Ullah Malik^{2*}, Naimisha Marneni^{3*}, Alex V. Mejia Garcia, MD³, Faiz Anwer, MD^{4,5}, Alok A. Khorana⁶ and Navneet S. Majhail, MD, MS⁷

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²University of Arizona, Tucson

³Cleveland Clinic, Cleveland

⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁵University of Arizona, Tucson, AZ

⁶Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH